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1 Introduction 
Knee joint damage is associated with degenerative joint diseases such as 
osteoarthritis. Lesions in the articular cartilage are the main reason for this degeneration. 
Humans do not have the endogenous capacity to repair these lesions, but, in contrast, adult 
newts such as Notophthalmus viridescens are able to reconstitute the damaged tissue and 
finally restore the knee joint function (Geyer et al., 2010). Therefore, the detailed 
Investigation of the regeneration process in the newt is essential in order to be able to 
transfer the healing process to humans in the future.  
1.1 Regeneration  
Some amphibians (e.g. axolotl and newts) are able to repair various damaged organs 
including the heart, eye lenses, and nerves, and to replace lost tissues due to their 
remarkable capability to perform regeneration (Gilbert, 2000). 
There are three major types of regeneration: The first type is morphallaxis. It occurs 
by reorganization of remaining cells after an injury to form new functional tissues. Hydras 
regenerate by this mechanism. If a hydra is bisected midway through the body stalk, the 
remaining cells at the cut surface will be reorganized, which will result in the formation of a 
new head or foot (Gilbert, 2000; Carlson, 2007). The second type is compensatory 
regeneration. In this process, cells divide to fill the lost structure without losing their 
differentiated phenotype (Gilbert, 2000). An example of this type is mammalian liver 
regeneration. After partial hepatectomy, the remaining hepatocytes at the injury site 
proliferate to fill the damaged area (Ledda-Columbano et al., 1993). The third type is 
epimorphosis. In this regeneration type, predominantly after injury, cells dedifferentiate to 
form a collection of undifferentiated cells. Afterward these cells proliferate and then they 
redifferentiate to form functional tissue (Gilbert, 2000; Stocum, 2006).  
1.1.1 Epimorphic regeneration 
Salamander limb restoration is an example for epimorphic regeneration. Upon 
dissection or autotomy (Figure 1, step 1), a wound healing process takes place (Figure 1, 
step 2). After 6 – 12 hr, epidermal cells migrate from the stump to the wound surface form an 
epidermis. Afterwards, the cells from the epidermis proliferate to form the apical ectodermal 
cap (AEC) (Figure 1, step 3) (Chernoff et al., 1995). During the next 4 days, the cells beneath 
the AEC such as bone cells, chondrocytes, fibroblasts, myocytes and neural cells loose their 
differentiated character and detach from one another to form an undifferentiated cell mass. 
This process is called dedifferentiation (Figure 1, step 4). Afterwards, the AEC induces the 
undifferentiated cells to proliferate to form a mesenchymal mass, called the blastema 
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(Figure 1, step 5) (Globus et al., 1960). In addition to the undifferentiated cells, resident stem 
cells, which reside in the wound area, also contribute to the mesenchymal cell population in 
the blastema (Odelberg, 2005; Morrison et al., 2006). Afterwards, the blastema tissue grows 
and expands its size from a small bud into an elongated cone. In the next regeneration 
stage, it undergoes a redifferentiation process, which starts from the proximal side of the 
blastema towards its distal tip (Figure 1, step 6). Afterwards, cartilage condensation and 
myogenesis initiate the morphogenesis event. They are followed by differentiation of 
connective tissue, vascular system, and establishment of nervous connections (Chaar et al., 
2006). The morphogenesis takes place until a functional limb is restored. At the end of the 
regeneration process, the newly-developed limb cannot be distinguished from its uninjured 
contralateral counterpart (Figure 1, step 6) (Gilbert, 2000; Chaar et al., 2006).  
 
 
Figure 1: Stages of limb regeneration in an adult newt (Notophthalmus viridescens) (adapted 
from Chaar et al., 2006). 
 
The main characteristic in this epimorphic regeneration is the formation of blastema 
(Brockes, 1997). Some researchers have tried for many years to reveal the cellular origin 
and potency of this unique tissue. Cells in blastema have been thought to have a high 
cellular plasticity, as they, after regeneration process, differentiate into various cells types, 
such as bone, muscle, skin, and cartilage cells. Therefore, some investigators have 
suggested that the blastema cells are pluripotent (Stocum, 1968; Pietsch, 1961; Holtzer, 
1969; Steen, 1970), when performing their experiments in larvae of Ambystoma maculatum, 
Ambystoma opacum, and punctatum. The method they used was grafting limb blastema to 
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ectopic sites such as the fin which supported the blastema growth and differentiation process 
(Pietsch, 1969; Stocum, 1968). 
A recent study from Kragl and coworkers in an axolotl limb regeneration model 
system contrasted the pluripotency of the blastema cells (Kragl et al., 2009). They employed 
a more precise technique by using integrated green fluorescent protein (GFP) transgene to 
track the major limb tissue development during limb regeneration in the axolotl. With this 
technique, they demonstrated that GFP+-labeled cartilage cells did not form myogenic cells in 
the regenerating limb. They also noticed that after GFP-labeled transgenic myotubes were 
grafted in the regenerating blastema, thereafter the green fluorescence signal was detected 
only in the regenerating muscle but not in the cartilagineous skeleton and epidermis. Based 
on these results, they concluded that blastema was a heterogeneous collection of restricted 
progenitor cells, with the cells in the blastema retaining a strong memory of their tissue or 
embryonic origin (Kragl et al., 2009).  
In contrast to the salamander, adult amniotes including lizards, birds, and mammals, 
cannot regenerate their limb (Yokoyama, 2008). Upon amputation, the limb stump only 
undergoes wound healing (Yokoyama, 2008). However, this process usually results in scar 
or keloid formation, which is composed mostly of collagen type I. The flexibility and the 
strength of these tissues are inferior in comparison to the original tissue (Hardy, 1989). 
Different assumptions have been proposed to explain why amniotes including 
mammals cannot perform this type of regeneration (Chaar et al., 2006). First, the wound 
healing process, which results in scar formation, is more efficient and faster than epimorphic 
regeneration (Brockes et al., 2001; Carlson, 1974). Second, the involvement of immune cells 
and cytokines such as tumor necrosis factor α during wound healing interferes with the 
regeneration response, finally leading to scar formation (Harty, 2003).  
Of note, some epimorphic regeneration can also be realized in mammals (Chaar et 
al., 2006). McGann and coworkers showed that treatment of murine C2C12 myogenic cell 
lines with protein extract from newt limb regeneration tissue induced a dedifferentiation 
process (McGann et al., 2001). In their experiment, they further observed that 18% of murine 
C2C12 cells were re-entered the cell cycle and lost their differentiated character after 
treatment with the regeneration extract. They could also show that hitherto unknown protein 
factors in the extract promoted this event (McGann et al., 2001). 
1.2 Eastern newt 
The Eastern newts (Notophthalmus viridescens) belong to the Salamandridae family 
which is endemic in North America. There are four known subspecies of the Eastern newt: 
The red-spotted newt (Notophthalmus viridescens viridescens), which lives in the Eastern 
and North East of the United States (Figure 2), the Central newt (Notophthalmus viridescens 
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louisianensis), which lives in the central area of the United States, the Peninsula newt 
(Notophthalmus viridescens piaropicola), which lives in Florida (Riemland, 2000). 
 
 
Figure 2: The adult red spotted newt (Notophthalmus viridescens viridescens). Image source: 
The image is kindly provided by Carina Schreiyäck from our research laboratory. 
 
The life cycle of the Notophthalmus viridescens consists of four distinct stages i.e. 
egg, aquatic larva, red eft (terrestrial juvenile) and adult (Petranka, 1998). The breeding 
season starts from late winter and lasts to early spring (Behler and King, 1996). Eggs are laid 
by female newts on submerged vegetation with a hatching period of 3 – 8 weeks (Behler and 
King, 1996). They can reach adulthood by three different ways: First, metamorphosis via a 
terrestrial juvenile (eft) stage to an aquatic lunged adult; Second, direct transformation into 
aquatic lunged adult; Third, paedomorphosis, maturation directly into an aquatic gilled adult 
without metamorphosis. Paedomorphosis exists only in few newt populations in certain areas 
such as coastal Massachusetts and Long Island (Mecham, 1967; Healy, 1974; Takahashi, 
2009; Takahashi and Parris, 2008). Terrestrial red efts leave their home ponds, spending 
their lives for three to seven years as terrestrial red efts in the wet forest or wet open land 
(Forester et al., 1991; Roe et al., 2008). After at least three years, the red efts return to 
aquatic habitats and become sexually mature. They undergo a second metamorphosis into 
the aquatic adult form during breeding season.  
Notophthalmus viridescens viridescens has a green skin color, smooth and mucous 
skin and a large tail (Gage, 1891; Gill, 1978).  
1.3 Osteoarthritis  
Osteoarthritis (OA) is the most common joint disorder in the world and characterized 
by pathological changes including localized loss of articular cartilage and formation of 
outgrowths at the joint margins (osteophytes) (Conaghan et al., 2008; Lark, 1995). In an 
aging community like in developed countries and athletes, OA has become a major 
healthcare issue. In Sweden, 8% of those aged between 50 to 70 years suffer from clinically 
relevant OA (Jacobsson et al., 1989).  
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OA usually shows distinct symptoms. Pain in the affected joint is the prominent 
sequelae of this disease. The intensity of the ache gets worse when the affected joint is used 
for physical activity. If the disease is severe, the pain still persists even after the joint rests 
(Manek et al., 2000). The second main symptom is stiffness. The affected joint is difficult to 
move or rotate, especially after a prolonged resting period such as sleeping and sitting. The 
third symptom of OA is muscle weakness. It is derived from the pain-induced reluctance to 
use the affected joint (Slemenda et al., 1997).  
There are several factors that contribute to the development of OA: The first factor is 
age. As the joints are getting older, the articular cartilage, which serves as smooth interaction 
surface of the mobile parts of the joint, is worn-out (Felson et al., 1995; Lawrence et al., 
1996). The next factor is obesity: Excessive body weight can cause overloading in the 
affected joints, which further increases the lesions in the articular cartilage (Zhang et al., 
2010). The last factor is injury: Especially rupture of the anterior cruciate ligament (tissue that 
connects and stabilizes knee joints) increases the risk of OA development substantially. The 
subsequent tear induces joint-instability and eventually leads to further lesions in the articular 
cartilage (Lohmander et al., 2004). 
Humans do not have an endogenous capacity to heal OA. This problem has been 
recognized as early as 1743 by Hunter. He noted that lesions of articular cartilage in OA 
cannot repair themselves, resulting in degenerative arthritis of the affected joint (Hunter, 
1743). There are distinct factors contributing to the limited regenerative capacity of articular 
cartilage. First, cartilage is not supported by a regenerative cell population. It is a collection of 
progenitor cells that have differentiated into a specialized cell type upon local tissue defect or 
loss (Matsiko et al., 2013; Buckwalter et al., 2005). Second, articular cartilage lacks 
vascularization. Therefore, cells from perivascular mesenchymal pools (progenitor cells 
which reside in the periphery of the blood vessel) cannot usually enter the lesion (Lindahl et 
al., 2003; Hunziker and Rosenberg, 1996).  
Severe articular cartilage damage in OA causes pain in the affected joint. This leads 
to restriction of patient mobility, which ultimately reduces their quality of life. To overcome 
this problem and in order to restore the function of the damaged tissue, joint replacement 
surgery is performed (Kasper et al., 2005). Other efforts to repair damaged articular cartilage 
have still failed to produce satisfying results, especially for extended cartilagineous lesions. 
One of the methods to “repair” small lesions is autologous chondrocyte implantation (Steinert 
et al., 2007). This technique uses - as one example - chondrocytes, which have been 
isolated from a cartilage tissue derived from a minor load-bearing area on the upper medial 
femoral condyle of the damage knee. After several weeks of in vitro cultivation, the cells are 
then transplanted into the lesional site (Brittberg et al., 1994). As mentioned, this method is 
not suitable for treatment of bigger cartilage lesions, which are normally present in OA 
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patients. At present, this technique is limited to repair small defects ranging from 2 to 10 cm2, 
partially based on the limited number of chondrocytes, which have to be taken from the 
donor tissue (Steinert et al., 2007). 
1.3.1 Pathological changes in articular cartilage during OA 
1.3.1.1 Healthy articular cartilage 
Articular cartilage is located at the ends of bones of a diathroidal joint. It provides a 
low friction bearing surface for movement and a high capacity to bear load as impact of 
locomotion. The thickness of this tissue in adult humans is only 1 - 2 mm, it forms a very thin 
layer at the distal end of an epiphyseal bone (Stockwell, 1971). In newt knee joint, the 
articular cartilage is not arranged as thin layer, but it covers major parts of the joint cap as 
shown in Figure 3. 
 
Figure 3: Healthy newt knee joint. Safranin-O staining was conducted in sagittal section of healthy 
newt knee joint. Due to high proteoglycan content in the articular cartilage, this tissue stains red. The 
Safranin-O staining shows thick articular cartilage in the femoral and the tibial joint cap. Original 
magnification x 50. fm, femur; ac, articular cartilage; tb, tibia. Image source: The image was provided 
by Carina Schreiyäck of our research group. 
 
Articular cartilage is composed of 65 – 80% water, 10 – 20% collagen type II, 5% 
aggrecan and less than 5% of other components (proteoglycans, biglycans, decorin, collagen 
type V, VI, IX, X, XI; hyaluronate, fibronectin and lipids) (Athanasiou et al., 2013).  
In comparison to other tissues, articular cartilage is sparsely populated with cells. The 
only cells residing in this tissue are the chondrocytes. However, they occupy only less than 
10% of the total volume of articular cartilage. These cells are located in small cavities 
(lacunae) and are scattered individually within the cartilage. They receive their nutrition via 
diffusion of substances from synovial fluid in the joint gap (Athanasiou et al., 2013; Cole et 
al., 2009). Mature chondrocytes in healthy cartilage do not proliferate, but they are 
metabolically active and responsive to soluble mediators such as growth factors, and 
fm 
tb 
ac 
 
Introduction 
 7 
interleukins (Athanasiou et al., 2013; Cole et al., 2009). Chondrocytes are important for the 
maintenance of the cartilage because they synthesize components of the extracellular matrix 
such as proteoglycans and collagens (Buckwalter et al., 2005).  
Based on the alignment of collagen fibers, biomechanical function and cellular 
morphology, the articular cartilage can be subdivided into four horizontal zones: Superficial 
zone, intermediate or middle zone, deep zone and calcified cartilage (Figure 4) (Matsiko et 
al., 2013; Cole et al., 2009).  
 
Figure 4: Structural organization of articular cartilage. The structural organization of articular 
cartilage from the superficial zone, the intermediate zone, the deep zone and the calcified cartilage 
(adapted from Matsiko et al., 2013). 
 
The superficial zone is the thinnest zone of the articular cartilage which accounts for 
10 – 20% of the total cartilage volume. It is recognizable by its high number of flattened 
chondrocytes. This zone has the highest water content, a relatively low proteoglycan density, 
densely packed collagen fibers (Weiss et al., 1968), and high tensile strength (Cole et al., 
2009).  
The intermediate zone accounts for 40 – 60% of total cartilage volume. The 
chondrocytes in this zone are usually spherical in shape and the cells are scattered in the 
matrix. The collagen fibers are thicker and the proteoglycan content is elevated. This zone 
provides the necessary resistance to compression (Cole et al., 2009). 
The deep zone constitutes 30% of the total cartilage volume. The chondrocytes are 
spherical in shape and they are arranged in columns. The proteoglycan content is also the 
highest as compared to the other zones (Cole et al., 2009).  
The calcified zone and the tidemark serve as barrier to vascular penetration and as 
transitional zone between cartilage and subchondral bone. Nutrition from subchondral bone 
cannot penetrate the calcified zone. Chondrocytes are still found in this zone and are 
randomly distributed in a matrix filled with apatitic salts (Cole et al., 2009). 
Superficial zone 
Intermediate zone 
Deep zone 
Tide mark 
Calcified cartilage 
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1.3.1.2 Articular cartilage in OA 
Articular cartilage of OA patients undergoes significant structural degenerations. It 
starts with localized disruptions and fibrillations of the collagen network in the superficial 
zone in articular cartilage (Buckwalter et al., 2005). The fibrillation of the collagen network is 
caused by denaturation of collagen type II network (Bennet et al., 1942; Stoop et al., 2001). 
In the late stadium of OA, the surface of articular cartilage becomes roughened. Fibrillations 
of the collagen network extend from superficial zone into deeper layer of articular cartilage. 
Afterwards, the superficial tips of the fibrillated cartilage tears release free fragment in the 
joint space. It causes reduction of the cartilage thickness until finally reaching the necrotic 
subchondral bone layer (Buckwalter et al., 2005).  
The articular cartilage degeneration process results in substantial reduction of 
proteoglycan content in this tissue. Matthews showed that the proteoglycan content was 
higher in healthy than in OA knee joint tissue (Matthews, 1953). This finding is supported by 
Bollet and coworkers, who investigated articular cartilage from different OA disease grades. 
They found that the proteoglycan content was getting lower as OA becomes more severe 
(Bollet et al., 1963).  
The articular cartilage degeneration process results also in the reduction of collagen 
type II content in this tissue (Venn and Maroudas, 1977). It was noticed by Venn and 
Maroudas, who found that the content of collagen type II in the osteoarthritic femoral head 
cartilage was lower than the one found in healthy tissue (Venn and Maroudas, 1977).  
Chondrocytes in the articular cartilage of OA patients show an unusual activity. As the 
disease worsens, they undergo programmed cell-death or apoptosis, which decreases their 
cell number dramatically (Meachim and Collins, 1962; Rothwell and Bentley, 1973). The 
proliferative activity causes also cell clustering, a unique chondrocyte phenotype in OA 
cartilage (Meachim and Collins, 1962; Rothwell and Bentley, 1973; Sandell and Aigner, 
2001).  
As the disease proceeds, the composition and structural alterations of the ECM 
stimulate chondrocytes to produce proteases including matrix metalloproteinases (MMPs) 
that further promote cartilage degeneration (Samuels et al., 2008). MMPs degrade important 
components of cartilage such as collagen type II and proteoglycans (Troeberg and Nagase, 
2012). MMP-1,-8,-13, and -14 are proteases that responsible for the degradation of collagen 
type II (Billinghurst et al., 1997; Reboul et al., 1996; Mitchell et al., 1996; Bau et al., 2002; 
Kevorkian et al., 2004). In addition, MMP-3 is the proteolytic enzyme which degrades the 
proteoglycans (Fosang et al., 1991).  
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1.3.2 Properties, development, and remodeling of healthy and OA bone 
1.3.2.1 Healthy bone 
Long bone can be subdivided into distinct parts (Figure 5). The subchondral bone is 
located next to the articular cartilage (Figure 5, inset). The epiphysis is located next to the 
subchondral bone. Adjacent to the epiphysis is the epiphyseal line. This tissue is a 
cartilagineous structure, which exists only during the growth phase and it disappears in 
adulthood. The metaphysis is located adjacent to the epiphyseal line (Figure 5). The 
epiphysis and the metaphysis are composed of trabecular bone. Another part of the long 
bone is the diaphysis. This bone is composed of cortical bone or the compact bone. Unlike 
the trabecular bone, cortical bone is dense and solid. The adult human skeleton is composed 
of 80% cortical bone and 20% trabecular bone (Clarke, 2008).  
 
 
Figure 5: Anatomy of an adult human long bone 
 
The periosteum is a fibrous connective tissue sheath that surrounds the outer cortical 
surface of bone (Figure 5), exception the joints. It contains blood vessels, nerve fibers, 
osteoblasts and osteoclasts (Clarke, 2008). The periosteum plays an important role in bone 
development and regeneration (Bourne, 1944; Colnot et al., 2012). Upon fracture, it can 
release progenitor cells, which can differentiate into osteoblasts. These cells then synthesize 
new bone matrix to heal the damage (Colnot et al., 2012). 
Endosteum is a membraneous structure surrounding the inner surface of cortical 
bone, trabecular bone and the central canal (Figure 5). It consists of simple flattened layers 
of osteoblasts, osteoclasts and osteoprogenitor cells (mesenchymal stem cells that can 
differentiate into osteoblasts) (Clark, 2005; Martini and Frederich, 2005). Endosteum plays 
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roles in regeneration and bone remodeling (Epker et al., 1965; Stoker and Epker, 1971; 
Martini and Frederich, 2005). The osteoclasts in this tissue perform bone resorption and the 
osteoblasts synthesize new bone matrix (Clarke, 2008).  
1.3.2.2 Development and remodeling of healthy long bone 
Long bone develops by endochondral ossification (Mackie et al., 2011). In this 
process, embryonic mesenchymal cells condense and differentiate into chondrocytes that 
form a cartilage template (Figure 6A). Then these cells proliferate, which expands the 
cartilage “model” in size. Afterwards, the chondrocytes in the mid-shaft of the model undergo 
a phenotypic conversion to hypertrophy (terminal stage of chondrocyte differentiation, which 
is characterized by enlargement of the cellular volume and the occurrence of gene 
expression markers such as collagen type X and alkaline phosphatase) (Sharma et al., 
2007). This event initiates the formation of primary ossification. In this stage, the hypertrophic 
chondrocytes express vascular endothelial growth factor (VEGF) (Zelzer et al., 2002). This 
growth factor promotes blood vessels to invade the cartilage template. Then, osteoblasts, 
which are surrounding the mid-shaft of the model, deposit a periosteal bone collar 
 (Figure 6B). Subsequently, the ossification process expands toward each end side of the 
cartilage model. During this process, osteoclasts remove the cartilage ECM, then osteoblasts 
deposit new bone matrix on the remnant (Figure 6C). A secondary center of ossification 
forms at each end of the cartilage model, which creates a growth plate between both centers 
of ossification (Figure 6D). The bone development process is finished, when the expanding 
primary center of ossification meets the secondary center of ossification (Figure 6E). The 
endochondral ossification starts during fetal life until growth is terminated in adulthood 
(Mackie et al., 2011). 
 
Figure 6: Illustration of long bone development by endochondral ossification. (A) The cartilage 
model of the future mature bone. (B) Formation of a periosteal bone collar and initiation of primary 
center of ossification. (C) Expansion of the primary center of ossification towards the end side of the 
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cartilage model of the future bone. (D) Formation of a secondary center of ossification at each end of 
the cartilage model and a cartilaginous growth plate between the primary and secondary center of 
ossification. (E) Formation of adult bone. The cartilagineous growth plate exists only in the actively 
developing bone (juvenile bone), and has disappeared in the adult bone. The only remaining cartilage 
is the articular cartilage at the ends of the bone (adapted from Mackie et al., 2011). 
 
In contrast to bone development, remodeling of bone takes place during the complete 
lifetime of a human organism. It is a continuing process by which bone is renewed to 
maintain its strength and mineral homeostasis (Clarke, 2008; Eriksen, 2010). 
If required, the remodeling process starts with bone resorption, which is performed by 
osteoclasts. Afterwards, osteoblasts start to synthesize new collagenous organic matrix 
(osteoid) to fill the resorption area. The osteoid is composed of unmineralized organic 
compounds, which predominantly consist of collagen type II. Then, mineralization of the 
osteoid takes places together with collagen deposition. In the final stage, the rate of collagen 
synthesis dramatically decreases while mineralization activity still continues until the osteoid 
matrix becomes fully mineralized to form a new bone. Thereafter, the osteoblasts are trapped 
within the newly mineralized bone in the bone lacunae and their volume shrinks. Then, they 
are called osteocytes. These osteocytes produce matrix proteins that regulate the exchange 
of minerals in the fluid within the lacunae (Hadjidakis, 2006; Clarke, 2008; Eriksen, 2010). 
1.3.2.3 Bone remodeling in OA 
In OA patients pathological changes also involve the subchondral bone and the 
development of osteophytes at the joint margins. 
 Subchondral bone remodeling  1.3.2.3.1
The important manifestation of subchondral bone remodeling in OA is sclerosis. It is 
characterized by a decrease in of mechanical stability, trabecular thickening, and an increase 
of bone stiffness (Lajeunesse et al., 1999). Some researchers suggested that sclerosis was 
caused by adaptive response of the tissue due to increase of mechanical stress on the 
subchondral bone (Chiba et al., 2011). Here, the increase of the mechanical stress originates 
from the mechanical loading that cannot be absorbed by damaged articular cartilage 
(Lajeunesse et al., 1999; Chiba et al., 2011).  
Osteoblasts are known to play important role in the development of subchondral bone 
sclerosis in OA. Researchers reported that this pathological phenotype was derived from 
abnormal osteoblast activity. They overproduced homotrimeric α1 of collagen type I that 
caused abnormal mineralization of the subchondral bone (Mansell et al., 1998; Bailey et al., 
2002). 
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 Osteophyte development 1.3.2.3.2
An osteophyte is a fibrocartilage-capped bony outgrowth, which can be detected at 
the margins of a diathroidal (joints that connect long bone), apophyseal (joints that connect 
bone in the spine) joint, and vertebral bodies (van der Kraan, 2007).  
Osteophytes form in the early development of OA and contribute to significant clinical 
symptoms such as joint pain and loss of function. The pain is probably caused by nerve 
compression (Matsumoto et al., 2002). Matsumoto and coworkers investigated the source of 
the pain in patients with osteophytes in vertebral bodies. They found that it originated from an 
entrapment of spinal nerves which was caused by the osteophytes (Matsumoto et al., 2002).  
The mechanism of development of this bony outgrowth has been exclusively 
investigated in experimental murine OA (Van der Kraan, 2007). The osteophyte growth is 
initiated by induction of mesenchymal stem cell proliferation, which takes place in the 
periosteum covering the subchondral bone and cartilage boundary (van der Kraan, 2007). 
Afterwards, the mesenchymal cells undergo chondrogenesis to form cartilage cells and 
deposit matrix molecules such as proteoglycans in the tissue. Chondrocytes, which reside in 
the center of this newly-formed cartilage, further differentiate into a hypertrophic phenotype. 
This phenotype is characterized by volume enlargement and gene expression markers such 
as collagen type X and alkaline phosphatase (Sharma et al., 2007; van der Kraan, 2007). 
Afterwards, endochondral ossification takes place producing bone and bone marrow cavities. 
The fully developed osteophyte is integrated with the subchondral bone. It composes of bony 
structure which is covered by a cartilage layer (van der Kraan, 2007). 
1.4 Newt as model organism to study regeneration of the knee 
joint 
Some vertebrates, such as axolotl and Xenopus, are able to regenerate body parts 
such as limb and tail (Hazard, 1959; Tanaka and Reddien, 2011). However, axolotls are not 
adult animals, because they retain their larval phenotype throughout their live. Therefore, 
they do not represent adult animals, which can still perform regeneration (Tompkins, 1978). 
The larvae of Xenopus laevis can restore their lost limb. However, they lose their 
regenerative capacity after metamorphosis (Muneoka et al., 1986). 
In contrast, adult newts still retain the exceptional ability to regenerate some of their 
body parts including appendages (Brockes et al., 1997), lenses (Henry et al., 2010), the 
heart (Borchardt and Braun, 2007), and some parts of the central nervous system (Berg et 
al., 2010). In addition, our group was successful to show that adult newts are able to heal 
knee joint defects after artificially induced OA. This was shown by using two different models: 
Collagenase- and surgically-induced OA. The first method (Figure 7A) is already reported 
elsewhere (Geyer et al., 2010). The second model was performed as shown in Figure 7B-D 
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(unpublished work of Dr. med. Matthias Geyer and Prof. Dr. med. Robert M. Dinser): The 
right limb knee joint was opened (Figure 7B), and the femoral cartilage was removed (Figure 
7C), thereafter, the wound was sealed with tissue glue (Figure 7D). 
 
 
Figure 7: Collagenase- and surgically-induced knee joint defect in newt. (A) Collagenase-
induced knee joint defect. Collagenase is injected intra-articularly in the knee joint to induce a knee 
joint defect. (B), (C), (D) Surgically-induced knee joint defect. The surgery method is performed by 
(B) opening the knee joint by transverse section, (C) removing the femoral cartilage, and (D) sealing 
the knee with tissue glue (Histoacryl®). Images source: Kindly provided by Prof. Dr. med. Robert M. 
Dinser
1
 of our group. 
 
In order to describe the severity of OA, a scoring system was developed using both 
clinical evaluation and histology (Geyer et al., 2010). The clinical assessment was conducted 
by investigating the defective position of the treated limb, atypical movements of the animals, 
loss of stretchability, and incident instability of the limb. Evaluation of the disease level with 
histology was performed with Giemsa, Safranin-O staining and immunohistochemistry (IHC) 
for collagen type II. The first two methods visualize the proteoglycan content and the last 
detects collagen components in the articular cartilage. 
Clinical evaluation of the collagenase treated knee joints showed an increment of the 
score, which peaked on day 6 after treatment. At this time point, the clinical examination 
demonstrated that the knee joint was inflamed and the animals did not tend to use it. After 
day 6 post treatment, the clinical score attenuated until it became indistinguishable from the 
respective buffer-injected knee joint. During this phase, the histological evaluation revealed a 
temporary loss of collagen type II and proteoglycan content, which also peaked on day 6 
after treatment. After this time point, the content of these components increased when the 
knee joint function restored (Geyer et al., 2010).  
1.5 cDNA Microarray  
To study the underlying mechanisms driving regeneration, cDNA microarray was 
performed using the regenerating newt knee joint after artificially induced damage 
                                                 
1
 Prof. Dr. med. Robert M. Dinser was killed by a drunken car driver during the experimental period of this disser-
tation. 
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(unpublished work from Dr. med. Matthias Geyer, Dr, rer. nat. Thilo Borchardt, and Prof. Dr. 
med. Robert M. Dinser). cDNA microarray is a powerful method to perform rapid expression 
profiling of thousands of genes during a unique biological process like knee joint 
regeneration in newts (Schena et al., 1995). This technique is based on selective 
hybridization of fluorescence-labeled cDNA from treated and control newt knee joint utilizing 
100.000 cDNA spots from custom-made newt cDNA library (Bruckskotten et al., 2012).  
cDNA microarray allows the characterization of genes, which play an important role in 
the regenerative process. Genes, which are involved in regeneration, will be differentially up- 
(or down-) regulated only in the treated knee joint but not in the control tissue. In order to 
characterize the genes, which play an important role in regeneration, a careful sample 
preparation for the cDNA microarray should be performed. It consists of common molecular 
biological techniques. It starts with RNA isolation from treated and control tissue. Afterwards, 
the transcripted segments are converted to fluorescence-labeled cDNA using reverse 
transcription reaction with dye-attached deoxynucleotides. The product is then hybridized 
with the DNA spots on the microarray chip (Hegde, et al., 2000; Leung and Cavalieri, 2003). 
cDNA microarray analysis of the regenerating newt knee joint, which preceded this 
doctoral work, resulted in 290 genes which were differentially regulated in both OA models. 
Among them, 172 genes could not be characterized because there was no known homology 
with the public DNA database. The rest of them (88 genes) were homolog to the public 
database and they were classified based on their predicted function into 13 groups 
(Figure 8): Cytoskeleton (7 genes), matricellular proteins (12 genes), matrix degradation  
(10 genes), energy generation in mitochondria (8 genes), signal transduction (17 genes), 
structural proteins (4 genes), metabolic pathways (4 genes), cytokines (2 genes), cell 
adhesion (3 genes), intracellular protein metabolism (7 genes), transcription/cell cycle  
(6 genes), unknown function (8 genes) and uncertain classification (30 genes) (see Figure 8) 
(unpublished work from Prof. Dr. med. Robert Dinser). For this doctoral study, 10 genes 
were selected from this selection for further investigation with real-time PCR and IHC 
experiments. They were secreted protein acidic and rich in cysteine (SPARC), periostin 
(POSTN), tenascin-C (TN-C), decorin (DCN), complement factor B (CFB), gamma β 
crystalline (CRYGB), retinol saturase (RETSAT), olfactomedin-like 3 (OLFML-3), thymosin 
beta 4 (TMSB4), complement factor B (CFB).  
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Figure 8: Classification of 88 differentially deregulated genes from the cDNA microarray of 
regenerating newt knee joint. Eighty-eight deregulated genes from the cDNA microarray were 
classified according to their predicted function based on their DNA sequence homology to the public 
database. Image source: Kindly provided by Prof. Dr. med. Robert M. Dinser of our group. 
1.6 Matricellular proteins and their role on repair and regeneration 
Extracellular matrix (ECM) proteins contribute directly to the organization and 
physical properties of the ECM. For example, collagen I serves as adhesive protein within 
bones, tendons and ligaments (Carragher et al., 1999). There are also groups of proteins in 
the ECM, which do not directly contribute to the formation of the structural elements. They 
serve as modulator of cell-matrix interactions and cell function. This group of proteins is 
called matricellular proteins. Some well-known examples of these proteins are secreted 
protein acidic and rich in cysteine (SPARC), which is also known as osteonectin or BM40, 
periostin (POSTN), tenascin-C (TN-C), and decorin (DCN) (Bornstein and Sage, 2002).  
1.6.1 SPARC 
SPARC is a 43 kDa glycoprotein. It was first described by three independent groups 
as a major constituent of bovine and human bone and as a protein secreted by proliferating 
calvarial cells (osteoblasts from skullcap bone) in vitro (Termine et al., 1981; Sage et al., 
1984; Sage et al., 1981; Otsuka et al., 1984). SPARC is a highly conserved protein among 
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different species such as C. elegans, Drosophila, chicken and mammals (Bradshaw et al., 
2001).  
SPARC consists of 3 modular domains (Figure 9): The acidic domain enables 
SPARC to bind hydroxyapatite which is a major component of bone matrix (Lane and Sage, 
1994). The second domain is homologous to the repeated domain in follistatin, which binds 
to activin and inhibin, members of transforming growth factor- superfamily (Lane and Sage, 
1994). The last domain is an extracellular Ca2+-binding domain. This domain is responsible 
for its affinity to different collagen types including I, III, and V, in a Ca2+-dependent fashion 
(Sasaki et al., 1997; Sasaki et al., 1998).  
 
 
Figure 9: Modular structure of human SPARC. Three structural modules of SPARC are the acidic, 
follistatin-like, and extracellular Ca
2+
- binding domain (adapted from Hohenester et al., 1997). 
 
During human embryonic development, SPARC is essential for skeletal muscle 
development. In fetuses 15 weeks of age, SPARC is found in the newly forming myotubes. In 
neonatal muscle, SPARC expression can still be detected in a few mononuclear cells 
(progenitor cells of myotubes). In adult human muscle, SPARC was detected in satellite 
cells. They are a collection of progenitor cells that have ability to generate new muscle fibres 
or to provide new myonuclei during postnatal growth (Jorgensen et al., 2009; Kadi et al., 
2005). 
SPARC is one of the most abundant non-collagenous matrix proteins. SPARC is 
expressed in the ECM especially in osteoids of trabecular bone (Termine et al., 1981), 
osteoblasts (Kelm et al., 1994), hypertrophic chondrocytes in the normal human tibial growth 
plate (Hecht and Sage, 2006), fibroblasts, smooth muscle and endothelial cells in the dermis 
of adult human skin (Hunzelmann et al., 1998).  
SPARC regulates cell growth by interaction with other ECM molecules such as 
various collagen types (Sage et al., 1984). The binding of SPARC to collagen type I, II, III, IV, 
V is the best characterized interaction and these interactions are facilitated by the 
extracellular Ca2-binding domain (Sasaki et al., 1998). SPARC has different affinities to the 
different collagen types. This is due to the tissue-specific glycosylation pattern of SPARC 
(Kaufmann et al., 2004). For example, SPARC expressed in bone is undergoing post-
translational glycosylation with mannose. Therefore, it has a high affinity to collagen I, which 
is abundant in bone. SPARC from blood platelets does not possess post-transcriptional 
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modification with mannose, so that it has a lower affinity to collagen I (Kaufmann et al., 
2004). 
SPARC is also known as counter-adhesive protein. SPARC, which is purified from 
parietal yolk sac cells, interferes the interaction of endothelial cells to ECM by binding to 
collagen type I. It causes rounding and apoptosis of endothelial cells (Sage et al., 1989). 
However, the mode of action of SPARC to modulate collagen interactions is still unknown. 
This matricellular protein may act exclusively in the extracellular space to modulate collagen 
interactions with cell-surface receptors or intracellularly in collagen trafficking and post-
translational modifications (Bradshaw, 2009). 
SPARC-null mice showed abnormal collagen fibril morphology and substantial 
collagen decrease in adult tissues including skin (Bradshaw et al., 2002), and in epididymal 
fat pads (Bradshaw et al., 2003). SPARC-null mice developed cataractogenesis because 
these animals do not express collagen type IV, which is important for lens transparency 
(Gilmour et al., 1998; Norose et al., 1998).  
Under pathological conditions including OA and RA, chondrocytes in the superficial 
and middle zones of articular cartilage express SPARC, while it is absent in these zones of 
normal/healthy cartilage (Nakamura et al., 1996). In healthy cartilage, weak SPARC signals 
emerge from a few chondrocytes in the deep zone. SPARC expression levels in 
chondrocytes can be induced by growth factors such as TGF-β1 (Nakamura et al., 1996). 
However, proinflammatory cytokines such as IL-1β and IL-1α decrease SPARC expression 
levels (Nakamura et al., 1996).  
SPARC involvement in regeneration has been shown for skin and bone tissue (Lane 
et al., 1994; Alford and Hankenson, 2006). In adult dermal repair, expression of this protein 
appears to promote blood vessel formation as it is expressed in high levels during the 
process (Lane et al., 1994). Angiogenesis is induced by plasmin, a serine protease which 
dissolves fibrin blood clots, cleaves SPARC within the follistatin-like region resulting in the 
production of peptides that stimulate angiogenesis (Iruela-Arispe et al., 1995). As 
angiogenesis is required for the dermal repair, SPARC is suggested to promote skin 
regeneration (Lane et al., 1994). In bone fracture healing, expression of this protein is 
detected in proliferating osteoblasts in the periosteum (Hirakawa et al., 1994). In addition, 
Alford and Hankenson suggested a role for SPARC in the fracture healing as a modulator of 
new bone formation, based on its upregulation throughout the healing process (Alford and 
Hankenson, 2006).  
1.6.2 Tenascins 
Tenascins are a highly conserved family of large oligomeric glycoproteins in the ECM 
and can be found only in vertebrates (Hsia and Schwarzbauer, 2005). There are currently 
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four tenascin paralogues that have been identified in mammals: C, R, X and W. Expression 
of these proteins is tightly regulated during development and throughout the life span of an 
organism. Upregulation of these proteins is also being observed during pathological states 
such as cancer and tissue injury (Hsia and Schwarzbauer, 2005). 
1.6.2.1 Tenascin-cytotactin  
Tenascin-cytotactin or tenascin-C (TN-C) was the first member identified and is, thus, 
the best characterized family member of tenascins. TN-C is an oligomeric protein and forms 
a hexameric structure by linking its monomer with a disulfide bridge. It has a molecular 
weight of 190 to 240 kDa depending on its glycosylation pattern (Pearson et al., 1988).  
TN-C has four domains: The TA domain functions as a bridge to form hexabrachions 
(Figure 10A). The various epidermal growth factor-like (EGFL) domains consist of 31 amino 
acids and contains 6 cysteine residues that participate in intrachain disulfide bonds (Jones 
and Jones, 2000). The fibronectin-III (FN-III) domains consist of two types: The conserved 
and spliced FN-III domains (see Figure 10B). The conserved domain shows homology with 
other tenascin members, and the spliced domain is a unique TN-C motif. It can only be found 
in TN-C and TN-X (Erickson, 1993). At the C terminus, the fibrinogen globe is located. It 
contains an EF-hand calcium binding site (Aukhil, 1993). 
TN-C is involved in tissue development including chondrogenesis (Mackie et al., 
1987). TN-C appears in the condensing mesenchyme of immature cartilage during chick’s 
bone development. The function of TN-C during chondrogenesis is modulating fibronectin 
interaction with mesenchymal cells that promote their differentiation to chondrocytes (Mackie 
et al., 1987). TN-C also appears in the cerebral cortex during rat brain development (Götz et 
al., 1997). This matricellular protein plays also a role in neuronal migration and axon 
pathfinding during brain development. These functions are mediated specifically by the EGFL 
domain (Fischer et al., 1997; Götz et al., 1997). TN-C knockout mice demonstrate an altered 
neuronal development, resulting in aberrant behavior like hyperactivity and poor 
sensorimotor coordination (Mackie and Tucker, 1999).  
TN-C is expressed in normal/healthy tissue, which is subjected to mechanical forces 
including osteotendinous junctions (OTJ) (Jarvinen et al., 1999). In adult rats, TN-C appears 
in this tissue when it is actively used for normal muscle construction. If OTJ is immobilized, 
then the TN-C expression disappears (Jarvinen et al., 1999). TN-C plays also an important 
role in normal hematopoietic system (Ohta et al., 1998). Deficiency of this matricellular 
protein leads to reduction of hematopoietic cells (such as stromal cells) and bone marrow cell 
proliferation (Ohta et al., 1998).  
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Figure 10: Molecular structure of TN-C. (A) Illustration of TN-C hexabrachions. The TN-C 
assembly (TA) domain connects six TN-C monomers. (B) Schematic representation of TN-C. TN-C 
consists of tenascin assembly (TA) domain, epidermal growth factor-like (EGFL) repeats, fibronectin-III 
(FN-III) domains and fibrinogen globe (FG) (adapted from Jones and Jones, 2000). 
 
Onda and colleagues reported that TN-C is expressed in regenerating newt limbs 
after amputation (Onda et al., 1990). By employing a monoclonal antibody specific for 
urodele TN-C (mAb MT1) in IHC experiments, they identified TN-C in the blastema of 
regenerating newt and axolotl limbs. It appeared as early as 5 days after amputation in the 
dedifferentiation area. Afterwards, it increased in the distal stump during preblastema stages. 
Some TN-C also appeared within cells in the wound epithelium. During blastema formation, 
high expression of TN-C emerged in the blastemal matrix and in a thick layer underlying the 
wound epithelium. In addition, they observed that TN-C reactivities were also found in the 
tendon, i.e. the myotendinous junction (site of connection between tendon and muscle) and 
periosteum in untreated limbs.  
In subsequent in-situ hybridization experiments, they used RNA probes, which 
specifically detect newt TN-C RNA transcripts. They were able to show that TN-C expression 
in wound epithelium, which they observed previously in IHC, originated from epithelial cells 
(Onda et al., 1991). They also detected other similarities with IHC as TN-C was expressed in 
all of the mesenchymal cells in the blastema tissue. During redifferentiation of these cells, 
TN-C expression was reduced and was restricted only to the condensing but not to 
differentiated tissue (Onda et al., 1991). 
Calve and coworkers found an involvement of TN-C during newt muscle regeneration 
(Calve et al., 2010). They used two methods: in vivo 3-dimensional spatiotemporal matrix 
B) 
A) 
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map and in vitro functional time-lapse imaging to observe the expression behavior of three 
ECM proteins: TN-C, hyaluronic acid and fibronectin. They showed that TN-C together with 
the other two ECM components created an environment that supported blastema 
development and thus, regeneration. Additionally, they demonstrated that TN-C promoted 
myoblast migration and myofiber fragmentation, which also facilitated blastema formation 
(Calve et al., 2010). 
TN-C is expressed in the OA cartilage. TN-C is re-expressed when the articular 
cartilage undergoes degeneration, whereas TN-C does not appear in normal cartilage. 
Treatment of primary human articular chondrocytes with TN-C accelerates the cellular 
proliferation rate followed by an increase in proteoglycan content in culture and upregulation 
of aggrecan expression (Nakoshi et al., 2010). 
1.6.3 Periostin  
Periostin (POSTN) was originally described as an osteoblast specific factor. It was 
first identified in a mouse osteoblastic cell line as a putative cell adhesion protein for 
preosteoblasts (Takeshita et al., 1993). The name derives from its preferential expression in 
the periosteum (Takeshita et al., 1993). 
In adult tissues, POSTN is expressed in the periodontal ligament of the dental pulp in 
murine and human organisms (Horiuchi et al., 1999). POSTN is secreted by fibroblasts and 
osteoblasts in the periodontal ligament (Horiuchi et al., 1999). In bone, POSTN is expressed 
only during embryonic development and to a lesser extent in neonates, young and adult 
rodents (Horiuchi et al., 1999; Litvin et al., 2004; Kii et al., 2010), in osteoblasts lining the 
trabecular bone (Horiuchi et al., 1999; Zhu et al., 2009; Ogita et al., 2008), and abundantly in 
the periosteum during embryogenesis and bone growth. However in bone, POSTN 
expression is absent in terminally differentiated mineralized tissues (Afanador et al., 2005; 
Wen et al., 2010). 
POSTN is expressed during development of collagen-rich, fibrous connective tissues 
subjected to mechanical stress such as heart valves (Rios et al., 2005; Kruzynska-Frejtag et 
al., 2004) and tendons (Yoshiba et al., 2007). Under pathological conditions, POSTN 
appears in adult tissues after myocardial, vascular and skeletal muscle injuries as well as 
during bone fracture healing (Wang et al., 2003, Nakazawa et al., 2004).  
There is evidence that POSTN is involved in tissue regeneration. POSTN promotes 
periodontal ligament repair by stimulating the proliferative and migratory capacity of human 
periodontal ligament cells (Padial-Molina et al., 2013). POSTN is also important in cutaneous 
wound healing (Nishiyama et al., 2011). POSTN knockout mice show a delay in re-
epithelization and in the reduction of keratinocyte proliferation which causes decreasing of 
wound healing capacity in comparison to wild-type mice (Nishiyama et al., 2011).  
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1.6.4 Decorin 
Decorin (DCN) is a small leucine-rich proteoglycan which is found to be associated 
with collagen fibrils in all connective tissues (Hocking et al., 1998). This proteoglycan has a 
molecular weight of approximately 90 kDa. In the skeletal system, it is located in the ECM of 
articular cartilage (Bock et al., 2001). 
DCN knockout mice have unusually lax and fragile skin, alterations in tendon 
structure, and abnormal periodontal ligaments. These alterations are all caused by an 
abnormal fibrillar organization of collagen type I, IV, VII, and IX in these tissues (Häkkinen et 
al., 2000; Reed and Iozzo, 2003). This is due to the fact that binding of DCN to collagen is 
required for proper fibrillogenesis (Danielson et al., 1997).  
DCN is an important protein for tissue repair and regeneration (Li et al., 2007). Gene 
transfer of this protein can promote skeletal muscle regeneration by stimulating myoblast 
differentiation, reducing fibrous scar formation, regulating expression and activity of several 
factors including TGF-β, and follistatin (Li et al., 2007). The capacity of DCN to regulate the 
activity of TGF-β is also present in skin wound healing (Zhang et al., 2012). When this 
proteoglycan is downregulated, the activity of TGF-β is increased, which then promotes scar 
formation that ultimately influences skin healing (Honardoust et al., 2012).  
1.7 Innate immune system and its role in regeneration 
Innate immunity protects organisms against invasion of infectious agents. It consists 
of cells and proteins, such as NK cells (Haller et al., 1977), eosinophils (Janeway et al., 
2002), and the complement system (Janeway et al., 2002), which are always present to 
defend against a wide range of distinct pathogens such as viruses, bacteria, fungi and 
eukaryotic parasites (Müller et al., 2008).  
Innate immunity is not only essential for the defense against pathogen invasion, some 
experiments showed also its importance in tissue repair and regeneration in mammals (mice) 
and urodele amphibians (axolotls and newts) (Jiang et al., 2005; Godwin et al., 2013; Kimura 
et al., 2003). Jiang and coworkers demonstrated that macrophage chemokine production 
was required to promote this tissue repair after bleomycin-induced acute mice lung injury. 
The respective inflammatory response required activation of toll-like receptors (TLR) 2 and 4 
as well as the adaptor protein myeloid differentiation primary response protein 88 (MyD88). 
They also showed that TLR2 and 4 knockout mice displayed impaired lung regeneration 
capacity after acute lung injury (Jiang et al., 2005). In addition, Godwin and coworkers 
showed that axolotls (Ambystoma mexicanum) required the immune system for proper 
regeneration activity including limb restoration after amputation (Godwin et al., 2013). In 
addition, macrophage infiltration was required for blastema formation during axolotl limb 
regeneration. Therefore, systemic macrophage depletion in amputated axolotls resulted in 
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sole wound closure. In treated animals, a blastema was formed and the subsequent 
reconstitution of a new limb structure was hindered (Godwin et al., 2013). Kimura and 
coworkers showed that complement components 3 (C3) and 5 (C5) are involved in newt limb 
and eye regeneration. By using ISH, C3 and C5 RNA transcripts can be detected in the 
blastema, regenerating lens vesicle and in the cornea. In contrast, in intact newt limb and a 
completely restored newt eye, the RNA of C3 and C5 cannot be detected with ISH. The 
differential expression of C3 and C5 in this process demonstrates their importance in newt 
limb and eye regeneration (Kimura et al., 2003). This collection of evidence demonstrates the 
significance of the innate immune system in regeneration. Based on these functions, some 
additional genes including TLR2, TLR5, and MyD88, which were absent in cDNA microarray, 
were included in the experiments of the thesis to elucidate role in knee joint regeneration.  
1.8 Vitamin A and its role in regeneration 
Vitamin A is the name of a group of fat-soluble retinoids (Ross, 2010). These 
compounds cannot be synthesized by any animal species and are only obtained from 
nutrition in the form of retinol, retinyl ester, and β-carotene. They are then oxidized to retinal 
and finally to retinoic acid in liver. The first compound is important for normal vision, while the 
final product has more diverse biological functions in repair, regeneration, development, and 
apoptosis (Bushue and Wan, 2010). In order to perform these roles, retinoic acid relies on 
binding to specific molecules. These receptors are retinoic acid (RAR) and retinoid X 
receptor (RXR). Each of them has three subtypes; α, β, and δ. They are all located in the 
transcription regulation sites of DNA in the nucleus. When the retinoids bind to these 
receptors, they activate gene expression, which is important for diverse biological function 
including the activation of aldehyde dehydrogenase (ALDH1), which is required for 
differentiation and development of human fetal islet cell (Bushue and Wan, 2010; Li et al., 
2014). 
The role of vitamin A in regulating tissue repair and regeneration has been described 
in amphibians including axolotl (Maden et al., 1982). Vitamin A regulates pattern formation 
during limb regeneration in this animal (Maden et al., 1982). Addition of external vitamin A 
into the regenerating limb resulted in proximodistal duplication. It stimulated also the growth 
of additional skeletal elements that were already present in the developing tissue (Maden, 
1983). The proximodistal regulation of vitamin A was also mediated by activation of retinoic 
acid receptors (RARs) (Pecorino et al., 1996).  
These functions of vitamin A stimulated also to investigate, whether these receptors 
are involved and play a role in newt knee joint regeneration. Thus, RARα, β, and δ as well as 
RXR were selected for real-time PCR experiments to quantify their expression level in 
regenerating newt knee joint.  
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Vitamin A derivatives may also have potential roles in regeneration (Maden, 1982). 
An example is a synthetic pharmaceutical compound called tazarotene. This drug induces 
the expression of retinoic acid receptor responder 1 (RARRES1) after binding to other 
retinoic acid receptor, RAR-β/δ (Nagpal et al., 1996). It was firstly identified by Nagpal and 
coworkers who observed that RARRES1 was upregulated when applying tazarotene in the 
skin raft (Nagpal et al., 1996).  
RARRES1 is known as inhibitor of tumor growth (Zhang et al., 2004). In cancer cells 
including nasopharyngeal carcinoma, its expression is downregulated through promoter 
hypermethylation (Shutoh et al., 2005). Ectopic expression of A and B isoforms of RARRES1 
in human colon cells suppress also the growth of cancer cells (Zhang et al., 2004). 
RARRES1 seems to have role in newt knee joint regeneration based on its differential 
upregulation in cDNA microarray (Unpublished work from Prof. Dr. med. Robert Dinser). 
Therefore, this expression of this gene was also quantified with real-time PCR analysis to 
confirm its upregulation value during knee joint regeneration. 
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1.9 Aim of this thesis  
As mammals cannot restore the function of tissue damage, especially upon severe 
damage of a diathrodial joint, it is of utmost interest to elucidate repair processes in animals 
that have this ability to be able to develop future strategies for the human beings. In contrast, 
adult newts are able to reconstitute damaged tissue, and to finally restore specifically knee 
joint function (Geyer et al., 2010). In order to elucidate the molecular mechanisms underlying 
the regenerative process, cDNA microarrays of reconstituting tissue were performed. Of the 
several candidate genes, which were found to be differentially regulated, those known for a 
role in regeneration, were selected for further investigation addressing the following research 
questions in this doctoral work: 
1. Evaluation and confirmation of the candidate genes with real-time PCR.  
2. Spatiotemporal analysis of expression pattern of selected gene candidates.  
3. Functional analysis of the selected candidate genes using siRNA-mediated knock-
down analysis. 
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2 Materials 
2.1 Animals 
All animals were obtained from the Charles Sullivan newt farm (Nashville, Tennesee, 
USA). The animals used in this study had undergone complete metamorphosis and were 
sexually mature, having ages ranging from 3 to 4 years. The maintenance of the animals was 
done by the animal care staff of the Max Planck Institute for Heart and Lung Research, Bad 
Nauheim, Germany, under supervision of Prof. Dr. med. Robert Dinser, Dr. med. Matthias 
Geyer and Dr. rer. nat. Thilo Borchardt. The newly incoming animals were kept in a 
disinfection solution containing 0.5% sulfamerazine for 2-3 hr. Afterwards they were 
maintained in aerated aquaria in the aquarium facility in groups of maximally 15 animals. The 
water temperature in the aquaria was set to 18–20°C. They were fed with gnat larvae and 
artemia twice a week. Animal care was conducted in accordance with the Guide for the Care 
and Use of Laboratory Animals published by the US National Institutes of Health (NIH 
Publication No. 85-23, revised 1996). Animal experiments were conducted according to the 
animal welfare act and approved by the Darmstadt regional administrative council. All animal 
experiments and surgery approaches were performed by Prof. Dr. med. Robert Dinser and 
Dr. med. Matthias Geyer. Tissues used as described in this thesis were provided for the 
realization of this work. 
2.2 Chemicals and materials 
Table 1: List of chemicals and materials 
Description Manufacturer 
6-well plates  Corning, Wiesbaden 
12-well plates  Corning, Wiesbaden 
24-well plates Corning, Wiesbaden 
Basal medium eagle (BME) with Earle's 
salts and 2.2 mg/ml NaHCO3 
Biochrom AG, Berlin 
β-mercaptoethanol  Merck, Darmstadt 
Bromophenol blue Sigma-Aldrich, Taufkirchen 
Bovine serum albumin (BSA) Carl-Roth, Karlsruhe 
3-(Cyclohexylamino)-1-propanesulfonic 
acid (CAPS)  
Carl-Roth, Karlsruhe  
Cell culture flask (25 cm2/75 cm2) Corning, Wiesbaden  
Cell strainer, 100 µm BD Falcon, BD Biosciences, Heidelberg 
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Description Manufacturer 
Cell strainer, 70 µm BD Falcon, BD Biosciences, Heidelberg 
Coverslips for microscope slides (20x20 
cm), (20x50 cm) 
Carl-Roth, Karlsruhe  
Crystal violet Carl-Roth, Karlsruhe 
Diethylpyrocarbonate (DEPC) Carl-Roth, Karlsruhe 
Dithiothreitol (DTT) (10 mM) Life Technologies, Darmstadt 
Dulbecco's Modified Eagle Medium 
(DMEM), 1 g/l glucose 
PAN Biotech, Aidenbach 
DMEM/Ham’s F12  PAA Laboratories, Cölbe 
Dimethylsulfoxide (DMSO) Sigma-Aldrich, Taufkirchen  
Ethylenediaminetetraacetic acid (EDTA) Carl-Roth, Karlsruhe 
Entellan® (microscope slide mounting 
medium) 
Merck, Darmstadt 
Fast green FCF Fluka Biochemika, Steinheim 
Fetal calf serum (FCS) Sigma-Aldrich, Taufkirchen 
Gelatin (cell culture tested) Merck, Darmstadt 
Giemsa’s azur eosin methylene blue 
solution  
Merck, Darmstadt 
Glycine Carl-Roth, Karlsruhe 
Hematoxylin Carl-Roth, Karlsruhe 
4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (HEPES) 
PAA Laboratories, Cölbe 
Histoacryl® (tissue glue) B. Braun, Melsungen 
Insulin transferrin selenium, 100x, (ITS) Biochrom AG, Berlin 
Kaiser's glycerol gelatine (microscope 
slide mounting medium) 
Merck, Darmstadt  
L-ascorbic acid (vitamin C)  Sigma-Aldrich, Taufkirchen 
L-glutamine PAA Laboratories, Cölbe 
LightCycler capillaries (20 µl) Roche, Mannheim 
May-Gruenwald solution Carl-Roth, Karlsruhe 
Methanol Carl-Roth, Karlsruhe 
Microfilter (non protein binding, 
SCAA/PF, 0.2 µm) 
Corning, Berlin 
Microscope slides for paraffin sections; 
Super Frost Plus 
R. Langenbrinck, Emmendingen 
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Description Manufacturer 
Minimum essential medium (MEM), 
supplemented with GlutaMAX™  
Life Technologies, Darmstadt 
Neubauer-improved chamber Marienfeld, Lauda-Königshofen 
Nonidet P40 Substitute Sigma-Aldrich, Taufkirchen 
Phosphate buffered saline, 10x, 1x, and 
0.7x (PBS) 
PAA Laboratories, Cölbe 
Penicillin/Streptomycin PAA Laboratories, Cölbe 
Proteinase-K PeqLab Laboratories, Erlangen 
RNase-free dH2O Applied Biosystems, Darmstadt 
Safranin-O Carl-Roth, Karlsruhe 
Sulfamerazine  Sigma-Aldrich, Taufkirchen 
TissueTek® OCT™ Compound 
(Embedding medium) 
Sakura, Staufen 
TransblotSD semi dry transfer cell Biorad laboratories, Munich 
Tricaine Sigma-Aldrich, Taufkirchen 
2-Amino-2-hydroxymethyl-propane-1,3-
diol (Tris) 
Carl-Roth, Karlsruhe 
Trypan blue Aldrich, Steinheim 
Xylene Carl-Roth, Karlsruhe 
Xylene cyanol Sigma-Aldrich, Taufkirchen 
All other reagents and solutions were obtained from Sigma-Aldrich (Traufkirchen), Merck 
(Darmstadt) or Carl-Roth (Karlsruhe). 
 
2.3 Media and solutions 
Table 2: List of media and solutions 
Name Composition 
4% 
Paraformaldehyde  
(PFA) 
4 g/100 ml PFA, 3 ml of 1 M NaOH, the mixture was stirred gently 
until the powder was dissolved, 1xPBS was added and pH was 
adjusted to 7.4 with HCl 
 
aDMEM/Ham’s F12 
(70% DMEM/Ham’s 
F12)  
0.7x DMEM/Ham’s F12 in sterile ddH2O 
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Name Composition 
Anesthetic solution 0.1% (w/v) tricaine 
aPBS (70% PBS) 
0.7x PBS in sterile ddH2O (The PBS concentration was reduced to 
amphibian osmolarity) 
Crystal violet  1% (w/v) crystal violet was dissolved in methanol  
Diethylpyrocarbonate- 
treated (DEPC) 
ddH2O 
0.1% (v/v) DEPC in ddH2O 
Lysis buffer 
50 mMTris, 1% (v/v) Nonidet P40 substitute, 1x complete protease 
inhibitor  
A1 cells medium 
70% BME supplemented with Earle’s salts (Biochrom), 10% (v/v) 
FCS, 100 U/ml penicillin, 10 µg/ml streptomycin, 2 mM L-glutamine, 
1x ITS, 10 mM NaHCO3, 25 mM HEPES 
B1H1 cells medium 
70% MEM supplemented with GlutaMAXTM, Earle’s salts; 10% (v/v) 
FCS, 100 U/ml penicillin, 10 µg/ml streptomycin, 1x ITS, 10 mM 
NaHCO3, 25 mM HEPES 
Primary newt 
chondrocytes medium  
70% DMEM/Ham’s F12, 5% FCS / 10% FCS, 25mM HEPES, 
100mM NaHCO3, 100 U/ml penicillin, 10 µg/ml streptomycin, 2 mM 
l-glutamine, 1x ITS, and 17.5 µg/ml vitamin C 
PCR loading buffer 
(6x) 
0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol,  
30% (v/v) glycerine diluted in ddH2O 
Proteinase K for IHC 10 µg/ml proteinase K, 50 mM Tris pH 8.0, 5 mM Na2EDTA 
RNA gel-loading 
buffer (1.5x) 
95% (v/v) formamide, 0.025% (w/v) bromophenol blue, 0.025% 
(w/v) xylene cyanol, 5 mM EDTA  
Tris borate EDTA 
(TBE), (10x) 
0.9 M Tris, 0.9 M boric acid, 20 mM EDTA, pH 8.0 
Tris acetic acid EDTA 
(TAE) electrophoresis 
buffer (50x)  
2 M Tris, 1 M acetic acid, 50 mM EDTA 
Weigert’s solution 
Solution A: 1% (w/v) haematoxylin, 95% (v/v) ethanol; Solution B: 
1.16% FeCl3.6H2O, 0.32% (v/v) HCl. Equal volumes of solution A 
and B were mixed and used within 4 weeks. 
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2.4 Enzymes 
Table 3: List of enzymes 
Description Manufacturer 
ABSOLUTE™ QPCR SYBR® Green  Thermo Fischer Scientific, Schwerte 
Accutase PAA Laboratories, Cölbe 
Collagenase P  Roche, Mannheim 
Collagenase type VII Sigma-Aldrich, Taufkirchen 
Pronase Sigma-Aldrich, Taufkirchen 
Proteinase K PeqLab, Erlangen  
Quantitect™ SYBR® Green PCR Kit  Qiagen, Hilden 
ShortCut® RNAse III  New England Biolabs, Frankfurt am Main 
SuperScript™ II Reverse 
Transcriptase  Life Technologies, Darmstadt 
Taq DNA polymerase master mix Qiagen, Hilden 
Trypsin/EDTA  PAA Laboratories, Cölbe 
Hyaluronidase Sigma-Aldrich, Taufkirchen 
 
 
2.5 Antibodies 
Table 4: List of primary antibodies 
Name 
Application 
(working conc./ 
incubation duration 
/temperature) 
Application 
(blocking so-
lution/dura-
tion/wash) 
Manufactu-
rer 
 
Secondary 
antibody 
Rabbit anti-
human TN-C 
IHC (10 µg/ml/         
1 hr/RT) 
5% BSA/        
30 min/PBS 
Millipore, 
Darmstadt 
Simple Stain 
MAX PO 
(Multi) anti-
mouse,-
rabbit 
(Histofine) 
Goat polyclonal 
anti-mouse 
SPARC (M-15) 
IHC (4 µg/ml/1 hr/ 
RT) 
IHC (2% BSA/ 
1 hr/PBS) 
Santa Cruz 
Biotechnolo-
gy, Dallas, 
USA 
Simple Stain 
MAX PO 
anti-goat 
(Histofine) 
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Name 
Application 
(working conc./ 
incubation duration 
/temperature) 
Application 
(blocking so-
lution/dura-
tion/wash) 
Manufactu-
rer 
 
Secondary 
antibody 
Mouse anti-
newt tenascin 
antibody (MT1) 
IHC (1:100/overnight 
/4°C) 
IHC (5% BSA + 
0.5% (v/v) 
Triton™X-100/ 
30 min/PBS+ 
0.5% 
Triton™X-100 
Development 
Studies 
Hybridoma 
Bank, Iowa 
City, USA 
SimpleStain 
MAX PO 
anti-mouse 
(Histofine) 
 
 
Table 5: List of isotype control antibodies 
Isotype control Manufacturer 
Rabbit polyclonal 
IgG 
Abcam, Cambridge, UK 
Goat polyclonal IgG Santa Cruz Biotechnology, Heidelberg 
 
Table 6: List of secondary antibodies 
Name 
Working 
conc. 
Blocking 
solution/duration 
Manufacturer 
Histofine Simple Stain 
MAX PO (Multi) anti-
mouse, -rabbit  
Undiluted Included/30 min 
Nichirei 
Bioschiences Inc., 
Tokyo, Japan  
Histofine Simple Stain 
MAX PO anti-goat 
Undiluted Included/30 min 
Nichirei 
Bioschiences Inc., 
Tokyo, Japan  
2.6 Molecular biological kits 
Table 7: List of molecular biological kits 
Name Manufacturer 
3-amino-9-ethylcarbazole (AEC) 
Vector Laboratories, Burlingame, CA, 
USA 
Nucleofector Kits for Human 
Chondrocytes 
Lonza, Cologne 
BLOCK-iT™RNAi TOPO® Transcription 
Kit 
Life Technologies, Darmstadt 
RNeasy Easy Plus Micro Kit Qiagen, Hilden 
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Name Manufacturer 
RNeasy Mini Kit  Qiagen, Hilden 
Superscript® II Reverse Transcriptase  Life Technologies, Darmstadt 
QIAquick Gel Extraction Kit Qiagen, Hilden 
TRIzol® Reagent  Life Technologies, Darmstadt 
2.7 PCR primers 
All of the primers (except siTN-C-F and siTN-C-R) were designed by Dr. med. 
Matthias Geyer using the Primer3 software (http://biotools.umassmed.edu/bioapps/primer3-
www.cgi) and the quality of the selected primers was analyzed (oligoanalyzer software,  
http://eu.idtdna.com/analyzer/applications/oligoanalyzer/). The primers were ordered from 
Sigma-Aldrich. The target genes of the primers were: complement factor B (CFB-1), decorin 
(DCN-1), gamma β crystalline (CRYGB), myeloid differentiation primary response gene 88 
(MyD88), retinoic acid receptor-α (RAR-α), retinoic acid receptor-β (RAR-β), retinoic acid 
receptor-δ (RAR-δ), retinoid x receptor (RXR), olfactomedin-like 3 (OLFML-3), secreted 
protein, acidic cysteine-rich or osteonectin (SPARC), periostin (POSTN), retinoic acid 
receptor responder 1 or tazarotene-induced gene 1 (RARRES1), retinol saturase (RETSAT), 
toll-like receptor 2 (TLR2), toll-like receptor 5 (TLR5), thymosin β4 (TMSB4), tenascin-C (TN-
C), and tenascin-C for siRNA generation (siTN-C). Primer sequences and used PCR 
conditions are listed in Table 8 
 
Table 8: List of real-time PCR primers 
Name Sequence (5'->3') 
MgCl2 
(mM) 
Ta (°C) 
CFB-1-f CACTGAAAGCCTCCCTCTATG 
2.5 54 
CFB-1-r CAAGGGAGCACTTTGAATAGG 
DCN-1-f TGCAGTTCCCTGGAATAAAAG 
3.5 56 
DCN-1-r TGGCACAAGAGGAGGAAATAC 
CRYGB-1-f GTCTACGAACACTCGGGATTC 
3.0 58 
CRYGB-1-r TCATCAGTGATCAGCTTCAGG 
MyD88-2-f TGCTTCTTTGAACCCAGAGAG 
3.0 58 
MyD88-2-r TCACTGGGTCAGGGTCATTAG 
NvRAR-α-f AGTACGCAAGGCTCATCAGG 
3.0 60 
NvRAR-α-r CGATGGTGAGTGTGGTGAAG 
NvRAR-β-f GCCTTACACTCAACCGAACC 
2.5 56 
NvRAR-β-r GTGGCTCTTGGAGTTTGTCC 
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Name Sequence (5'->3') 
MgCl2 
(mM) 
Ta (°C) 
NvRARδ-f TCAACAAGGTGACACGGAAC 
3.0 60 
NvRAR-r TCCTGATGTGCTTTGCTGAC 
NvRXR-f AGTGGTGTGAACGAGGAAATG 
4.0 60 
NvRXR-r GAAGTGAGGGATACGCTTGG 
NvS21_f ATCATGCGTCAATCCAGATG 
2.5 54 
3.0  56 
NvS21_r CATGTTCCAGTGCCACAAAG 
3.5  58 
4.0  60 
OLF-1-f GGAAGTCGACGAGAAGTTGAC 
3.5 58 
OLF-1-r TTCTGAAGTTCCCATCAGGTC 
OSN-1-f CAGCGTCAGTGAGTTTGAGAG 
4.0 58 
OSN-1-r TGTGACAAGGACGTTCTTCAG 
POSTN-1-f TCGTGGGGAATCTATAAGCTG 
2.5 54 
POSTN-1-r TCATTTCCATGCAGACAGAAC 
RARR-1-f AAAAAGTTGGAACGTGCTCTG 
3.0 60 
RARR-1-r ACTTTTCCCACATCACCAAAC 
Retsat-1-f TCATAATGGACCAGCTGACTG 
3.0 58 
Retsat-1-r CAACAACGTGTGATACGCTTC 
TLR2-1-f AGCAAGACTTGTCTGCCTACC 
4.0 54 
TLR2-1-r CTCAGAAGGCTTGTTGACTCC 
TLR5-2-f CGCTTGTGAAGAATACCATTG 
3.0 60 
TLR5-2-r GGCTTTGTCATGGAGCTTTAG 
TMSB4-1-f TGCAAAGATGTCTGACAAACC 
2.5 54 
TMSB4-1-r ATAAGAAGGCAATGCTTGTGG 
TN-C-1-f GGTGACTCCATGACCTACCAC 
2.5 56 
TN-C-1-r CCAATGGAACCAGTTTACACC 
 
Table 9: List of primer to generate esiRNA tenascin-C 
Name Sequence (5’- 3’) Amplicon 
length 
siTN-C-F GCGGGTTGACCTCAAATGT 
560 bp 
siTN-C-R GTCGTCAGGGCAAGTGACT 
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2.8 Softwares 
Table 10: Softwares 
Name Manufacturer 
ND-1000 V3.5.2 PeqLab Biotechnology, Erlangen 
Leica Application Suite (LAS) Ver. 
4.0.0.  
Leica Microsystems, Wetzlar 
GraphPad Prism 
GraphPad Software Inc., San Diego, 
California 
Oligoanalyzer  
Integrated DNA Technologies, Inc, Iowa, 
USA 
2.9 Instruments  
Table 11: List of instruments 
Name Manufacturer 
Cryostat microtome (Leica CM 3050S) Leica Microsystems, Wetzlar 
Gel documentation (Genius I) Syngene, Cambridge, UK 
Incubator (C150) Binder GmbH, Tuttlingen 
LightCycler® 1.5 Instrument  Roche, Mannheim 
Microscope (Leica DMI 6000D) Leica Microsystems, Wetzlar 
PCR instrument (GeneAMP PCR system 
9700) Life Technologies, Darmstadt 
Photometer (Nanodrop®) PeqLab, Erlangen 
Rotation instrument (Cat RM5) Cat RM Zipperer, Staufen 
Swing Mill MM 301 Retsch, Haan 
UV Transilluminator (BTS-20.M) Progen Scientific, London, UK 
LightCycler® Carousel Centrifuge Roche, Mannheim,  
Microscope camera (Leica DFC 295)  Leica Microsystems, Wetzlar 
Microscope Axiovert 2s  Zeiss, Jena 
Milli-Q Biocell  Millipore, Darmstadt  
Paraffin microtome (Microm HM 340 E 
Coolcut) Thermo Fisher Scientific, Schwerte 
Centrifuge (Multifuge 3SR) Thermo Fisher Scientific, Schwerte 
Centrifuge 5417C Eppendorf, Hamburg 
Centrifuge (Biofuge®, Primo® R) Thermo Fisher Scientific, Schwerte 
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2.10 Organs and tissues 
Newt knee joint tissues were available from previous experiments which were 
performed by Dr. med. Matthias Geyer, Prof. Dr. med. Robert Dinser, and Carina 
Schreiyäck (Section 2.1).  
Paraffin embedded human tissues (RA bone tissue) were available from joint 
replacement surgery at the Orthopedic Department of the University of Gießen. The paraffin 
embedded tissues were available and used to evaluate the specificity of the SPARC 
antibody. All of the human tissues were taken with the approval of the ethics committee of 
the Justus-Liebig-University of Giessen, Germany. All patients gave informed consent and 
fulfilled the criteria of the American College of Rheumatology.  
 
Table 12: List of organs and tissues 
Tissue  Name Storage Description 
Leg, 
newt 
OP5-
3R12 
Paraffin-
embedded 
Surgically-treated newt leg, 10 days after 
injury 
Leg, 
newt 
OP5-
3L12 
Paraffin-
embedded 
Sham-operated control newt leg, 10 days 
after injury 
Leg, 
newt 
OP5-
6R12 
Paraffin-
embedded 
Surgically-treated newt leg, 10 days after 
injury 
Leg, 
newt 
OP5-
6L12 
Paraffin-
embedded 
Sham-operated control newt leg, 10 days 
after injury 
Leg, 
newt 
OP2-
6L20 
Paraffin-
embedded 
Sham-operated control newt leg, 20 days 
after injury 
Leg, 
newt 
OP2-
4L20 
Paraffin-
embedded  
Sham-operated control newt leg, 20 days 
after injury 
Leg, 
newt 
OP2-
4R20 
Paraffin-
embedded 
Surgically-treated newt knee leg, 20 days 
after injury  
Leg, 
newt 
OP2-
4L20 
Paraffin-
embedded 
Sham-operated control newt leg, 20 days 
after injury 
Leg, 
newt 
OP1-
23R47 
Paraffin-
embedded 
Surgically-treated newt leg, 40 days after 
injury 
Leg, 
newt 
OP1-
23L47 
Paraffin-
embedded 
Sham-operated control newt leg, 40 days 
after injury 
Leg, 
newt 
OP1-
24R47 
Paraffin-
embedded 
Surgically-treated newt leg, 40 days after 
injury 
Leg, 
newt 
OP1-
24L47 
Paraffin-
embedded 
Sham-operated control newt leg, 40 days 
after injury 
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Tissue  Name Storage Description 
Leg, 
newt 
OP1-
12R47 
Paraffin-
embedded 
Surgically-treated newt leg, 40 days after 
injury 
Leg, 
newt 
OP1-
12L47 
Paraffin-
embedded 
Sham-operated control newt leg, 40 days 
after injury 
Leg, 
newt 
901JL09 
Paraffin-
embedded 
Buffer-injected control newt leg, 10 days after 
injury 
Leg, 
newt 
901MR12 
Paraffin-
embedded 
Collagenase-injected newt leg, 10 days after 
injury 
Leg, 
newt 
Col6-
7R11 
Paraffin-
embedded 
Collagenase-injected newt leg, 10 days after 
injury 
Leg, 
newt 
Col6-
7L11 
Paraffin-
embedded 
Buffer-injected control newt leg, 10 days after 
injury 
Leg, 
newt 
Col6-
16L19 
Paraffin-
embedded 
Buffer-injected control newt leg, 20 days after 
injury 
Leg, 
newt 
901HR22 
Paraffin-
embedded 
Collagenase-injected newt leg, 20 days after 
injury 
Leg, 
newt 
Col6-
8R19 
Paraffin-
embedded 
Collagenase-injected newt leg, 20 days after 
injury 
Leg, 
newt 
Col6-
8L19 
Paraffin-
embedded 
Buffer-injected control newt leg, 20 days after 
injury 
Leg, 
newt 
OP2-
1L20 
Paraffin-
embedded 
Sham-operated control newt leg, 20 days 
after injury 
Leg, 
newt 
Col6-
3L40 
Paraffin-
embedded 
Buffer-injected control newt leg, 40 days after 
injury 
Leg, 
newt 
Col6-
3R40 
Paraffin-
embedded 
Collagenase-injected newt leg, 40 days after 
injury 
Leg, 
newt 
 Coltest2-
2R35 
Paraffin-
embedded 
Collagenase-injected newt leg, 40 days after 
injury 
Leg, 
newt 
ColTest2-
2L35 
Paraffin-
embedded 
Buffer-injected control newt leg, 40 days after 
injury 
Bone, 
human 
RA348 
Paraffin-
embedded 
Bone tissue derived from RA patients during 
joint replacement surgery 
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2.11  List of cells and cell lines  
Table 13: List of cells and cell lines 
Name Species Source 
B1H1  
N. viridescens 
viridescens 
Kindly provided by Prof. Jeremy Brockes from 
University College London, UK 
Chondrocytes 
N. viridescens 
 viridescens 
Isolated by Carina Schreiyäck during this 
doctoral work 
A1 
N. viridescens  
viridescens 
Kindly provided by Prof. Jeremy Brockes from 
University College London, UK 
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3 Methods 
3.1 Animal models of OA and differential expression analysis with 
cDNA microarray 
Experiments established for this section were performed by Dr. med. Matthias Geyer. 
Carina Schreiyäck, Dr. rer. nat. Thilo Borchardt, Dr. rer. nat. Mario Looso and Prof. Dr. med. 
Robert Dinser. In these experiments, two OA models were used in newts. The first was an 
intra-articular injection of collagenase into the newt right knee joint which caused knee joint 
instability leading to artificial OA (Geyer et al., 2010). The second model was surgically 
induced OA. In this model, the right knee of the newt was opened by transverse section in 
the skin. Afterwards, femoral cartilage was removed with a scalpel. Finally, the lesion was 
sealed with tissue glue (Histoacryl®). The left knees of the animals were slightly opened and 
closed with tissue glue to serve as control. The newts were sacrificed at 9–47 days after 
knee surgery or collagenase injection. The treated as well as the control legs were removed 
after sacrificing the animals. The tissues were embedded in paraffin and were used for the 
present study.  
The initial microarray analysis was performed by Dr. med. Matthias Geyer and Prof. 
Dr. med. Robert Dinser. For this study, 5 animals from each of the OA models were 
sacrificed. Their knees, treated as well as the control, were removed and pooled into two 
groups. The first group consisted of treated or untreated knees from two animals (pool A), 
respectively. The second group consisted of treated or untreated knees from three animals 
(pool B), respectively. The RNA was isolated from those knees and cDNA was generated. 
The cDNA was labeled and cDNA microarray was performed in the Max Planck Institute for 
Heart and Lung Research, Bad Nauheim, Germany. Dr. med. Matthias Geyer and Prof. Dr. 
med. Robert Dinser performed the evaluation of the cDNA microarray generated data which 
were used for the present study.  
3.2 Preparation of newt knee joint paraffin tissue 
Preparation of newt knee joint paraffin tissues was performed in order to provide 
samples for histological analysis including IHC and H&E, Pappenheim, and Safranin-O 
staining. The preparation of paraffin tissues used in this doctoral work, were performed by 
Carina Schreiyäck (technical assistant).  
The preparation of the newt knee joint paraffin tissues was performed according to 
the following method: The animals were anesthetized. Then, they were sacrificed and the 
legs were cut with scalpel. Afterwards, the legs were preserved by incubation in 4% 
paraformaldehyde or formaldehyde overnight at RT. On the following day, the knee joints 
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were washed twice with 1xPBS, at RT, each for 5 min. Because the tissues contained bony 
components, decalcification was performed by incubation in 20% (w/v) Na2EDTA for 2 weeks 
at RT. Then, the tissues were washed two times with 1xPBS at RT for 5 min. Thereafter, 
dewatering of the sample was performed by incubating them in ascending dilution series of 
ethanol, which was dissolved in 1xPBS (e.g. 50% for 30 min, 75% for 60 min, 96% for  
90 min, 100% for 90 min, and 100% overnight) at RT. Afterwards, the knee joints were rinsed 
two times with xylene for 45 min at RT. Afterwards, the knee joint tissues were incubated in a 
solution containing 50% (v/v) of ethanol and paraffin for 1 hr at 60°C. Thereafter, they were 
incubated another three times in paraffin for 1 hr. Then, the tissues were incubated in a 
paraffin solution for 12 hr at 60°C. Finally, the casting of paraffin block for the tissues was 
performed, and then kept at RT or 4°C for further use.  
3.3 Cell biological methods 
3.3.1 Pre-coating of culture plates/flasks with gelatin  
In order to culture newt cells, the cultured plates/flasks were pre-coated with gelatin 
to allow adhesion of newt-derived cells. Two percent (w/v) gelatin was diluted in aPBS and 
then sterile-filtered. The gelatin solution was incubated in a cell culture flask/plate for at least 
5 min and discarded before using the container for cultivating newt-derived cells.  
3.3.2 Quantification of cells 
To determine the cell numbers, the cells were resuspended in PBS, mixed with trypan 
blue and incubated for 2 min. The unstained cells were counted in a Neubauer-improved 
chamber. The cell concentration (cells/ml) was determined using the formula: average 
counted cell number x 104. 
3.3.3 Isolation of primary newt chondrocytes  
The isolation of the primary newt chondrocytes was performed by Carina Schreiyäck 
for this doctoral work. In order to obtain these cells, first, the newts were submerged in 
disinfection solution containing 0.5% sulfamerazine overnight at RT in order to prevent 
bacterial contamination. Afterwards, the animals were anesthetized. Thereafter, by means of 
surgery, cartilage tissues from several joints such as thigh, hip, and shoulder were isolated 
and collected in aDMEM/Ham’s F12 culture medium. Subsequently, in order to release the 
cartilage cells from their ECM, the tissue was incubated with 0.5% (w/v) pronase diluted in 
primary newt chondrocytes medium + 5% (v/v) FCS for 1.5 hr at 25°C. Later on, the cells 
were washed with aPBS. The rest of the ECM component was digested with 1 ml of 0.5% 
(w/v) collagenase P diluted in primary newt chondrocytes medium + 5% (v/v) FCS overnight 
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at 25°C. Thereafter, the cells were separated from the degraded ECM component product by 
filtration using a cell strainer (100 µm), and then the filtrate was purified again with another 
cell strainer (70 µm). Afterwards, the primary newt chondrocytes were washed 2-3 times in 
the culture medium. Later, the number of the viable cells was counted in a Naubauer 
chamber with trypan blue staining (see Section 3.3.2). Then, the chondrocytes were 
cultivated in several wells of a gelatin pre-coated 96 well-plate at 25°C.  
3.3.4 Culture of newt cell lines 
Primary newt chondrocytes, A1 cells and B1H1 newt cells were cultivated in 
monolayers with their respective culture medium as described in Section 2.3. in the gelatin 
pre-coated cell culture flasks and incubated at 25°C without CO2 supplementation. After 
achieving confluency, cells were detached with 0.5 mg/ml trypsin, 0.22 mg/ml EDTA in aPBS 
and then seeded into two flasks (1:2) and further cultured. 
3.4 Molecular biological methods 
3.4.1 RNA isolation 
RNA isolation from newt cell lines was done with the RNeasyPlus Micro Kit due to the 
low amount of the available cells. RNA was isolated according to the manufacturer’s 
instructions. The RNA concentration was determined with a Nanodrop® photometer. The 
RNA was stored at -80°C until further use. 
RNA isolation from newt organs/tissues was done with the TRIzol® reagent. Frozen 
newt organs/tissues were put on ice. RNase-free small metal balls and 1 ml TRIzol® reagent 
were added in the newt organ/tissue. Afterwards, the tissue was grinded by rigorous shaking 
in a swing mill MM 301 at 30 cycles/sec for 5 min. Then, the RNA was extracted according to 
manufacturer’s instructions. The RNA was quantified with Nanodrop® photometer and then 
stored at -80°C until further use.  
3.4.2 Reverse transcription 
500 or 1000 ng of purified RNA samples were transcribed to cDNA using the reverse 
transcriptase kit (Superscript® II Reverse Transcriptase) according to the manufacturer’s 
instructions. The cDNA was stored at -20°C until further use. 
3.4.3 Real-time PCR 
The relative quantification of gene expression was done with real-time PCR. The list 
of the genes and primers can be found in Section 2.7. The RNAs used were kindly provided 
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by Dr. med. Matthias Geyer and corresponded to the RNA used for the microarray 
experiment as described in Section 3.1. The RNA was transcribed to cDNA with method 
described in Section 3.4.2. Real-time PCR quantification was done with the QuantiTect 
SYBR® Green PCR kit or ABSOLUTE™ QPCR SYBR® Green mix kit with reaction mixture 
as follows:  
 
Real-time PCR mixture  
SYBR Green mix  1x 
cDNA 2 µl  
Forward primer 0.5 µM 
Reverse primer 0.5 µM 
MgCl2 (2.5 mM – 4.0 mM) for Quantitect™ SYBR® Green PCR Kit 
 (3.0 mM – 5.0 mM) for ABSOLUTE™ QPCR SYBR® Green Mixes 
Final volume 20 µl 
The PCR reactions were centrifuged with a LightCycler® 1.5 Carousel centrifuge. 
Afterwards, the samples were transferred to the LightCycler® Instrument and the following 
program was applied: 
95°C 15 min Initial denaturation  
95°C 15 sec Denaturation  
X °C2 35 sec Annealing         40-50 cycles 
72°C 30 sec Elongation and fluorescence acquisition  
 
During the amplification, SYBR® Green dye intercalated into the newly generated 
double-stranded DNA (dsDNA). The fluorescence signal was measured at the end of the 
elongation phase. As the amplification proceeded, the number of the dsDNA product 
increased. The increase of the PCR product was reflected by the increase of the 
fluorescence signal. In conclusion, the amount of PCR product was proportional to the 
intensity of the fluorescence signal which was measured at the end of the elongation phase. 
Cycle threshold (Ct) was defined as the number of amplification cycles required for the 
fluorescence signal intensity exceeding the background level. The lower the concentration of 
the starting DNA template, the longer the fluorescence signal exceeded the background 
levels hence the higher the Ct value. Amplification using a constant ratio of serial DNA 
dilutions yielded a constant increment of the Ct value and a linear standard curve was 
formed. The gradient/slope of the standard curve was available for the calculation of the 
efficiency of the PCR. The Ct value, the standard curve and the slope value were determined 
                                                 
2
 The annealing temperatures of each primer set are listed in Section 2.7. 
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using the LightCycler® software. Afterwards, the amplification efficiency was deducted from 
the slope by the following formula: Amplification efficiency (E) = 10(-1/slope). In order to perform 
a valid relative quantification using real-time PCR, the amplification efficiency had to be 2 ± 
0.05. Real-time PCR conditions (annealing temperature and magnesium chloride (MgCl2) 
concentration) for each primer pair were optimized to perform a valid and reproducible 
relative quantification of the selected candidate genes.  
 
Real-time PCR optimization  
For each primer pair, two real-time PCR parameters were optimized: the annealing 
temperature and the MgCl2 concentration. To determine the optimal MgCl2 concentration, 
serial DNA dilutions as template were prepared (e.g. 1:5, 1:15, 1:45, and 1:135), then the 
PCR using the serial DNA dilutions for each MgCl2 concentration (e.g. 2.5 mM, 3.0 mM,  
3.5 mM, 4.0 mM and 4.5 mM) for different annealing temperatures (e.g. 54°C, 56°C, 58°C, 
and 60°C) were performed to achieve the above mentioned PCR efficiencies of E= 2 ± 0.05. 
 
Evaluation of amplification specificity 
The specificity of the primer pairs was analyzed with a melting curve analysis. This 
melting curve analysis was done directly after the DNA amplification. In the melting curve 
analysis, the dsDNA was denatured by increasing the temperature continuously from 50°C to 
99°C. As the dsDNA denatured, the intercalated SYBR Green dye was released, and the 
fluorescence signal decreased. The PCR product has a specific melting temperature, which 
can be differentiated from unspecific PCR products or primer dimer formation. If the melting 
curve analysis showed two or more peaks, the relative quantification could not be evaluated.  
 
Relative quantification real-time PCR (Ct) 
Real-time PCR experiments were performed with their optimized MgCl2 concentration 
and annealing temperature. Each primer pair was amplified in parallel to a primer pair of a 
reference gene (newt ribosomal protein S21). Each PCR was performed in triplicates and the 
average Ct values were generated. Ct was calculated by subtracting the average Ct values 
of candidate genes with the average Ct values of reference gene. The standard deviation of 
Ct was calculated according to the following formula:  
Std. deviation CT = ((Std. deviation CT sample)
2 + (Std. deviation CT reference 
gene)2)1/2 
Standard deviation of Ct is a measure of dispersion the Ct values around the 
average Ct value.  
CTs were calculated by subtracting CT of the sample with CT of the reference 
sample (e.g. untreated control). The standard deviation values of CT (S) were the same 
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as the standard deviation of the CT of the sample. The difference between the samples was 
evaluated using the following formula: 
 
Fold change = 2-CT± S 
3.5 Histological and immunological methods  
3.5.1 Tissue section preparation 
Five µm thick paraffin tissue sections were prepared from paraffin-embedded tissues 
using a microtome (Microm HM 340 E Cool-Cut). The tissue sections were mounted on 
microscope slides, and dried in a 37°C incubator overnight. They were stored at RT until 
further use. 
3.5.2 Pappenheim staining  
Pappenheim staining was used to visualize articular cartilage content in the newt 
knee joint specimen. The staining process was based on combination of a May-Gruenwald 
and a Giemsa staining solution. With the Pappenheim staining, the cartilage area was 
stained violet.  
Paraffin-embedded tissues were incubated in xylene for 10 min twice to dissolve the 
paraffin component. Afterwards, the tissues were hydrated by incubating the tissues with a 
serial incubation of 100% and 96% ethanol each for 10 min. The hydration process was 
continued by incubating the tissues with 80%, 70%, and 50% ethanol each for 5 min. After 
washing the ethanol remnant by incubating the tissues in PBS for 5 min, the tissues were 
incubated with May-Gruenwald solution for 5 min. The May-Gruenwald remnant was washed 
with PBS for 2 min. Afterwards, the tissues were incubated with Giemsa staining solution for 
15 min. The Giemsa staining solution was prepared by diluting the Giemsa stock solution 
with PBS (1:10). Then, the remaining staining solution in the tissues was washed with PBS 
for 5 min. Thereafter, the tissues were acidified with 1% (v/v) acetic acid for 30 sec. In order 
to stabilize the tissues for microscopy observation, the tissues were dehydrated and 
mounted. Dehydration of the tissues was performed by incubation with serial dilution of 
ethanol (e.g. 96% and 100%) each for 2 min. The tissues were incubated with xylene twice 
each for 2 min. Finally, they were mounted with Entellan®.  
3.5.3 Safranin-O staining  
Safranin-O staining was used to visualize articular cartilage content in newt knee joint 
specimen. The staining process was based on a combination of Weigert solution, Fast Green 
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(FCF) solution, and Safranin-O. With the Safranin-O staining, the cartilage area was stained 
red/pink.  
Paraffin-embedded tissues were incubated in xylene for 10 min twice to dissolve the 
paraffin component. Thereafter, the tissues were hydrated by incubating the tissues with 
descending ethanol series of 100% and 96% ethanol each for 10 min. The hydration process 
was continued by incubation the tissues with descending ethanol series of 80%, 70%, and 
50% ethanol each for 5 min. After washing the tissues in PBS for 5 min, they were incubated 
in Weigert solution for 10 min. Thereafter, the tissues were washed with tap water for 10 min. 
Then, the tissues were stained with 0.05% (w/v) Fast Green (FCF) solution for 5 min. 
Thereafter, the tissues were stained with 1% (v/v) acetic acid for 10 sec. Subsequently, the 
tissues were stained with 0.1% (w/v) Safranin-O solution for 5 min. In order to stabilize the 
tissues for microscopic examination, the tissues were dehydrated in an ascending ethanol 
series and xylene. Finally, the tissues were mounted in Entellan®.  
3.5.4 Hematoxylin and Eosin staining  
Hematoxylin and eosin staining was used for tissue overview. Nuclei were stained 
blue (hematoxylin), cytoplasm and extracellular matrix pink (based on the affinity to the eosin 
dye). Deparaffinization of paraffin-embedded sections was done by incubating the sections 
twice in xylene for 10 min. To restore the water saturation, the tissue sections were 
incubated in decreasing ethanol concentrations (100%, 96%, and 70% in distilled water) 
each for 5 min each. Afterwards, the sections were incubated in PBS for 5 min. Then, the 
sections were incubated in hematoxylin solution (described in Section 2.3) for 7 min and then 
washed with tap water for 1 min. Subsequently, the sections were incubated in eosin solution 
(described in Section 2.3) for 7 min, then washed again with tap water. To dehydrate the 
tissue sections, they were incubated in an ascending series of different ethanol dilutions 
(50%, 70%, 96% and 100%) for 5 min each. At the end, the tissue sections were mounted in 
Entellan®.  
3.5.5 Immunohistochemistry 
Immunohistochemistry (IHC) is an immunological technique to identify and visualize 
target antigens in a tissue section. A given target molecule antigen is visualized by using a 
specific primary antibody and an appropriate secondary antibody tagged with either a 
fluorescent label or an enzymatic tag (Coons et al., 1942). Used primary antibodies are listed 
in Section 2.5. 
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3.5.5.1 IHC using paraffin-embedded tissue sections 
Five µm thick paraffin-embedded joint sections (described in Section 2.10) were 
deparaffinized by incubating them in xylene and a descending ethanol series (100%, 96%, 
and 70% ethanol). The pH and isotonic level of the sections were adjusted and equilibrated 
with PBS for 5 min. Due to fixation with formaldehyde or paraformaldehyde prior to 
embedding the tissue in paraffin, the antigen/epitope as binding site for the primary antibody 
is often blocked. Antigen/epitope retrieval is required in order to give access for the antibody 
reaction with the antigen. Here, antigen retrieval was conducted with 10 µg/ml proteinase K 
diluted in TE buffer pH 8.0 (see Section 2.3) for 5 min at 37°C. To increase the proteolytic 
capacity of the enzyme, a pre-incubation of the proteinase K solution at 37°C was carried out 
for at least 30 min before it was applied to the slides. The proteolytic activity of proteinase K 
was then stopped by incubating the sections in PBS for 5 min. 3-amino-9-ethylcarbazole 
(AEC) was used as chemiluminescent detection reagent. Thus, endogenous peroxidase 
activity within the tissue sample needed to be inhibited by incubating the section in 3% H2O2 
in methanol for 10 min at 4°C. Afterwards, the sections were washed twice with PBS for 
5 min. Unspecific binding of the antibody was blocked by incubating the tissue sections with  
40 µl to 200 µl (based on the size of the tissue on the slide) of blocking reagent (see Section 
2.5). Incubation with the primary antibody (see Section 2.5) was either performed at RT for  
1 hr or overnight at 4°C (conditions depending on the primary antibody as described in 
Section 2.5). Afterwards, the unbound antibody was removed by incubating the tissue 
section three times for 5 min each in washing buffer composed of PBS or PBS supplemented 
with 0.5% Triton X-100 (see Section 2.5). Afterwards, the secondary antibody (as described 
in Section 2.5) was added to the section followed by an incubation for at least 10 or 30 min 
(see Section 2.5). The non-bound secondary antibody was removed by washing three times 
with PBS for 5 min each. Afterwards, the immunoreaction of the antibody was developed by 
adding 3-amino-9-ethylcarbazole (AEC kit) to the tissue section. The emerging pink or red 
signal was observed under a transmitted-light microscope. When the signal intensity was 
clearly visible without background staining, the chemoluminescent reaction was stopped by 
incubating the slides in PBS. Finally, the sections were mounted with Kaiser’s glycerol 
gelatine. 
3.5.5.2 IHC stainings to evaluate TN-C expression during newt knee joint 
regeneration in the collagenase and surgery model 
IHC stainings of regenerating newt knee joints after 10, 20, and 40 days of 
collagenase- and surgically-induced OA are performed using protocol as mentioned in 
Section 3.5.5.1. For each time point of the collagenase model, IHCs were performed with 
knee joint sections from two animals (n=2) and for each time point of the surgery model, the 
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experiments were performed with knee joint sections of three animals (n=3). For illustration, 
only one representative picture for each time point in both OA models is presented in Section 
4.2.2 for collagenase model and Section 4.2.3 for surgery model. A summary of TN-C 
expression based on all of the IHC results is presented in Section 4.5. 
3.6 Knockdown experiments using endoribonuclease-prepared 
small interfering RNAs 
Small interfering RNAs (siRNAs) are a collection of short RNA molecules (20-25 
bases) which bind to mRNA of a specific gene transcript and block the protein expression 
(Hamilton et al., 1999; Elbashir et al., 2001).  
For our experiments, TN-C-specific siRNAs were introduced into primary newt 
chondrocytes. For this purpose, a custom-made TN-C siRNA pool was generated. The TN-C 
siRNA was derived from a RNAse III digested 560-bp-TN-C-dsRNA fragment. This siRNA is 
called endoribonuclease-prepared siRNA (esiRNA). The preparation of the esiRNA was 
based on modification of the work which was reported elsewhere (Yang et al., 2002). TN-C 
esiRNA was designed from the newt’s TN-C sequence data (TransID7000), which was kindly 
provided by Dr. rer. nat. Mario Looso and Dr. rer. nat Thilo Borchardt from the Max Planck 
Institute for Heart and Lung Research, Bad Nauheim, Germany. Synthesis of TN-C esiRNA 
was done with the help of BLOCK-iT RNAi TOPO Transcription Kit and ShortCut® RNase III 
as shown in Figure 11.  
As control, lacZ esiRNA was generated. lacZ is a gene in enteric bacteria (e.g. 
Escherichia coli). It encodes β-galactosidase which hydrolyzes the disaccharide lactose into 
glucose and galactose. lacZ is not present in the newt’s genome and, thus, is a suitable 
control.  
The TN-C and lacZ esiRNA were introduced into newt chondrocytes using 
nucleofection, and the knockdown was determined with relative quantification using real-time 
PCR. 
Methods 
 46 
 
 
Figure 11: esiRNA generation using BLOCK-iT RNAi TOPO Transcription Kit and RNAse III.(A) A 
primer pair (siTN-C forward and siTN-C reverse) was used to amplify a 560 bp newt TN-C cDNA 
product which was located 100 bp downstream of the start codon. (B) The 5’- and 3’- terminal of PCR 
product was then linked to the Block-iT T7 linker coupled with topoisomerase enzyme (TOPO).        
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(C) Afterwards, the secondary PCR was done with Block-iT T7 primer and siTN-C reverse to produce 
the sense DNA template. Antisense DNA template was produced by performing PCR of the linking 
reaction product with siTN-C forward and Block-iT T7 primer. (D) Sense RNA and antisense RNA 
products were synthesized by conducting in-vitro transcription of sense DNA template and antisense 
DNA template, respectively. (E) The sense RNA and the antisense RNA products were purified and 
annealed to produce dsRNA, then (F) the dsRNA was digested with RNAse III to produce (G) 21 bp 
TN-C siRNA. 
3.6.1 Generating TN-C and negative control lacZ esiRNA 
In order to synthesize TN-C esiRNA, a 560 bp DNA fragment, which was located  
100 bp downstream of the newt TN-C start codon, was amplified from a newt chondrocyte-
derived cDNA template using siTN-C-F and siTN-C-R primers (the resulting DNA fragment is 
presented in Figure 12, lane B). For lacZ control esiRNA, a 1000 bp DNA fragment was 
amplified from plasmid containing lacZ (pcDNA™ 1.2/V5-GW/lacZ) with primers lacZ-forward 
and lacZ-reverse (Figure 12, lane C). The plasmid and lacZ primers were components of the 
kit. Both amplifications were prepared according to the following protocol: 
Taq DNA Polymerase master mix  2.5 U/reaction 
10 µM siTN-C-F or 10 µM lacZ forward  0.2 µM or 1.3 ng/µl 
10 µM siTN-C-R or 10 µM lacZ reverse  0.2 µM or 1.3 ng/µl 
cDNA template   1 µl 
Final reaction volume  40 µl 
The PCR reaction was done in a thermo cycler (GeneAmp PCR System 9700), with a 
reaction program as follows: 
94°C 3 min Initial denaturation  
94°C 30 sec Denaturation  
55°C 30 sec Annealing  
72°C 1 min Elongation   
72°C 10 min Final elongation  
 
In order to evaluate the specificity of the amplification product, the PCR product was 
mixed with PCR loading buffer and run on a 1.5% (w/v) high-resolution agarose gel 
submerged in TAE buffer. A 100 bp DNA ladder was used. The gel was run by applying a 
constant voltage of 100 V for approximately 1 hr. The separated DNA was stained by 
incubating the agarose gel in ethidium bromide solution and visualized using a UV 
transilluminator. 
35 cycles 
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Figure 12: Primary amplification products of newt TN-C (lane A) and lacZ (lane B) 
 
The amplification product was linked with a DNA linker containing T7 promoter 
through a bound-topoisomerase catalyzed linking reaction. The linking reaction mixture was 
composed of 3 µl of supplied sterile water, 1 µl of supplied salt solution, 1 µl of Block-iT T7 
TOPO® linker, and 1 µl of PCR product. The reaction mixture was accomplished by 
incubating the mixture at 37°C for 15 min. 
In order to provide antisense and sense DNA template for in-vitro transcription, two 
parallel amplifications with each DNA template TN-C and lacZ fragment-linked Block-iT T7 
TOPO® linker were performed. The amplification reaction mixtures were prepared as follows:  
 
Reaction mixture to provide DNA template for generation of antisense TN-C ssRNA 
Taq DNA Polymerase master mix 2.5 U/reaction 
75 ng/µl Block-iT™ T7 primer  1.5 ng/µl 
10 µM siTN-C-forward 0.5 µM 
TN-C TOPO linking reaction product 1 µl 
Final reaction volume 40 µl  
 
Reaction mixture to provide DNA template for generation of sense TN-C ssRNA 
Taq DNA Polymerase master mix 2.5 U/reaction 
75 ng/µl Block-iT™ T7 primer 1.5 ng/µl 
10 µM siTN-C-reverse 0.5 µM 
TN-C TOPO linking reaction product  1 µl 
Final reaction volume  40 µl 
 
Reaction mixture to provide DNA template for generation of antisense lacZ ssRNA 
Taq DNA Polymerase master mix 2.5 U/reaction 
75 ng/µl Block-iT™ T7 primer  1.5 ng/µl 
65 ng/µl lacZ-forward 3.25 ng/µl 
lacZ TOPO linking reaction product 1 µl 
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Final reaction volume 40 µl 
 
Reaction mixture to provide DNA template for generation of sense lacZ ssRNA 
Taq DNA Polymerase master mix 2.5 U/reaction 
75 ng/µl Block-iT™ T7 primer  1.5 ng/µl 
65 ng/µl lacZ-reverse 3.25 ng/µl 
lacZ TOPO linking reaction product 1 µl 
Final reaction volume 40 µl 
 
The PCR reactions were done in a thermo cycler (GeneAmp PCR System 9700), with 
a reaction program as follows:  
 
95°C 15 min Initial denaturation  
94°C 30 sec Denaturation  
55°C 30 sec Annealing  
72°C 1 min Elongation   
72°C 10 min Final elongation  
 
The amplification product resulted in generation of antisense and sense TN-C cDNA 
template (Figure 13, lane A, B), and antisense and sense lacZ cDNA template (Figure 13, 
lane C, D) respectively. 
 
 
Figure 13: Secondary amplification products of newt TN-C (lane A, B) and lacZ (lane C, D) 
 
The expected amplification reaction product was purified with Qiaquick Gel Extraction 
Kit according to the manufacturer’s protocol.  
35 cycles 
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Afterwards, RNA transcription reactions were performed with the four purified reaction 
products to synthesize ssRNA of sense and antisense of TN-C and lacZ RNA according to 
the BLOCK-iTRNAi TOPO Transcription Kit instruction.  
Then, BLOCK-iT™ RNA Purification Kit was used to purify the RNA transcript 
products. The purification was performed by following the manufacturer’s instructions. The 
concentration and quality of purified ssRNA were determined by a Nanodrop® 
spectrophotometer.  
In order to generate dsRNA, 10 µg of each sense and antisense ssRNA of TN-C and 
lacZ were mixed and the mixtures were incubated in pre-boiled 250 ml of water in a 500 ml 
beaker glass and cooled slowly to RT for at least 2 hr. 
esiRNA was generated using ShortCut®RNase III. The enzyme converts long dsRNA 
of TN-C and lacZ into 21-bp TN-C (lane A, Figure 14) and lacZ (lane B, Figure 14) esiRNAs 
respectively. The reaction was performed according to the manufacturer’s instructions.  
 
 
Figure 14: Polyacrylamide gel electrophoresis of (I) TN-C and (J) lacZ esiRNA showed RNA 
bands of 21 bp. 
3.6.2 Purification of esiRNA product 
The esiRNA products were mixed with 73 mMRNase-free sodium acetate pH 5.5, 
0.8% (v/v) RNase-free glycogen and 70% RNase-free ethanol. To induce RNA precipitation, 
the mixture was incubated at -20°C for 2 hr. Then, the RNA was spun 20817xg for 15 min at 
RT to obtain a RNA pellet. The RNA pellet was washed with 120 µl of 80% (v/v) RNase-free 
ethanol by incubation at RT for 10 min. The ethanol was discarded by removing the ethanol 
after centrifugation at 20817xg for 5 min at RT. The RNA pellet was air-dried for 10 to  
15 min. The RNA pellet was dissolved in 20 µl of RNase-free double-distilled water and 
stored at -80°C until further use. 
3.6.3 Evaluation of esiRNA quality  
Polyacrylamide gel electrophoresis (PAGE) can be applied for RNA detection and 
quality assessment. Polyacrylamide was chosen instead of agarose because polyacrylamide 
gel pore diameter is smaller compared to the one of agarose gels, which allows 
A B 
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differentiation of RNAs at the single nucleotide level (Alberts,. 2002). The protocol of RNA 
PAGE was adapted from a previous study (Rio et al., 2010).  
 
Preparing RNA polyacrylamide gel : 
Urea  48% (w/v) 
40% acrylamide/bis (19:1)  6% (v/v) 
10x TBE buffer 1x  
DEPC-treated ddH2O up to 30 ml  
The gel mixture was incubated in hot water to accelerate urea dissolution. After the 
urea was dissolved, the mixture was cooled down to RT, then the following reagents were 
added to the mixture sequentially: 
10% ammonium persulfate 0.9% (w/v) 
Tetramethylethylenediamine 0.08% (v/v)  
After polymerization was completed, the gel was pre-run (without sample) at 118 V for 
45 min in order to remove excess persulfate. Afterwards, the RNA sample was mixed with 
RNA loading buffer (see Section 2.3), the mixture was heated at 95°C for 5 min and then 
directly chilled on ice to denature RNA secondary structure. The gel was run by applying a 
constant voltage of 118 V.  
In order to visualize the RNA, the gel was incubated in SYBR® Gold nucleic acid gel 
stain dissolved in TBE buffer pH 7.8. The incubation was performed under light agitation in 
the absence of light for 40 min. Finally, the RNA was visualized in an UV transilluminator.  
3.6.4 Knockdown of TN-C expression in primary newt chondrocytes 
In order to knockdown the TN-C expression in primary newt chondrocytes, TN-C and 
lacZ esiRNA (negative control) were introduced into the cells by nucleofection using Human 
Chondrocyte Nucleofector™ Kit (Lonza).  
3.6.4.1 Introduction of esiRNA into primary newt chondrocytes  
In order to obtain reliable results, the nucleofection experiment was performed two 
times. Both experiments employed the same protocol. The differences between them were 
the number of the nucleofected primary newt chondrocytes. The first experiment used 
400000 cells/nucleofected esiRNA and the second employed 725000.cells/nucleofected 
esiRNA.  
In order to prepare the cells for the nucleofection experiment, the newt chondrocytes 
were incubated with culture medium supplemented with 5 U of hyaluronidase at 25°C 
overnight. 
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On the next day, the cells were washed with aPBS and detached with 0.5 mg/ml 
trypsin, 0.22 mg/ml EDTA in aPBS at RT. Two cell pellets, each containing 400000 cells (first 
experiment) or 725000 cells (second experiment), were prepared by centrifugation of the 
detached chondrocytes with 300xg for 10 min at RT. 
Introduction of TN-C esiRNA into the primary newt chondrocytes was performed by 
mixing a cell pellet with 100 µl of nucleofector final solution and 257.62 ng (20 pmole) of 
TN-C esiRNA. The mixtures were transferred to cuvettes and then the introduction of esiRNA 
in the cells was conducted in the nucleofector instrument with program T-023. Shortly after 
treatment, the chondrocytes were dissolved in 1 ml of culture medium. Afterwards, 
introduction of 257.62 ng (20 pmole) of lacZ esiRNA into the primary newt chondrocytes was 
performed according to the same protocol. 
The nucleofected cells were then incubated at 25°C on 2% gelatin pre-coated 6 well-
plates (first experiment) or 12 well-plates (second experiment) for RNA isolation to evaluate 
the knockdown of TN-C mRNA expression. In the second experiment, adhesion and scrape 
motility assays were performed after esiRNA nucleofection to evaluate the effect of TN-C 
knockdown on adherence and migration behavior of newt chondrocytes. Thus, 300000 
nucleofected cells were seeded to 6 well-plates to perform these assays.  
3.6.5 Scrape motility assay 
The scrape motility assay required a confluent cell monolayer. Therefore, 24 hr after 
nucleofection, 30000 TN-C and lacZ esiRNA nucleofected cells from the 6 well-plates were 
detached and seeded onto two wells of a 24 well-plates pre-coated with 2% (w/v) gelatin. 
Thereafter, the newt chondrocytes were grown for 24 hr to form a confluent monolayer. 
Then, a defined area in the cell monolayer was uncovered by creating a straight line through 
the cell layer with a pipette tip. Afterwards, the cell debris was washed with aPBS and the 
remaining cells were incubated in 25°C for 12 hr. The migrated cells were investigated by 
taking images in defined areas of uncovered cell monolayer using phase-contrast 
microscope (Figure 15). For each nucleofected cells, the migrated cells in the two defined 
areas of two wells were calculated. 2 – 3 defined areas were selected for the image 
acquisition. The image acquisition was repeated every 2 hr until 22 hr of incubation time. The 
cells, which were migrated into two defined scraped area of each wells, were counted. 
Thereafter, the average and the standard deviation were calculated.  
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Figure 15: The process of the newt chondrocytes migration in the scrape motility assay. The cell 
monolayer was scratched with a pipett tip to form straight line of uncover cell layer (0 hr). After 12 hr, a 
movement of the cells were detected (12 hr). Finally, at 22 hr, the uncover area was closed by the 
migrated chondrocytes. 
3.6.6 Adhesion assay 
Confluent primary newt chondrocytes were detached with accutase. Afterwards, each 
of 15000 TN-C and lacZ esiRNA nucleofected cells were seeded on the three wells of 24 
well-plates pre-coated with 2% (w/v) gelatin. Subsequently, the plate was incubated under 
light shaking in a water-bath with water temperature of 22°C for 1 hr. During this incubation, 
the plate was positioned just above the water surface. Thereafter, culture medium was 
aspirated and the plate was washed with aPBS to discard the non-adherent cells. Then, the 
attached chondrocytes were stained with crystal violet for 5 min. Then, the number of cells 
which had adhered to the bottom of the plate of each well was counted. Thereafter, the 
average cell number and the standard deviation were calculated. 
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4 Results 
The cDNA microarray experiments were performed with regenerating newt knee 
joints after collagenase- and surgically-induced knee joint damage. The deregulated 
candidate genes, which were known to be involved in tissue repair and regeneration, were 
selected for further investigation. In addition, distinct candidate genes of the innate immune 
system and vitamin A biosynthesis, which were related to the cDNA microarray study, and 
supposed to be linked to the candidate genes collection. Afterwards, the deregulation of 
these genes was evaluated with relative quantification using real-time PCR.  
4.1 Relative quantification of selected candidate genes  
The quantification of gene expression of the candidate genes was calculated based 
on Ct (see Section 3.4.3). The complete results of the relative quantification of all 18 
genes are presented in appendix (section 9.4). The key of the matricellular proteins (e.g.  
TN-C, SPARC, POSTN, and DCN), the innate-immune system (e.g. CFB and TLR2), and the 
vitamin A pathway (e.g. RARRES1) are presented in this section.  
In the relative gene expression quantification, a gene was assigned to be upregulated 
when the deregulation value was higher than 2.0-fold, unregulated when the deregulation 
value was between 2.0 – 0.5-fold and downregulated when the deregulation value was 
between 0.5 – 0.0-fold. 
There were some value differences in the candidate genes between the 2-pool (pool 
A) and the 3-pool animals (pool B). These discrepancies between the both pools might be 
explained by different degrees of knee joint damage. 
4.1.1 Relative quantification of selected candidate genes of matricellular 
proteins 
4.1.1.1 Relative quantification of TN-C 
TN-C was selected because TN-C is known to be expressed during limb regeneration 
and limb development (Onda et al., 1990; Onda et al., 1991). An additional reason was the 
real-time PCR relative quantification of TN-C, which showed that TN-C was one of the 
strongly upregulated genes (upregulation value exceeded 5.0-fold, except on day 40 in the 
surgery model). 
In the collagenase model (Figure 16), the TN-C upregulation pattern was obviously 
different between pool A and B. In the pool A, the upregulation decreased from 22.4-fold on 
day 10 after treatment to 3.8-fold on day 40 after treatment. In contrast, in the pool B, the 
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upregulation value of TN-C expression was increased from 3.5-fold on day 10 after treatment 
to 12.2-fold on day 40 after treatment. 
In the surgery model, there were also obvious differences of the TN-C upregulation 
pattern between pool A and B. In the pool A, the TN-C upregulation decreased from 15.6-fold 
on day 10 after treatment to 10.1-fold on day 20 after treatment, then finally it returned to 
normal (1.2-fold) on day 40 after treatment. In contrast, the upregulation in the pool B 
increased from 12.3-fold on day 10 after treatment to 33.8-fold on day 20 after treatment, 
afterwards it decreased also to normal (0.7-fold) on day 40 after treatment.  
 
Figure 16: Relative quantification of TN-C during newt knee joint regeneration after collagenase 
and surgically-induced OA. The TN-C upregulation in pool A and B was analysed with real-time 
PCR relative to S21 ribosomal protein expression (normalisator gene) at day 10 (Coll D10) and at day 
40 (Coll D40) after collagenase-induced OA and at day 10 (OP D10), at day 20 (OP D20), and at day 
40 (OP D40) after surgically-induced OA. The presented values are the average of the x-fold change 
of TN-C mRNA expression and the standard deviation. 
. 
4.1.1.2  Relative quantification of SPARC 
SPARC was selected because SPARC is known to play important roles in bone 
development (Orlando et al., 2013) and is expressed in human knee joints in OA and 
rheumatoid arthritis (RA) (Nakamura et al., 1996).  
In the collagenase model, there was a different expression of SPARC expression 
between the pool A and B (Figure 17). On day 10 after treatment, SPARC was only 
upregulated in the pool A (2.1-fold), and unregulated in the pool B (1.4-fold). On day 40 after 
treatment, SPARC was only upregulated in the pool B (2.6-fold), and normal in the pool A 
(1.7-fold).  
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In the surgery model, the different SPARC expression between the pool A and B 
occurred only on day 10 after treatment. In the pool B, SPARC was upregulated (2.5-fold), 
but in the pool A, SPARC was normal (1.4-fold). On day 20 after treatment, SPARC was 
upregulated in both pools (3.4-fold in the pool A; 2.4-fold in the pool B). On day 40 after 
treatment, SPARC was not dysregulated in both models. 
 
Figure 17: Relative quantification of SPARC during newt knee joint regeneration after 
collagenase and surgically-induced OA. The SPARC upregulation in pool A and B was analysed 
with real-time PCR relative to S21 ribosomal protein expression with real-time PCR relative to S21 
ribosomal protein expression (normalisator gene) at day 10 (Coll D10) and at day 40 (Coll D40) after 
collagenase-induced OA and at day 10 (OP D10), at day 20 (OP D20), and at day 40 (OP D40) after 
surgically-induced OA. The presented values are the average of the x-fold change of SPARC mRNA 
expression and the standard deviation. 
4.1.1.3 Relative quantification of POSTN 
POSTN was examined because it promotes wound healing in murine skin (Elliot et 
al., 2012) and bone (Horiuchi et al., 1999).  
Relative quantification of POSTN expression is presented in Figure 18. In the 
collagenase model, there were some differences in expression between pool A and B. On 
day 10 after treatment, only the pool A showed that POSTN was upregulated (2.8-fold), 
whereas in the pool B, POSTN expression was normal (1.3-fold). Likewise, on day 40 after 
treatment, only in the pool B POSTN was upregulated (4.9-fold), whereas in the pool A, 
POSTN was not dysregulated (1.7-fold). 
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In the surgery model, POSTN was upregulated on day 10 after treatment (2.3-fold in 
the pool A; 3.3-fold in the pool B) and on day 20 after treatment (3.9-fold in the pool A and 
8.9-fold in the pool B). However, on day 40 after treatment, POSTN expression returned to 
normal (1.3-fold in the pool A; 0.7-fold in the pool B). 
 
 
Figure 18: Relative quantification of POSTN during newt knee joint regeneration after 
collagenase and surgically-induced OA. The POSTN upregulation in pool A and B was analysed 
with real-time PCR relative to S21 ribosomal protein expression (normalisator gene) at day 10 (Coll 
D10) and at day 40 (Coll D40) after collagenase-induced OA and at day 10 (OP D10), at day 20 (OP 
D20), and after 40 days (OP D40) surgically-induced OA. The presented values are the average of the 
x-fold change of POSTN mRNA expression and the standard deviation. 
4.1.1.4 Relative quantification of DCN 
DCN was examined because this protein is known to promote regeneration and 
repair in various tissues such as muscle (Li et al., 2007), skin (Shafritz et al., 1994), and 
tendon (Lu et al., 2013). 
Relative quantification of DCN in the regenerating knee joints in the newts is 
presented in Figure 19. In the collagenase model, the deregulation values of DCN 
expression 10 days after treatment opposed each other between the pool A and B. They 
were upregulated in the pool A (8.6-fold) but downregulated in the pool B (0.4-fold). On day 
40, DCN was slightly upregulated in the pool A (2.4-fold), whereas in the pool B, DCN was 
not dysregulated (1.7-fold).  
In the surgery model, DCN was upregulated only on day 20 after treatment (2.1-fold 
in 2-pool animals), whereas at the other time points, DCN was normal (deregulation value 
was not higher than 2.0). 
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Figure 19: Relative quantification of DCN during newt knee joint regeneration after collagenase- 
and surgically-induced OA. The DCN upregulation in pool A and B was analyzed with real-time PCR 
relative to S21 ribosomal protein expression (normalisator gene) at day 10 (Coll D10) and at day 40 
(Coll D40) after collagenase-induced OA, and at day 10 (OP D10), at day 20 (OP D20), and after 40 
(OP D40) surgically-induced OA. The presented values are the average of the x-fold change of DCN 
mRNA expression and the standard deviation. 
4.1.2 Relative quantification of candidate genes from innate immune system 
4.1.2.1 Relative quantification of CFB 
CFB was selected because complement components were expressed in the newt 
during regeneration of limbs after amputation and in regenerating lens vesicles after local 
eye injury (Kimura et al., 2003). In addition, based on real-time PCR relative quantification, 
CFB was strongly upregulated (deregulation value was higher than 5-fold) at day 10 and day 
20 in the surgery model.  
In both OA models, CFB was upregulated at all analyzed time points except in the 
pool A at day 40 of the collagenase model (Figure 20). In the collagenase model, at day 10 
after treatment, CFB was upregulated in both pools (4.5-fold in the pool A and 3.2-fold in the 
pool B). However, at day 40 after treatment, CFB was upregulated only in the pool B 
(4.9-fold), whereas in the pool A, CFB was not dysregulated (0.8-fold).  
In the surgery model, CFB was upregulated at all analyzed time points. However, the 
difference in values was large, for example at day 10 after treatment (11.8-fold in the pool A 
versus 4.5-fold in the pool B), and more prominent at day 20 after treatment (4.4-fold in the 
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pool A versus 23.6-fold in the pool B). At day 40 after treatment, the differences were less 
(5.2-fold in the pool A versus 6.9-fold in the pool B) in comparison to the previous time 
points. 
 
Figure 20: Relative quantification of CFB during newt knee joint regeneration after collagenase 
and surgically-induced OA. The CFB upregulation in pool A and B was analysed with real-time PCR  
relative to S21 ribosomal protein expression (normalisator gene) at day 10 (Coll D10) and at day 40 
(Coll D40) after collagenase-induced OA and at day 10 (OP D10), at day 20 (OP D20), and at day 40 
(OP D40) after surgically-induced OA. The presented values are the average of the x-fold change of 
CFB mRNA expression and the standard deviation. 
4.1.2.2 Relative quantification of TLR2 
TLR2 was included because of the involvement of TLR2 in regeneration and repair in 
various tissues (Brown et al., 2007). The result of relative quantification of TLR2 in the 
surgery model (Figure 21) showed that TLR2 was upregulated only at day 10 after treatment 
(8.9-fold in the pool A and 6.6-fold in the pool B). At day 20 after treatment, however, the 
TLR2 upregulation decreased (2.1-fold in the pool B) or became normal in the pool A  
(0.6-fold). Finally, at day 40 after treatment, TLR2 was normal (0.7-fold in the pool A and 
0.5-fold in the pool B). In the collagenase model, TLR2 seemed not to be activated during the 
regeneration process, because TLR2 was not found to be present at all time points.  
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Figure 21: Relative quantification of TLR2 during newt knee joint regeneration after collagenase 
and surgically-induced OA. The TLR2 upregulation in pool A and B was analysed with real-time 
PCR relative to S21 ribosomal protein expression (normalisator gene) at day 10 (Coll D10) and at day 
40 (Coll D40) after collagenase-induced OA and at day 10 (OP D10), at day 20 (OP D20), and at day 
40 (OP D40) after surgically-induced OA. The presented values are the average of the x-fold change 
of TLR2 mRNA expression and the standard deviation. 
4.1.3 Relative quantification of genes of the vitamin A pathway 
4.1.3.1 Relative quantification of RARRES1 
RARRES was included as it is involved in tissue proliferation and differentiation 
(Ohnishi et al., 2009). In addition, it was the only gene from the vitamin A pathway found to 
be upregulated in the cDNA microarray.  
The disagreement of deregulation values between the pool A and B was found to be 
pronounced in RARRES1 (Figure 22). In the collagenase model, at day 10 after treatment, 
RARRES1 was only upregulated in the pool A (4.6-fold), but not dysregulated in the pool B 
(1.7-fold). In the surgery model, at day 10 after treatment, RARRES1 was upregulated only in 
the pool A (2.7-fold) but normal in the pool B (1.0-fold). Likewise, at day 20 after treatment, 
the RARRES1 upregulation only occurred in the pool B (3.7-fold) but not in the pool A 
 (1.0-fold). At day 40 after treatment in both models, RARRES1 was normal again. 
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Figure 22: Relative quantification of RARRES1 during newt knee joint regeneration after 
collagenase and surgically-induced OA. The RARRES1 upregulation in pool A and B was analysed 
with real-time PCR relative to S21 ribosomal protein expression (normalisator gene) at day 10 (Coll 
D10) and at day 40 (Coll D40) after collagenase-induced OA and at day 10 (OP D10), at day 20 (OP 
D20), and at day 40 (OP D40) after surgically-induced OA. The presented values are the average of x-
fold change of RARRES1 mRNA expression and the standard deviation. 
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4.2 Spatial expression of dysregulated proteins 
4.2.1 Expression of TN-C and physiological appearance of a healthy newt knee 
joint  
In a healthy newt knee joint, TN-C was localized in the periosteum (black arrow, 
Figure 23B), and absent in the femoral and tibial articular cartilage (green arrow,  
Figure 23B). In addition, there was no immunoreactivity of the rabbit polyclonal IgG (isotype 
control) in the newt knee joint (Figure 23C).  
 
 
Figure 23: TN-C expression and physiological appearance of a healthy newt knee joint. (A) 
Safranin-O staining. Due to its high proteoglycan content, articular cartilage was stained red. IHC 
staining (B) against TN-C and (C) against rabbit polyclonal IgG (isotype control). A 5-µm healthy 
newt knee joint section was incubated with 10 µg/ml anti-human TN-C or rabbit polyclonal IgG (isotype 
control). TN-C was detected along the periosteum after staining with AEC substrate (black arrow). 
There was no antibody reactivity in the newt knee joint incubated with the isotype control. Original 
magnification x 50. The inset shows the situation in more detail (original magnification x 200). ac, 
articular cartilage; fm, femur; tb, tibia; prs, periosteum. 
 
In order to validate the result and to check the cross-reactivity of the antibody, TN-C 
expression in a healthy newt knee joint was further investigated using the newt-specific 
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antibody, MT-1 (Onda et al., 1990). Similar results were obtained. Strong reactivity of the 
MT1 antibody in the periosteum was detected (see Figure 24).  
 
 
Figure 24: Validation of TN-C expression in healthy newt knee joint using the newt-specific 
antibody MT-1. A 5-µm healthy newt knee joint section was incubated with MT-1 antibody. TN-C was 
detected along the periosteum after staining with AEC substrate (arrows). Original magnification x 50. 
ac, articular cartilage; fm, femur; tb, tibia; prs, periosteum.  
4.2.2 Spatiotemporal TN-C expression during newt knee joint regeneration in 
the collagenase model 
Previous examinations showed that joint-luxation and detachment of muscles from 
bone and the periarticular zone were observed as early as at day 6 after collagenase 
injection (Geyer et al., 2010). In this study, at 10 days after collagenase injection, there was 
no disruption of the anatomical axis of femur and tibia (joint-luxation) as a consequence of 
collagen degradation due to intra-articular collagenase injection into newt knee joint (see 
Figure 25A). Safranin-O staining showed that the effect of collagenase injection was already 
evident by a reduction of the proteoglycan density within the femoral and tibial articular 
cartilage (arrows, Safranin-O, Figure 25A). This alteration was not seen in the corresponding 
buffer-injected knee joint section (arrows, Safranin-O, Figure 25B).  
At day 10 after treatment, TN-C was found along the periosteum surrounding the 
femur and tibia (arrow, IHC, Figure 25A). The TN-C localization along the periosteum on the 
10-day collagenase-injected newt knee joint was similar to that in the healthy newt knee joint 
(Figure 23B). 
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Figure 25: TN-C expression and physiological appearance of a newt knee joint 10 days after (A), 
collagenase injection and (B) buffer injection. (A), (B) Safranin-O staining. Due to its high 
proteoglycan content, articular cartilage was stained red. (A), (B) IHC staining of TN-C. A 5-µm 10 
days post intra-articular collagenase- or buffer-injected newt knee joint section was incubated with 10 
µg/ml anti-human TN-C. The reactivity of the antibody (red signal) was detected along the periosteum 
after staining with AEC substrate (arrow). Original magnification x 50. The inset shows the situation in 
more detail (original magnification x 400). Depicted here are images from a representative IHC 
staining / representative IHC stainings. ac, articular cartilage; fm, femur; prs, periosteum; tb, tibia. 
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At day 20 after collagenase injection, the disruption of the anatomical axis (joint-
luxation) was evident (Safranin-O and H&E, Figure 26A). The disruption of the articular 
cartilage was also noticeable. The Safranin-O staining (proteoglycan staining) was absent in 
the deep zone of the femoral articular cartilage (green arrow, Safranin-O, Figure 26A). 
Nevertheless, in the buffer-injected knee joint, proteoglycan staining covered the complete 
femoral and tibial articular cartilage (Safranin-O, Figure 26B). 
In the treated knee joint, there was amorphous-looking undifferentiated tissue, 
surrounding the femur and tibia at the site of the defect. The H&E staining revealed that the 
appearance of the cells in the amorphous-looking tissue was fusiform and they had relatively 
big and distinct nuclei (H&E, Figure 26A). In contrast to the collagenase-injected joint, no 
undifferentiated tissue in the corresponding buffer-injected knee joint section was detected 
(H&E, Figure 26B). 
The IHC 20 days post collagenase treatment showed a TN-C localization along the 
periosteum (black arrow, IHC, Figure 26A) and in the undifferentiated tissue (blue arrow, 
IHC, Figure 26A). In the buffer-injected knee joint, TN-C appeared only along the periosteum 
(arrow, IHC Figure 26B). 
At day 40 after collagenase injection in the newt knee joint, additional alterations 
emerged in the regenerating newt knee joint. First, the normal anatomical axis was restored 
(Figure 27A). However, the joint gap between the femoral and tibial articular cartilages was 
still clearly visible (black arrow, Safranin-O, Figure 27A). Second, the undifferentiated tissue, 
which was located adjacent to the femur and tibia at the site of damage, was no longer 
detectable. A newly-formed tissue appeared next to the damaged area. The tissue was 
stained red with Safranin-O staining, this meant that it was composed of proteoglycan, 
indicating that new articular cartilage was formed (nac, Safranin-O, Figure 27A).  
Safranin-O staining of the femoral and the tibial old-defected articular cartilages at 
day 40 of the treated knee joint of the collagenase model indicated slightly lower 
proteoglycan density (blue arrows, Safranin-O, Figure 27A) in comparison with the femoral 
and tibial articular cartilage of the corresponding buffer-injected knee joint (arrows, Safranin-
O, Figure 27B).  
IHC at day 40 after collagenase treatment showed localization of TN-C that was 
distributed in the newly-formed articular cartilage (arrow, IHC, Figure 27A). Interestingly, the 
TN-C localization was absent in the femoral and tibial old-defected articular cartilages (oac, 
IHC, Figure 27A). In contrast, the IHC of the corresponding buffer-injected knee joint section 
against TN-C showed only specific TN-C localization along the periosteum (arrows, IHC, 
Figure 27B).  
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Figure 26: TN-C expression and physiological appearance of a newt knee joint 20 days after (A) 
collagenase- and (B) buffer injection. (A), (B) Safranin-O staining. Due to its high proteoglycan 
content, articular cartilage was stained red (black arrow). (A) Absence of proteoglycan in the articular 
cartilage of collagenase-treated joint was shown (green arrow). Original magnification x 50. (A), (B) 
H&E staining for tissue overview. Original magnification x 50. (A), (B) IHC staining of TN-C. A 5-
µm 10 days post intra-articular collagenase- or buffer-injected newt knee joint was incubated with 10 
µg/ml anti-human TN-C. The reactivity of the antibody (red signal) was detected in the undifferentiated 
tissue and in the periosteum after staining with AEC substrate (arrow). Original magnification x 50. The 
inset shows the situation in more detail (original magnification x 400). Depicted here are images 
from a representative IHC staining / representative IHC stainings. The IHC images are a 
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representative result from two IHC stainings ac, articular cartilage; fm, femur; tb, tibia; prs, periosteum; 
ut, undifferentiated tissue. 
 
Figure 27: TN-C expression and physiological appearance of a newt knee joint 40 days after (A) 
collagenase- and (B) buffer-injection. (A), (B) Safranin-O staining. Due to its high proteoglycan 
content, articular cartilage was stained red. Original magnification x 50. (A), (B) IHC staining for  
TN-C. A 5-µm 40-day post intra-articular collagenase- or buffer-injected newt knee joint section was 
incubated with 10 µg/ml anti-human TN-C. The reactivity of the antibody (red signal) was detected 
within (A) the newly-formed articular cartilage and (B) along the periosteum after staining with AEC 
substrate (arrow). Original magnification x 50. The inset shows the situation in more detail (original 
magnification x 400. Depicted here are images from a representative IHC staining / 
representative IHC stainings. ac, articular cartilage; fm, femur; tb, tibia; nac, newly-formed articular 
cartilage; prs, periosteum; oac, old-defected articular cartilage. 
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4.2.3 Spatiotemporal TN-C expression during newt knee joint regeneration in 
the surgery model 
At day 10 after the surgically-induced knee joint defect, due to the surgical procedure, 
a small area of the superficial zone of femoral articular cartilage was defected (blue arrow, 
Figure 28A). Pappenheim staining of the knee joint showed that proteoglycan loss was found 
in and around the defect area (blue arrow, Pappenheim, Figure 28A). On the other hand, the 
proteoglycan density of the corresponding knee joint negative control undergoing sham 
surgery was intact (ac, Pappenheim, Figure 28B). 
To study TN-C localization 10 days after surgically-induced knee joint defect, IHC was 
performed with treated and sham operated newt knee joint sections using TN-C antibody. 
TN-C was localized in the defect area (blue arrow, IHC, Figure 28A) and along the 
periosteum (black arrow, IHC, Figure 28A). On the sham operated knee joint, TN-C was 
restricted to the periosteum (arrow, IHC, Figure 28B).  
Investigation of TN-C expression 20 days after treatment showed newts with their 
femoral and tibial articular cartilage of the treated knee joint almost completely removed. The 
surgery treatment had left debris of the old-defected articular cartilage, which could be 
visualized with Safranin-O staining of the knee joint (black arrow, Safranin-O, Figure 29A). 
Another result of the surgery treatment was a disruption of the anatomical axis or joint-
luxation of the treated joint.  
In addition, at this time point, undifferentiated tissue was formed adjacent to the femur 
and tibia at the defect site (ut, Safranin-O, Figure 29A). 
Meanwhile, the corresponding control sham operated knee joint was morphologically 
intact. There was no alteration of the proteoglycan density of the femoral and the tibial 
articular cartilages (arrows, Safranin-O, Figure 29B). 
The IHC of the 20-day surgically-treated knee joint showed a TN-C localization in the 
undifferentiated tissue (blue arrow, IHC, Figure 29A) and in the old-defected articular 
cartilage (black arrow, IHC, Figure 29A). In the sham operated knee joint, TN-C was 
detected only along the periosteum (arrow, IHC, Figure 29B). 
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Figure 28: TN-C expression and physiological appearance of a newt knee joint 10 days after (A) 
surgery and (B) sham surgery treatment. (A), (B) Pappenheiem staining. Due to its proteoglycan 
content, articular cartilage was stained blue. Original magnification x 50. (A), (B) IHC against TN-C. A 
5-µm 10 day post surgery or sham operated newt knee joint section was incubated with 10 µg/ml anti-
human TN-C. The reactivity of the antibody (red signal) was detected at the defect area (blue arrow) 
and along the periosteum (black arrows). Original magnification x 50. The inset shows the situation in 
more detail (original magnification x 400). Depicted here are images from a representative IHC 
staining / representative IHC stainings. ac, articular cartilage; fm, femur; tb, tibia; da, defect area; 
prs, periosteum; 
 
 
Results 
 70 
 
Figure 29: TN-C expression and physiological appearance of a newt knee joint 20 days after (A) 
surgery or (B) sham surgery treatment. (A), (B) Safranin-O staining. Due to its proteoglycan 
content, articular cartilage was stained red. Original magnification x 50. (A), (B) IHC against TN-C A 
5-µm 20-day post-surgery or sham operated newt knee joint section was incubated with 10 µg/ml anti-
human TN-C. The reactivity of the antibody (red signal) was detected in the undifferentiated tissue 
(blue arrow) and in the old-defected articular cartilage (black arrow). Original magnification x 50. The 
inset shows the situation in more detail (original magnification x 400). Depicted here are images 
from a representative IHC staining / representative IHC stainings. ac, articular cartilage; oac, old-
defected articular cartilage, fm, femur; tb, tibia; ut, undifferentiated tissue; prs, periosteum. 
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At day 40 after surgery treatment, the anatomical axis of the treated knee joint was 
restored (Figure 30A). The Safranin-O staining of this tissue showed that the old-defected 
articular cartilage had been repaired. The proteoglycan density of the femoral cartilage 
increased substantially (black arrow, Figure 30A) and covered all of the femoral cartilage 
area, whereas in the tibia articular cartilage proteoglycan was detected only at the deep zone 
of the tibial articular cartilage (blue arrow, Figure 30A). The medial and superficial zones had 
not yet been covered by proteoglycan. In addition, the corresponding sham operated knee 
joint was morphologically intact (Figure 30B). 
 
Figure 30: TN-C expression and physiological appearance of a newt knee joint 40 days after (A) 
surgery or (B) sham surgery treatment. (A), (B) Safranin-O staining. Due to its proteoglycan 
content, articular cartilage was stained red. Original magnification x 50. (A), (B) IHC against TN-C. A 
5-µm 40-day post-surgery or sham operated newt knee joint section was incubated with 10 µg/ml anti-
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human TN-C. The reactivity of the antibody (red signal) was detected in the undifferentiated tissue 
(blue arrow). Original magnification x 50. The inset shows the situation in more detail (original 
magnification x 400). Depicted here are images from a representative IHC staining / 
representative IHC stainings.ac, articular cartilage; oac, old-defected articular cartilage, fm, femur; 
tb, tibia; ut, undifferentiated tissue; prs, periosteum. 
 
The IHC of the 40-day surgery or sham operated knee joint section revealed that the 
TN-C localized extracellularly in the newly-formed articular cartilage (arrow, IHC, 
Figure 30A). Moreover, the IHC of the corresponding control sham operated newt knee joint 
against TN-C showed localization of TN-C only along the periosteum (arrow, IHC, Figure 
30B).  
4.3 Summary of spatiotemporal TN-C expression of the 
collagenase and surgery model 
Expression of TN-C at the protein level could be demonstrated in all IHC stainings of 
treated and control knee joint sections of the surgery and collagenase model. The IHC 
experiments were performed with newt knee joint sections from 2 animals (n=2) of 
collagenase and 3 animals (n=3) of surgery models. Representative images were already 
presented previously (Section 4.2). The summary of the spatial expression of TN-C in the 
regenerating newt knee joint in the surgery model and collagenase model is presented in 
Table 14: 
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Table 14: Summary of TN-C spatial expression from collagenase and surgery model. For each 
OA model, locations of TN-C expressions are listed. In the collagenase model, IHC staining was 
performed with two animals (n=2) and in surgery model, IHC experiments were conducted with three 
animals (n=3). T, treated knee joint; C, control knee joint; coll, collagenase; 1/2, TN-C was detected in 
the respected tissue in one from two animals; 2/2, TN-C was detected in the respected tissue in all two 
animals; 1/3, TN-C was detected in the respected tissue in one from three animals; 2/3, TN-C was 
detected in the respected tissue in two from three animals; 3/3, TN-C was detected in the respected 
tissue in all three animals.  
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4.4 Evaluation of TN-C contribution to the regenerative process 
TN-C was shown to be involved during knee joint regeneration. In order to investigate 
whether the participation of TN-C was essential in this process, gene expression knockdown 
experiments were performed. In order to conduct this experiment, a newt cell population, 
which expressed constitutively abundant TN-C, was selected. 
4.4.1 TN-C expression levels in different newt cell populations 
To analyze the mRNA expression level of TN-C, total RNA from different newt 
chondrocyte populations (2, 4, and 5 months), newt myotubes (A1), and newt blastemal cells 
(B1H1) was isolated. Afterwards, cDNA was synthesized by reverse transcription reaction 
from equal RNA concentrations. Thereafter, real-time PCR was performed with the cDNA to 
obtain the TN-C expression relative to ribosomal protein S21 (Ct) (Figure 31). TN-C 
expression levels varied among the cell populations tested. The highest expression was in 
the 5-month-old newt chondrocytes, followed by the 4-month-old newt chondrocytes, and the 
A1 cells, afterwards the 2-month-old newt chondrocytes, and finally the B1H1. Based on the 
abundant constitutive TN-C expression in 5 months old primary newt chondrocytes, these 
cells were selected for TN-C knockdown in vitro using esiRNA.  
 
Figure 31: Relative quantification of TN-C in different newt chondrocyte populations, newt A1 
cells, and newt B1H1 cells. Relative quantification of TN-C expression in different primary newt 
chondrocyte populations (5-, 4- and 2-months), newt myotube cells (A1) and newt blastema cells 
(B1H1) was performed using real-time PCR. The presented values are the average of –Ct and the 
standard deviation. 
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4.4.2 TN-C knockdown in primary newt chondrocytes  
After producing TN-C esiRNA and lacZ esiRNA, they were introduced into primary 
newt chondrocytes using the human chondrocyte nucleofector kit (Amaxa, Lonza). In order to 
confirm the reliability of the knockdown experiment, the nucleofection was performed two 
times. All of the two experiments showed that the self-made esiRNA was able to silence the 
expression of TN-C in newt chondrocytes. 48 hr after the first nucleofection experiment, TN-
C expression was reduced to 0.55-fold or 45% (p<0.01) in the TN-C esiRNA nucleofected 
cells in comparison to the control (Figure 32). The second experiment even exhibited a 
stronger gene silencing than the first. The gene expression from the TN-C esiRNA 
nucleofected cells was reduced to 0.29-fold or 71% (p<0.01) in comparison to the control 
(Figure 33).  
 
 
Figure 32: First experiment of TN-C knockdown in primary newt chondrocytes. TN-C expression 
was reduced to 0.55-fold or 45% reduction (p<0.01) in TN-C esiRNA nucleofected newt primary 
chondrocytes in comparison to lacZ esiRNA nucleofected cells. The presented values are the average 
of x-fold changes and the standard deviation. 
1.00 
0.55 
0
0.5
1
Control
(lacZ esiRNA)
TN-C knockdown
(TN-C esiRNA)
x
-f
o
ld
 c
h
a
n
g
e
 o
f 
T
N
-C
  
m
R
N
A
 e
x
p
re
s
s
io
n
 
** 
Results 
 76 
 
Figure 33: Second experiment of TN-C knockdown in primary newt chondrocytes. TN-C 
expression was reduced to 0.29-fold or 71% reduction (p<0.01) in TN-C esiRNA nucleofected newt 
primary chondrocyte in comparison to lacZ esiRNA nucleofected cells. The presented values are the 
average of x-fold changes and the standard deviation. 
4.4.3 Effect of TN-C knockdown on adhesion and motility of the primary newt 
chondrocytes 
In order to evaluate the effect of the TN-C knockdown in the primary newt 
chondrocytes to their adhesion capacity, 48 hr after esiRNA introduction into the primary 
newt chondrocytes, adhesion assay was performed. The result of the quantification 
experiment showed that TN-C knockdown newt chondrocytes appeared to have reduced 
capacity to attach to the bottom surface of the cell culture plate (545 adherent cells) as 
compared to the control (634 adherent cells) (see Figure 34). But the reduction was not 
statistically significant (p=0.133). 
1.00 
0.29 
0
0.5
1
Control
(lacZ esiRNA)
TN-C knockdown
(TN-C esiRNA)
x
-f
o
ld
 c
h
a
n
g
e
 o
f 
T
N
-C
  
m
R
N
A
 e
x
p
re
s
s
io
n
 
** 
Results 
 77 
 
Figure 34: The effect of TN-C knockdown to the adhesive capacity of the primary newt 
chondrocytes 48 hr after esiRNA nucleofection. The capacity of TN-C knockdown chondrocytes to 
adhere on the bottom of the cell culture appeared to be lower than the control cells, but the reduction 
was not statistically significant (p=0.133). The presented values are the average number of adherent 
TN-C knockdown and control newt chondrocytes with the standard deviation. 
 
The effect of TN-C knockdown on the migratory capacity of the primary newt 
chondrocytes were analyzed using scrape motility assay. The result of this experiment 
showed that the migratory capacity of the TN-C knockdown cells was lower than the control 
at 12 hr incubation time. However, at the later time points, the number of migrated TN-C 
knockdown cells was higher than the control (Figure 35). Taken together, the difference of 
the migrated cell numbers was not statistically significant (p>0.1).  
ns 
634 
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Figure 35: The effect of TN-C knockdown in the motility capacity of the primary newt 
chondrocytes. The number of the migrated TN-C knockdown newt chondrocytes appeared to be 
lower than the control at 12 hr incubation time. However, at the later time points, the number of the 
migrated TN-C knockdown cells was higher than the respective control. Taken together, the difference 
of the number was not statistically significant (p>0.1). The presented values are the number of 
migrated cell and their standard deviations. 
4.4.4 Effect of TN-C knockdown on expression level of SPARC and DCN 
SPARC and DCN are matricellular proteins which are known to be involved in the 
knee joint regeneration process. In order to evaluate the effect of TN-C knockdown at the 
mRNA expression level of SPARC and DCN, a relative quantification (Ct) of these genes 
was calculated with the TN-C and lacZ esiRNA nucleofected cells at 48 hr after treatment 
using real-time PCR. The result of the quantification showed that TN-C knockdown did not 
affect SPARC (Figure 36) and DCN (Figure 37) expression. 
ns ns ns 
ns ns 
ns 
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Figure 36: SPARC expression in TN-C-knockdown primary newt chondrocytes. Primary newt 
chondrocytes were nucleofected with 20 pmole of TN-C esiRNA and lacZ esiRNA (control). Using real-
time PCR, x-fold change of SPARC mRNA expression was calculated using relative quantification 
(Ct). SPARC expression was not altered in TN-C esiRNA nucleofected cells in comparison to lacZ 
esiRNA nucleofected cells. The presented values are the average of x-fold and the standard deviation. 
 
 
Figure 37: DCN expression in TN-C knockdown primary newt chondrocytes. Primary newt 
chondrocytes were nucleofected with 20 pmole of TN-C esiRNA and lacZ esiRNA (control). Using real-
time PCR, x-fold change of DCN mRNA expression was calculated using relative quantification (Ct). 
DCN expression was not altered in the TN-C esiRNA nucleofected cells in comparison to lacZ esiRNA 
nucleofected cells. The presented values are the average of x-fold changes and the standard 
deviation. 
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4.5 Expression of SPARC during newt knee joint regeneration 
SPARC is expressed during remodelling and repair in different tissues (e.g. muscle 
and bones) and some investigators suggested its function in regeneration (Jorgensen et al., 
2009). Based on the results from microarray and real-time PCR analysis, SPARC was found 
to be upregulated in regenerating newt knee joint. Therefore, the expression pattern of this 
protein was investigated with IHC. Before applying this experiment in the newt tissue, 
establishment of a reliable IHC protocol was performed.  
4.5.1 Optimization of newt non-specific SPARC antibody in human RA bone 
tissue 
There was no newt-specific SPARC antibody commercially available. Therefore, a 
polyclonal SPARC antibody, which was specific for mouse and human tissue, was selected 
for the IHC study. Subsequently, a preliminary protocol optimization was performed with 
human RA bone tissue, before applying this antibody in IHC of newt knee joint sections.  
In the human tissue, there was a remodeling zone, where new bone was formed in 
the cartilage. It was characterized by pink color after staining with H&E (Figure 38A). 
Osteoblasts were found in the remodeling zone (green arrow, Figure 38B), and in the later 
process of bone remodeling, some of the cells were embedded into bone matrix and turned 
into osteocytes (blue arrow, Figure 38B). Osteoblasts are known to express SPARC, 
therefore the optimization was performed in this tissue.  
Establishment of the IHC protocol using the chosen antibody was successful. SPARC 
expression was detected in the remodeling zone (Figure 38C, D), and specifically along the 
osteoid layer wherein osteoblasts were located (black arrow, Figure 38D).  
In addition, a background signal, which is usually derived from non-specific binding of 
Fc receptor of the antibody, was absent, and there was no immunoreactivity of isotype 
control antibody in the remodeling zone (Figure 38E).  
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Figure 38: SPARC expression in human bone from an RA patient. (A) H&E staining of a RA 
bone tissue section for tissue overview. Original magnification x 50. (B) The inset shows a 
remodeling zone surrounded by newly-formed bone. Original magnification x 400. IHC staining 
against (C), (D), SPARC and against (E) goat polyclonal IgG (isotype control). A decalcified RA 
bone tissue section (5-µm) was incubated with 4 µg/ml anti-SPARC or goat polyclonal IgG. A specific 
cellular SPARC expression was detected in the remodeling zone after staining with AEC substrate 
(arrow, C). Strong SPARC expression was detected along the osteoid layer in the remodeling zone 
(arrow, D). (D) The inset shows the situation in more detail (original magnification x 400). (E) Isotype 
control showed no signal. Original magnification x 50. rz, remodeling zone; ac, articular cartilage; nb, 
newly-formed bone; os, osteocytes; osd, osteoid; ob, osteoblasts. 
4.5.2 SPARC expression in healthy newt knee joint 
The IHC for SPARC in healthy newt knee joints revealed its localizations in different 
areas (arrows, Figure 39A, B, C). This matricellular protein could be observed on the 
subchondral bone (green arrow, Figure 39B), the calcified zone of the articular cartilage 
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(black arrow, Figure 39B), the deep zone of articular cartilage (blue arrow, Figure 39B), the 
osteocytes in the bone (black arrow, Figure 39C), the blood vessel (yellow arrow, Figure 
39C), and on the skin (red arrow, Figure 39C). 
Background signal, which is usually derived from non-specific binding of Fc receptor 
of the antibody, was absent. The isotype control of the SPARC antibody (goat polyclonal 
IgG) did not show immunoreactivity in the remodeling zone (Figure 39D).  
 
Figure 39: SPARC expression in a healthy newt knee joint. IHC staining against (A), (B), (C) 
SPARC and against (D) goat polyclonal IgG (isotype control). A 5-µm newt knee joint section was 
incubated with 4 µg/ml anti-SPARC or goat polyclonal IgG. Then, the section was counterstained with 
hematoxylin. The SPARC expression was detected on the subchondral bone (green arrow, B), on the 
calcified zone of the articular cartilage (black arrow, B), on the deep zone of articular cartilage (blue 
arrow, B), on the osteocytes in the bone (black arrow, C), on the blood vessel (yellow arrow, B), and 
on the skin (red arrow, B). (A) IHC staining against SPARC with original magnification x 50. (B), (C) 
The inset shows the situation in more detail. Original magnification x 200. (D) There was no signal in 
the isotype control. Original magnification x 50. ac, articular cartilage; bv, blood vessel; der, dermis; 
dz, deep zone of articular cartilage; calc, calcified zone of articular cartilage; fm, femur; sb, 
subchondral bone; tb, tibia. 
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4.5.3 SPARC expression in regenerating newt knee joints after 20 and 40 days 
of surgery treatment  
After optimization of IHC protocol for usage in newt tissue, the antibody was then 
used to evaluate the spatiotemporal expression of SPARC during knee joint regeneration 
after surgically-induced OA. Twenty-days after surgical removal of articular cartilage in the 
newt knee joint, SPARC was differentially upregulated in the cDNA microarray and was 
confirmed with real-time PCR (see Section 4.1.1.2). However, 40 days after surgery 
treatment, SPARC expression was not dysregulated on microarray and real-time PCR. In 
order to observe the spatiotemporal expression of SPARC during knee joint regeneration, 
IHC experiments using samples 20 and 40 days after surgery treatment were performed.  
In the 20-day post-surgical knee joint tissue, SPARC expression was restricted to the 
osteocytes (arrow, Figure 40A, B; blue arrow, Figure 40C, D), on the skeletal muscle (black 
arrow, Figure 40C, D), along the periosteum (red arrow, Figure 40C, D).  
Interestingly, in the control newt knee joint undergoing sham surgery, SPARC could 
not be detected in the osteocytes (Figure 40E, F, G) and the skeletal muscle (Figure 40G). 
Instead, it was found to be expressed along the endosteum (black arrow, Figure 40F) and 
the periosteum (red arrow, Figure 40F). 
In contrast to the strong expression of SPARC in the femur and the tibia, no SPARC 
signal was observed at the defected articular cartilage, and the undifferentiated tissue (data 
not shown). 
At day 40 after treatment, SPARC expression in the surgically-treated (Figure 41A, B) 
and in the sham operated knee joint (Figure 41C, D) was restricted only to the skin. 
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Figure 40: SPARC expression in the 20-day post-surgically-induced knee joint defect. IHC 
staining of (A), (B), (C), (D) surgically-treated and (E), (F), (G) sham operated knee joint against 
SPARC. A 5-µm 20-day post-surgically-induced knee joint defect or sham operated newt knee joint 
section was incubated with 4 µg/ml anti-SPARC or goat polyclonal IgG. Then, the section was 
counterstained with hematoxylin. SPARC expression was detected in the osteocytes (black arrow, A, 
B; blue arrow, C, D), on the muscle (black arrow, C, D), along the periosteum (red arrow, C, D, E, F), 
and along the endosteum (black arrow, E, F). (A), (C), (E), (G) IHC staining against SPARC with 
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original magnification x 50. (B), (D), (F) The inset shows the situation in more detail. Original 
magnification x 200. fm, femur; os; osteocytes; tb, tibia; ms, muscle; prs, periosteum; end, endosteum. 
 
 
Figure 41: SPARC expression in a 40-day post-surgical inflicted newt knee joint defect. IHC 
staining for SPARC in (A), (B) surgically-treated and (C), (D) sham operated newt knee joints. A 
5-µm 40-day post-surgical inflicted knee joint defect or post-sham operated newt knee joint section 
was incubated with 4 µg/ml anti-SPARC or goat polyclonal IgG. Thereafter, the section was 
counterstained with hematoxylin. The SPARC reactivity was observed only on the skin (arrow, A, B, C, 
D). (B), (D) The inset shows the situation in more detail (original magnification x 200). ac, articular 
cartilage; der, dermis; fm, femur; tb, tibia; ut, undifferentiated tissue. 
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5 Discussion 
The remarkable ability of newt to regenerate many kinds of tissues is well known. An 
example of this is the knee joint restoration after collagenase- (Geyer et al., 2010) and 
surgically-induced knee joint damage (unpublished work from Dr. Matthias Geyer and Prof. 
Dr. med. Robert Dinser). The animals restore the defect until the formation of a functional 
knee joint is achieved. In contrast, mammals such as human and mice cannot repair this 
defect, and finally the affected knee joint will lose its function. In order to elucidate why and 
how the newt can perform this kind of regeneration, expression analysis using cDNA 
microarray was performed that showed several genes which were upregulated during this 
repair process (unpublished work from Dr. med. Matthias Geyer, Prof. Dr. med. Robert M. 
Dinser, and Dr. rer. nat. Thilo Borchardt). The involvement of these genes in the newt knee 
joint regeneration suggested potential molecular mechanisms, which have been addressed 
in this doctoral thesis.  
5.1 Molecular mechanisms during knee joint regeneration in newt  
The suggested mechanisms, which might play an important role in the newt knee joint 
regeneration process, were the innate immune system, the vitamin A pathway, and 
matricellular proteins. 
5.1.1 Role of the innate immune system during knee joint regeneration in the 
newt 
Evidence for the involvement of the innate immune system during regeneration in 
newt was shown by participation of the complement system during newt limb and eye repair 
(Kimura et al., 2003). They showed that complement component 3 was expressed in the 
blastema during newt limb regeneration and in the cornea and iris during newt eye repair. In 
addition, they showed that other members of the complement family such as complement 
component 5 were also expressed in the wound epithelium, regenerating newt limb, as well 
as lens vesicles and cornea during newt eye repair (Kimura et al., 2003). 
In this doctoral work, CFB (another member of complement system of the alternative 
pathway) appeared to be involved in knee joint regeneration, because its expression was 
strongly upregulated at every time point during knee joint regeneration. Real-time PCR 
quantification of CFB confirmed the results of the cDNA microarray. 
TLRs and their adaptor molecule MyD88 are known to be involved in lung repair 
processes after acute injury (Jiang et al., 2005). Activation of these molecules is essential to 
prevent apoptosis of airway epithelial and endothelial cells in the injured lung (Jiang et al., 
2005).  
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In our experiments, participation of TLRs in knee joint regeneration was 
demonstrated by upregulation of TLR2 and TLR5 at day 10 of the surgery model. At later 
time points, their expression decreased. In contrast, in the collagenase model, TLRs 
appeared not to be involved. However, the strong upregulation of these receptors at this time 
point was not supported by the activation of MyD88 (see Section 9.4). This finding contrasts 
the fact that MyD88 is usually mediating TLR2 and TLR5 activation in the innate immune 
system (Akira et al., 2001). In order to confirm the expression of these receptors at day 10 in 
the surgery model, spatial expression analysis was tried to be established with IHC. 
Nevertheless, the effort was hampered by unspecificity of the antibody when it was applied 
on newt tissues. An alternative method like ISH was not conducted because of some 
technical problems which are discussed in Section 5.2.3.  
5.1.2 Role of the retinoic acid pathway during knee joint regeneration in the 
newt 
Upregulation of RARRES1 in the cDNA microarray indicated an involvement of the 
retinoic acid pathway during knee joint regeneration. This molecule was selected as 
candidate gene in this doctoral study because it has the capability to inhibit growth of human 
colon tumor cells (Wu et al., 2011). Tumor growth and tissue repair are related events, since 
tumor development is known to be an uncontrolled repair process (Haddow, 1972; Schäfer 
and Werner, 2008). In addition, the relation between tumor growth and tissue repair can be 
observed from similarity of the gene expression profile between the renal regeneration / 
repair process and the development of renal cell carcinoma (Riss et al., 2006). Of note, 
almost 77% of genes expressed during both events are regulated concordantly.  
In this doctoral study, relative quantification of RARRES1 did not confirm the 
upregulation of this protein in the cDNA microarray. The real-time PCR analysis 
demonstrated that the upregulation of RARRES1 was only present in one pool of the animals 
(see Figure 22). Therefore, it was difficult to deduct, whether this gene is really deregulated 
during the repair process. 
Nonetheless, the idea to investigate the role of the vitamin A and its derivatives in 
knee joint regeneration was continued by selecting vitamin A receptors including RAR, , 
and δ. They were selected because they play an important role in newt limb regeneration 
(Brockes, 1997). They mediate proximodistal respecification of blastema cells. Another ability 
of the cells is to locate their position during blastema formation (Brockes, 1997). However, 
our real-time PCR experiments showed that RARs and RXR were not dysregulated (see 
Table 15). Therefore, it can be concluded that the role of RARs and RXR during knee joint 
healing in newt was not prominent. 
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5.1.3 Role of matricellular proteins during knee joint regeneration in newt 
Matricellular proteins are matrix proteins with an important function as regulator of cell 
behavior such as cell adhesion, proliferation, and apoptosis (Bornstein and Sage, 2002). 
They are also known to be associated with regeneration (Midwood et al., 2004). Dynamic 
expressions of these proteins (e.g. TN-C, hyaluronic acid, and fibronectin) direct cellular 
behaviors and provide instructive cues in newt muscle cell repair (Calve et al., 2010). 
In this doctoral work, matricellular proteins such as DCN, POSTN, TN-C, and SPARC 
were differentially upregulated in newt knee joint regeneration in the collagenase- and 
surgically-treated animal groups. Their activation suggested a possible involvement in this 
process.  
The role of DCN in newt’s tissue regeneration is still unknown. From other animal 
models, including humans, this matricellular protein has been supposed to promote cartilage 
healing (Grogan et al., 2014). In this process, DCN induces COL2A1 expression, a gene 
which is responsible for the production of the alpha 1(II) chain of type II collagen that is found 
primarily in articular cartilage (Grogan et al., 2014). 
Likewise, the role of POSTN in tissue regeneration of the newt is also still unknown. 
In other animal models such as rats, involvement of this protein is reported during the 
regeneration of bone tissue. In rat, POSTN promotes healing of bone fractures by recruiting 
preosteoblastic cells into provisional callus (a temporary tissue which is formed after bone 
fracture). The tissue is then removed after bone repair is completed (Kojima et al., 2007; 
Nakazawa et al., 2004).  
The role of SPARC in newt tissue regeneration is also unknown. In mammals, this 
matricellular protein is involved in bone repair after injury (Alford and Hankenson, 2006). 
cDNA microarray and subsequent real-time PCR quantification indicated that SPARC is 
involved in knee joint regeneration, and in order to analyze the expression of this 
matricellular protein during the repair process, IHC against SPARC was performed.  
5.1.3.1 SPARC expression: Analysis, predicted function, and role in knee joint 
regeneration 
Due to its properties as the most abundant non-collagenous protein in the bone 
(Termine et al., 1981), SPARC localization was predominantly located in this tissue and also 
in cartilage of a healthy newt knee joint. 
 SPARC expression in healthy knee joint 5.1.3.1.1
In the bone of the healthy newt knee joints, SPARC was expressed in osteocytes. 
There is no scientific report which had already showed SPARC in osteocytes of newt’s bone. 
In other animals including humans, Metsäranta and coworkers showed that expression of 
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SPARC is involved in development processes. They found that this matricellular protein is 
expressed in the osteocytes of calvarial bone matrix of the developing fetus (Metsäranta et 
al., 1989). This was also supported by other findings that showed only young (mineralizing) 
osteocytes expressing SPARC while aged, quiescent osteocytes did not synthesize this 
protein (Jundt et al., 1987). Therefore, SPARC expression in the osteocytes of healthy adult 
newt bone might be a false positive IHC result, because this tissue was not in the 
development phase. For future studies, in order to confirm this assumption, detection of 
quiescent osteocyte markers such as sclerostin should be conducted (Robling et al., 2008). If 
the SPARC expressing osteocytes express sclerostin, then the SPARC signal in the healthy 
adult newt bone is a false positive result. In order to investigate, whether the SPARC 
expressing osteocytes are part of mineralizing tissue, detection of dentin matrix protein-1 
(DMP-1) can be performed, as dentin matrix protein-1 (DMP1) is a protein which is 
synthesized only by actively mineralizing osteocytes (Bonewald, 2011).  
In articular cartilage of healthy newt knee joints, SPARC expression was found in the 
calcified, and the deep zone of articular cartilage. Until this time, there is no scientific report 
about appearance of this protein in this tissue in the newt model system. In other animals 
including humans, the expression of SPARC in these locations was already described. 
Nakamura and coworkers observed that in the deep zone of healthy articular cartilage, 
SPARC expression could be detected weakly in some chondrocytes (Nakamura et al., 1996). 
However, the appearance of this protein in healthy cartilage seems to be controversial. Some 
recent publications showed that detectable SPARC expression can only be observed in 
hypertrophic chondrocytes in cartilage undergoing calcification (Ikeda-Isogai et al., 2012) or 
degenerative disease such as OA (Goyal et al., 2010). Therefore, in order to evaluate the 
validity of IHC staining, which showed SPARC expression in the healthy articular cartilage, 
confirmatory experiments should be performed in the future, e.g. detection of collagen type X 
to elucidate whether SPARC expressing cells are hypertrophic chondrocytes (Kielty et al., 
1985).  
In addition to bone and cartilage, SPARC was also expressed in the skin, and in 
blood vessels. Scientific reports that describe the expression of SPARC in these tissues in 
newt have not yet been published. Investigation of SPARC expression in human skin was 
performed by Hunzelmann and coworkers. By using northern blotting, ISH, and IHC, they 
noticed that in healthy skin, this matricellular protein was present in the vascular cells and 
basement membranes of the dermis. They suggested that this protein might play a role in 
differentiation and maintenance of healthy human skin (Hunzelmann et al., 1998).  
 SPARC expression in the regenerating newt knee joint 5.1.3.1.2
Spatial SPARC expression in regenerating and control newt knee joint beginning at 
day 20 in surgery model was different when compared with the healthy tissue. In the treated 
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knee joint, SPARC could be detected in the osteocytes, the skeletal muscle and the 
periosteum. SPARC expression in the skeletal muscle was most prominent during knee joint 
regeneration at day 20 of the surgery model. Based on investigations in other animal models, 
it could be shown that the expression of SPARC in the skeletal muscle was important for 
regeneration. Studies in the human fetuses showed that SPARC is detected only in 
differentiating tissues such as developing myofibers; afterwards, the expression level 
decreases when the tissue becomes differentiated (Jorgensen et al., 2009). SPARC was 
therefore suggested to induce regeneration and muscle reformation (Jorgensen et al., 2009). 
However, in the knee joint regeneration, abundant SPARC expression in the skeletal muscle 
did not relate to any regeneration/repair process. The location of SPARC was quite distant 
from the damaged area (see Section 4.5.3). In order to confirm this result, it would have been 
very helpful, if there had been other IHC experiments with regenerating knee joint from other 
animals at the same time point (day 20 of the surgery model). Unfortunately, the experiment 
could not be performed, due to tissue limitation. 
Abundant SPARC appearance was also found in the periosteum, which was located 
adjacent to the SPARC expressing skeletal muscle (see Section 4.5.3). This matricellular 
protein is synthesized by osteoblasts, which are located in the inner surface of the 
periosteum (Gilbert, 2000; Baldini et al., 2008). SPARC supports the mineralization process 
during new bone formation. It provides healthy bone for tissue maintenance. Increased 
expression of this protein is observed only during fracture repair (Delany et al., 2003). It 
could not be completely clarified, why the expression of this protein was elevated in the 
treated tissue in comparison to the control knee joint. Thus, in order to confirm this result, 
some additional IHC stainings should be performed with different animals in the same time 
point in the future. In this doctoral work, the experiment could only be performed once due to 
tissue limitation.  
These additional experiments should also evaluate the difference in spatial 
expression pattern between the healthy and the control knee joint. For example, the 
presence of SPARC in the articular cartilage and the blood vessel, which emerged only in the 
healthy tissue but were absent in the control knee joint. Here, both tissues should have 
similar SPARC expression pattern.  
As conclusion, SPARC could be observed in different areas in a healthy newt knee 
joint. Although, its expression is required for the normal maintenance of the tissue, in the 
regenerating knee joint, based on the SPARC IHC staining, the appearance of this 
matricellular protein seemed not to correlate with the repair process. Therefore, additional 
experiments are required to confirm this assumption in the future, which is also important to 
elucidate the different of spatial expression pattern between healthy and control knee joint.  
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In contrast to SPARC with its expression in the regenerating tissue not correlating 
with regeneration processes, the presence of TN-C during the healing process seemed to be 
important and one of the most interesting findings of this doctoral work.  
5.1.3.2 TN-C and its role in knee joint regeneration in newt  
As early as in 1990, a research group led by Roy A. Tassava pioneered the work that 
detected TN-C in the blastema tissue during newt limb regeneration. They noticed that 
appearance of this matricellular protein was related to the repair, because it appeared only in 
the tissue related to this process such as wound epithelium, blastema, and condensing 
mesenchyme. After these tissues were completely differentiated and finally became a 
functional limb, the TN-C expression disappeared (Onda et al., 1990). One year later, 
another group showed that this matricellular protein was present during scar free skin wound 
healing. By using IHC staining, they found that TN-C expression in this process was involved 
in the regeneration process (Donaldson et al., 1991). Until today, there are some more 
reports that show the involvement of this protein during regeneration processes in different 
newt’s tissues such as in the caudal spinal cord (Caubit et al., 1994), neural retina (Mitashov 
et al., 1995), skeletal muscle (Calve et al., 2010), and recently in the heart (Mercer et al., 
2012) 
Although numerous investigations in different tissues have already been performed, 
none of them showed that this protein is actually required for regeneration, for example by 
conducting knockdown experiments. Therefore in this doctoral work, the investigation was 
not only performed on the mRNA (real-time PCR) and protein expression level (IHC), an 
additional functional analysis (knockdown) was also conducted. The results of this 
experiment are discussed in more detail in Section 5.1.3.2.3.  
In the knee joint regeneration, the expression pattern of TN-C was also associated 
with the repair process. It emerged in the defect area, undifferentiated tissue, and newly-
formed articular cartilage. Interestingly, the expression pattern seemed to be unique in each 
OA model. 
 TN-C expression in both OA models 5.1.3.2.1
On day 10 after treatment, there was already a spatial expression difference between 
both OA models. In the surgery model, from three analyzed animals, TN-C was present in 
the periosteum, while expression in the defected articular cartilage was present only in two of 
them. Meanwhile, in the collagenase model, from two analyzed animals, TN-C localization 
was found only in the periosteum but not in the articular cartilage (see Section 4.3).  
It can therefore be speculated that the TN-C expression in the defected articular 
cartilage in the surgery model was a part of the inflammatory response because this 
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matricellular protein is highly upregulated in the damaged articular cartilage and synovial joint 
(Chevalier et al., 1994). The appearance of TN-C in these tissues can induce inflammatory 
factors such as IL-1 and IL-6 (Patel et al., 2011). In inflammatory arthritis including RA, TN-C 
is also abundantly expressed in the cartilage and synovium (a thin layer of membrane that 
lines joint capsule and secretes synovial fluid) (Salter, 1993). The elevated amounts of this 
protein in the RA joints are thought to induce joint inflammation through interaction of the 
fibrinogen-like globe domain of TN-C with TLR4 (Midwood et al., 2009). The appearance of 
TN-C during inflammation can also be found in humans during injury such as skin wounds 
(Betz et al., 1993), and asbestos-induced lung damage (Kaarteenaho-Wiik et al., 2000). 
TN-C does not only induce inflammatory responses but is also activated by infections such 
as in the lung of tuberculosis patients (Kaarteenaho-Wiik et al., 2000).  
It is interesting to analyze why TN-C expression was not present in the damaged 
articular cartilage in the newt knee joint of collagenase model. It can be speculated that the 
absence of this matricellular protein probably correlates with the inflammatory response. In 
the previous report, it was shown that the severity of the disease peaked on day 6 after intra-
articular injection of collagenase (Geyer et al., 2010). At this time point, the treated knee joint 
was already inflamed, the joint was swelling (Geyer et al., 2010). Thus, the inflammatory 
process had already been initiated. Consequently, TN-C should also be upregulated. 
However, it could not be clarified, whether the inflammatory response still exists on day 10 
after treatment. In fact, each treated animal developed an unique disease kinetic. Therefore, 
in order to investigate whether inflammatory response exists in the treated newt knee joint of 
collagenase model, expression of TLR4 and IL-1 can be analyzed in the future using IHC or 
ISH. 
In addition, the absence of TN-C expression in the articular cartilage of newt knees 
joint in the collagenase model can also be related to the absence of structural damage of the 
treated articular cartilage. Veje and coworkers investigated TN-C expression in femoral head 
cartilages of human knee OA. They demonstrated that TN-C accumulated only in the areas 
displaying structural damage such as fibrillated cartilage (Veje et al., 2003). 
At day 20 after treatment, the difference of the TN-C expression pattern still emerged 
between both models. In all of the three surgically-treated animals, traces of TN-C were 
present in the defected cartilage remnant and additionally in the undifferentiated tissue. In 
contrast, in the collagenase model, TN-C signals were absent in the damaged articular 
cartilage of two analyzed animals. This protein emerged only in the undifferentiated tissue.  
The TN-C appearance in the defected articular cartilage in the knee joint of all 
animals in the surgery model was still hypothesized as part of the inflammatory response. 
These ideas are derived from our previous study, which demonstrated that the clinical score 
that asseses the severity of the disease, was still high at day 20 after intra-articular 
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collagenase injection (Geyer et al., 2010). Logically, this inflammatory response also 
occurred in the damaged articular cartilage of animals in the collagenase model. TN-C 
should therefore be expressed in the damaged articular cartilage in the knee joint at 20 days 
post collagenase-treated animals. This assumption should also be confirmed by investigating 
the expression of relevant inflammatory factors such as IL-1 and IL-6 as previously 
mentioned. 
Expression of TN-C in the defected articular cartilage in the knee joints of surgically-
treated animals can also be elicited by tissue remodeling and repair process. The 
appearance and the involvement of TN-C during epimorphic regeneration including limb 
regeneration after amputation (Onda et al., 1990; Onda et al., 1991) and muscle 
regeneration (Goetsch et al., 2003; Calve et al., 2010) is already known. The proposed 
function of this matricellular protein is providing an extracellular environment, which promotes 
regeneration process (Calve et al., 2010).  
Interestingly, TN-C did not appear in the articular cartilage in the knee joint 20 days 
after collagenase treatment, although there is a visible repair process in this tissue. The 
Safranin-O staining demonstrated an increase of proteoglycan content in the damaged 
articular cartilage 20 days after treatment in comparison with 10 days after treatment. This 
assumption that there was a repair process in the articular cartilage should be confirmed, 
because the differences of the proteoglycan content in the articular cartilage in knee joints 
between the 20 and the 10 day collagenase treated animals can also be caused by the 
variability of disease severity. For future studies, in order to investigate, whether repair 
processes occur in the articular cartilage of collagenase treated animals, the chondrocyte 
proliferation activity can be investigated using IHC staining against proliferating cell nuclear 
antigen (PCNA) (Nakoshi et al., 2010).  
20 days after artificially induced knee joint damage, all of the animals in the surgi-
cally- and collagenase-treated groups demonstrated an undifferentiated tissue formation in 
their treated newt knee joint. The formation of this tissue structure was also found in the 
previous knee joint regeneration after intra-articular collagenase injection study (Geyer et al., 
2010). In this doctoral study, it could be shown that TN-C was expressed abundantly in this 
tissue. During limb regeneration after amputation, this matricellular protein appears 
abundantly in blastema (Onda et al., 1990; Onda et al., 1991), and in dedifferentiated 
mononucleate progenitor cells in muscle regeneration (Calve et al., 2010). TN-C expression 
in the damaged skeletal muscle can promote fragmentation and cell cycle reentry which 
result in formation of mononucleate progenitor cells (Calve et al., 2010). Thus, the function of 
TN-C in the undifferentiated tissue is promoting synthesis of the undifferentiated tissue.  
On the last analysis time point (on day 40 after treatment), the newly formed articular 
cartilage was detected in the regenerating knee joint of all three analyzed animals in the 
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surgery model. The newly formed tissue was assembled in the area where the defected 
articular cartilage was located at day 20 after treatment. Interestingly, TN-C could be 
detected abundantly in this newly formed articular cartilage. The function of this matricellular 
protein in chondrogenesis is already known (Mackie et al., 1987). TN-C promotes 
differentiation of mesenchymal progenitor cells into mature cartilage (Mackie et al., 1987). 
The capability of TN-C to promote chondrogenesis is mediated by its FN-III domain (Murphy 
et al., 2000). This domain modulates adhesion behavior of the mesenchymal cells and 
induces proliferation of these cells (Murphy et al., 2000).  
In the corresponding collagenase model, the newly formed cartilage emerged only in 
one of the two analyzed animals. This tissue was formed adjacent to the damaged cartilage. 
TN-C was expressed in this newly formed tissue. However, this matricellular protein was 
absent in the old-damaged articular cartilage. The selective appearance of TN-C indicated 
that the repair activity of cartilage occurred only in the newly formed cartilage but is absent in 
the old-defected tissue. This idea is derived from the fact that TN-C promotes chondrocyte 
differentiation and proliferation in the developing and OA articular cartilage (Mackie et al., 
1987; Nakoshi et al., 2010). For future studies, this assumption should be confirmed by 
performing experiments such as IHC against proliferating cell nuclear antigen (PCNA) to 
prove whether the TN-C expressing chondrocytes really exhibit proliferation activity. In order 
to confirm chondrocyte differentiation, IHC against SOX9 can also be performed. SOX9 is a 
transcription factor of the sex-determining region Y-chromosome family, which is required for 
differentiation of different cell lineages including chondrocytes (de Crombrugghe et al., 2000; 
Hattori et al., 2008). Because SOX9 can also induce differentiation of several cell lineages, 
identification of its target gene including Col2a1 should be performed to show chondrocyte 
differentiation in the newly formed and old-defected articular cartilage (Hattori et al., 2008). 
Another animal at day 40 of the collagenase model showed undifferentiated tissue 
formation and the TN-C expression co-localized in this tissue (data not shown). It can be 
speculated that this treated animal had a different disease kinetic than the other animals. i.e. 
the regeneration process of this animal seemed to proceed longer than others 
In addition, in the spatial expression study, there was also TN-C expression in tissue 
not related to the regeneration process. For example, the appearance of TN-C in the bone 
marrow in the treated and control knee joint of day 10 and 20 after surgery treatment. There 
are two possible explanations for this observation: First, it can be speculated that TN-C 
localization in the bone marrow is derived from adipocytes, which have recently been 
reported to express this matricellular protein (Catalan et al., 2012). Adipocytes can originate 
from bone marrow mesenchymal stem cells, which in mammals such as human and mice, 
exist abundantly in the bone marrow (Beresford et al., 1992; Nuttall et al., 2014). 
Unfortunately, there is no report in newt which shows that adipocytes can originate from 
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bone marrow. Second, the other speculation proposes that the TN-C expression in bone 
marrow is required for hematopoiesis (formation of blood cellular component) (Nakamura-
Ishizu et al., 2012). Probably, due to surgery treatment, in the surgically-treated and sham-
operated knee joint, the animals lost some blood that had to be replaced by hematopoiesis. 
This activity could also have triggered TN-C expression in the bone marrow of both tissues.  
As conclusion, based on the assumption that the appearance of TN-C is important in 
regeneration, its selective expression in certain tissues implicates different regeneration 
mechanisms in both OA models. In order to confirm this assumption, additional experiments 
need to be performed (e.g. investigating the animals at later time points).  
 Relative quantification versus spatiotemporal analysis of TN-C expre-5.1.3.2.2
ssion during newt knee joint regeneration 
Real-time PCR quantification of TN-C in both OA models showed that this 
matricellular protein was highly expressed at 10 days after treatment and then the expression 
level was reduced dramatically at 40 days after treatment (except pool animals B in 
collagenase model) (see Figure 16). This fact seemed to contradict the result of 
spatiotemporal analysis by IHC which showed that there was no abundant TN-C expression 
in both models at 10 days after treatment. The expression of this matricellular protein was 
only restricted to the small defect area and periosteum in the surgically-treated animals and 
only along the periosteum in the collagenase-treated newts. The contradiction was also 
evident at 40 days after treatment. At this time point, IHC results showed that TN-C 
expression was increased dramatically especially in the articular cartilage.  
There were some possibilities why the result of IHC analysis of TN-C expression did 
not correlate with the real-time PCR quantification of this matricellular protein. One possibility 
could be the difference of the transcription and the translation kinetic of this gene during knee 
joint regeneration. Another possibility is the variability of the TN-C expression in each treated 
animals due to variability of disease severity (see Section 5.2.2) 
The assumption that TN-C played important roles in the knee healing process needed 
also to be validated. Thus, functional analyses were carried out by performing a TN-C 
knockdown in newt-derived cells / cell lines.  
 Establishing expression knockdown in newt and its implication in 5.1.3.2.3
functional analysis of TN-C 
Establishing gene expression knockdown in the newt is a challenging effort due to the 
limited number of sequence informations and commercial reagents for performing 
knockdown experiments such as siRNA. So far, only three sets of experiments are reported. 
Recently, Witman and coworkers were able to knockdown the expression of micro RNA 128 
(miR-128) using antagomirs (Witman et al., 2013). An antagomir is a chemically engineered 
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oligonucleotide which binds specifically to microRNA and elicits its degradation (Krützfeld et 
al., 2005). Two other groups employed morpholino oligonucleotides (MOs) to knockdown 
genes including pax-6 (Madhavan et al., 2006) and the oocyte-type linker histone B gene 
(Maki et al., 2010) in the newt. MO-mediated expression knockdown is a widely used tool to 
conduct functional analysis of a gene of interest in vivo (Summerton et al., 1997). MOs 
employ oligomers which are composed of approximately 25 morpholine bases that are 
specifically targeted via complementary base pairing to the transcription product of interest. 
The binding of the MOs with the mRNA creates a steric hindrance for proper transcript 
processing and translation, therefore, protein synthesis is not possible (Summerton et al., 
1997; Summerton et al., 1999). 
In this doctoral work, the MO technique was not selected for the TN-C expression 
knockdown, due to the limited financial budget and the unavailability of animals. As 
alternative, in vitro knockdown was performed using esiRNA-mediated gene silencing. A TN-
C-specific esiRNA was produced based on nucleotide information from newt-omics, a 
database which was recently established at the Max Planck Institute in Bad Nauheim 
(Bruckskotten et al., 2012). Two separate knockdown experiments were performed in 
primary newt chondrocytes and the expression of the gene reduced to 0.45-fold in the first 
experiment and to 0.29-fold in the second.  
In this doctoral work, a direct examination (in vivo) of the influence of TN-C 
knockdown in the restoration of the tissue could not be performed. Some representative 
experiments, which were able to be performed in vitro, were selected to investigate the effect 
of the TN-C gene silencing on cellular properties of newt chondrocytes. The adhesion assay 
was one of the selected methods to address this objective, since an earlier studies showed 
that this experimental setting can be used for investigating and measuring the repair capacity 
of a tissue (Park et al., 2009). Park and coworkers investigated the role of TLR4 blockade in 
the induction of tooth regeneration. They evaluated the adhesive capacity of odontoblasts (a 
cell type which covers the outer space of dental pulp that produces the dentin of a tooth) to 
collagen-coated plate. They found an increase of the adhesive capacity of the cells that 
correlated with tooth regenerative capacity (Park et al., 2009). In newt regeneration, Brockes 
showed that cellular properties such as adhesion, was required during tissue patterning (a 
process which controls the position and organization of cells in a certain tissue) of 
differentiated blastema cells during newt appendage regeneration (Brockes, 1997). 
In this study, it was hypothesized that the silencing of TN-C in newt chondrocytes 
resulted in a reduction of the regenerative capacity, reflected by the reduction of the 
adherence ability of the TN-C knockdown newt chondrocytes (Ishida et al., 1997). In order to 
evaluate the hypothesis, an adhesion assay was performed, and the result of the 
experiments showed that the TN-C expression knockdown decreased the adhesion of the 
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cells to the surface of cell culture plates. However, the difference between TN-C knockdown 
cells and control cells was not statistically significant.  
The second study, which was performed to evaluate the effect of TN-C knockdown in 
newt chondrocytes, was the scrape motility assay. Some experiments demonstrated the 
relation between cell motility and tissue repair (Lallier et al., 2007; Zhang et al., 2013). Lallier 
and coworkers investigated periodontal regeneration, and they found that the process relied 
on migratory capacity of distinct cell types including gingival fibroblasts (a cell type found in 
periodontal connective tissue). They conducted a motility assay to prove their hypothesis 
(Lallier et al., 2007). Studies in a human gastric wound healing in vitro model showed that 
also the migrative capacity of gastric epithelial cells increased during the wound healing 
process (Zhang et al., 2013). In the newt model system, there is also evidence of a 
correlation between migratory capacity in tissue repair process during skeletal muscle 
regeneration (Calve et al., 2012). Calve and coworkers observed that TN-C-coated 
substrates enhanced the migration of primary newt muscle cells (myoblasts) in comparison 
to control substrates (laminin- and matrigel- coated substrates). This event correlated with 
myoblast fragmentation, which is a process of muscle dedifferentiation for subsequent 
epimorphic regeneration to restore the damage tissue (Calve et al., 2012).  
Based on the same principle, in this doctoral work, it was hypothesized that the 
silencing of TN-C expression of newt chondrocytes may cause a reduction of the 
regenerative capacity of the cells, which was shown in the reduction of their migratory 
capacity. In order to answer this hypothesis, the motility of newt chondrocytes was 
investigated using the scrape assay. The result of the study exhibited that in the majority of 
analyzed incubation times, TN-C knockdown cells exhibited a tendency of higher migratory 
capacity than the control, but altogether, it was not statistically significant.  
In addition, we hypothesized that in supporting regeneration, TN-C probably 
collaborated with or influenced other ECM components, that were also upregulated in this 
process e.g. SPARC and DCN. This idea derived from the newt muscle regeneration model. 
Here, TN-C collaborates with other ECM components such as fibronectin and hyaluronic 
acid. They form a dynamic expression pattern during skeletal muscle regeneration (Calve et 
al., 2010). The result of relative quantification of SPARC and DCN mRNA from the TN-C 
knockdown in primary newt chondrocytes showed that the silencing of TN-C transcript did 
not affect the expression of these matricellular proteins.  
Discussion 
 98 
5.2 Analysis of obstacles during investigation of knee joint 
regeneration in newt  
Although newts are an attractive animal model to study molecular mechanisms, which 
underlie knee joint regeneration, some obstacles, which significantly influenced the results in 
this thesis, emerged during this doctoral study.  
5.2.1 The newt as animal model for research 
The red-spotted newts are not endemic in Europe. Their natural habitat is located at 
the east coast of North America. Therefore, this research project relied substantially on the 
delivery from the country of origin. In one case, there was a delay in the shipping of the 
animals due to regulations that limit amphibian shipping to Europe from the USA in order to 
prevent spreading of infectious disease (unpublished report from Prof. Dr. med. Robert 
Dinser and Dr. rer. nat. Thilo Borchardt). The consequence of this regulation was a limited 
number of animals available for the investigations. As solution to resolve this problem, 
recently the Max Planck Institute in Bad Nauheim has been trying to breed and culture the 
animal in an artificial environment. Until now, the effort has not yet been fully successful, due 
to the long breeding (6 months) and culturing time (3 years) until the animals become adult 
and ready to be used for research purposes. As a comparison, other animal model for 
studying regeneration, the axolotl (Ambystoma mexicanum), can be easily bred in animal 
housing facilities. They have also a relatively short period to reach sexual maturity 
(approximately 5 months; Clare, 2012). 
The low number of animals as planned which could be used in this study increased 
the variability of the results. This is reflected by the expression analysis of the newt knee joint 
tissue after artificially induced damage as discussed below. 
5.2.2 Problem during transcriptome analysis 
The initial transcriptome analysis using cDNA microarray was performed in order to 
reveal molecular mechanisms underlying knee joint regeneration. Several experimental 
approaches were conducted in order to achieve the best possible result. Nevertheless, some 
problems arose due to limitations of the utilized technique. One of the weaknesses was the 
moderate sensitivity of the cDNA microarray (Hicks et al., 2008). It was reflected in the 
susceptibility of the assay against background interferences. The hybridization signal from 
fluorescently labeled cDNA samples of day 20 of the collagenase model was disturbed by a 
high background signal. Therefore, only hybridization signals from two investigated time 
points (days 10 and 40) could be used (unpublished report from Prof. Dr. med. Robert M. 
Dinser, Dr, med. Matthias Geyer, and Dr. rer. nat. Thilo Borchardt). In contrast to the 
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collagenase technique, the surgery method produced a reliable hybridization signal (data not 
shown). The background level was low and did not disturb the specific signal from the 
deregulated genes.  
Validation of deregulation values of the selected genes from the cDNA microarray 
with real-time PCR was also accompanied by variability. There was a disagreement of 
deregulation values of some selected genes between pool A and B animals. An obvious 
example is the deregulation values of DCN at day 10 after collagenase treatment (see 
Section 4.1.1.4). In this selected example, there was an extreme value difference (pool A, 
8.6-fold; pool B, 0.4-fold). In this doctoral work, the exact reason of the discrepancy of the 
deregulation status and value differences of selected gene expressions between pool A and 
B could not be fully investigated. A possible explanation could be that each treated animal 
developed a varying degree of disease severity. Thus, it presumably reflects to the 
dissimilarity of expression values between both pool animals. These differences between the 
two animal pools in some genes generated the problematic situation to deduce the 
importance of these genes during the knee joint restoration process. In order to solve this 
problem, spatial expression analysis using IHC was performed for some selected genes such 
as TN-C and SPARC to provide additional information for the role of the selected genes in 
the repair mechanism. 
5.2.3 Problem during establishment of spatial expression analysis  
The spatial expression analysis using IHC was also challenged by the lack of cross-
reactivity of commercially available primary antibodies to newt-specific proteins. Therefore, 
tedious investigations of antibodies cross-reactivities were performed before applying them 
for spatial expression analysis in newt tissues. In this doctoral study, only two antibodies 
including anti-human TN-C and anti-mouse and –human SPARC were used for spatial 
expression analysis.  
ISH can be used as alternative approach for investigating spatial expression of gene 
of interest. This technique allows the detection of specific nucleic acid molecules by using a 
DNA/RNA probe that specifically detects newt-specific gene transcription products in 
morphologically preserved tissue sections. The probe was synthesized based on nucleotide 
sequence information from newly-established newt-omics database (Bruckskotten et al., 
2012).  
During this doctoral work, the protocol to investigate the spatial expression of TN-C 
using ISH was developed. Unfortunately, the established ISH protocol was only able to 
detect gene transcripts in newt blastema cryosections (data not shown). ISH of healthy newt 
knee joint paraffin sections to detect TN-C expression in periosteum was unsuccessful. The 
reason could be that due to the long preparation time of paraffin-embedded tissue, the 
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quality and abundance of the mRNA of interest was strongly reduced (Salmon et al., 2012; 
Shao et al., 2006).  
However, it is feasible that ISH can be performed in paraffin preserved tissues in the 
future. A recent study showed that the integrity of mRNA step can be preserved by using 
RNAlater/EDTA mixture in decalcification step during establishment of paraffin sections of 
bone-containing tissue and shorter decalcification time (overnight) (Belluoccio et al., 2013). 
In this technique, RNAlater (Life Technologies), a proprietary tissue storage reagent, which 
stabilizes and protects cellular RNA is mixed with EDTA, and this solution is used to decalcify 
the bone tissue (Belluoccio et al., 2013).  
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6 Summary 
Lesions of articular cartilage are still leading to irreversible degenerative joint 
diseases including osteoarthritis (OA). Aside pain, the disease results in loss of function of 
the affected joint and severe disability and a substantial reduction of quality of life of the 
affected patient. The human does not have the endogenous capacity to restore the structure 
and the function of the osteoarthritic knee joint damage. In contrast, animals such as the red-
spotted newt (Notophthalmus viridescens viridescens) are able to repair complete organs 
and tissues including joints after artificial damage by collagenase treatment and surgery. The 
underlying mechanisms of this regenerative process can be further investigated by cDNA 
microarray showing distinct genes, which were differentially upregulated in both models for 
OA. 
Based on these results, in this doctoral project, the genes, that were found to be 
upregulated in the cDNA microarray study and additional genes from the vitamin A pathway, 
and the innate immune system, both known to be involved in repair processes were selected 
for real-time PCR analysis to primarily quantify their deregulation status. Here, real-time PCR 
study confirmed the deregulation of distinct molecules including secreted protein acidic and 
rich in cysteine (SPARC), periostin (POSTN), decorin (DCN), complement factor B (CFB), 
tenascin-C (TN-C), toll-like receptor 2 (TLR2), and retinoic acid receptor responder 1 
(RARRES1).  
Among these selected factors, TN-C was the most interesting one, because the 
deregulation of this matricellular protein was the most prominent among the other selected 
candidates.  
IHC analysis revealed that the spatial expression of TN-C during the knee joint 
regeneration process was unique in each OA model. At day 10 and 20 after surgery 
treatment, TN-C appeared in the defected articular cartilage of the treated knee joints in two 
of three analyzed animals. In contrast, in the animals of the collagenase model, the TN-C 
expression was absent in the defected articular cartilage. It supported the idea of a 
differential initiation of the repair process depending on the type of the damage inflicted. The 
appearance of this matricellular protein in the defected articular cartilage in the animals of the 
surgery model can be seen as a part of an inflammatory response during the injury process. 
At day 20 after treatment, undifferentiated tissue emerged in the regenerating newt knee joint 
of all analyzed animals. TN-C was expressed abundantly in this tissue, which is a further 
indication of its involvement in the knee joint regeneration. At day 40 after treatment, all of 
the three analyzed animals in the surgery model and one animal of the two analyzed animals 
in the collagenase model demonstrated expression of TN-C in the newly formed articular 
cartilage. Here, TN-C could promote the formation of this tissue. In the regenerating knee 
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joint of one analyzed animal in the surgically-treated animals, TN-C appeared only in the 
newly formed articular cartilage, but it was absent in the old-defected cartilage.  
In order to investigate whether the involvement of TN-C was functionally important for 
the knee joint regeneration process, gene silencing experiments were conducted in newt 
primary chondrocytes using TN-C esiRNAs in vitro, introduced into the primary newt 
chondrocytes by nucleofection. In two independent experiments, TN-C expression could be 
reduced to 0.55-fold (45% reduction) and 0.29-fold (71% reduction), the effect of one-time 
TN-C gene silencing on regenerative capacity of newt chondrocytes with respect to migration 
and adhesive capacity of these cells did not result in a statistically significant effect. In 
addition, in order to elucidate the effect of TN-C knockdown on other dysregulated candidate 
genes including SPARC and DCN, relative quantification of the transcription product of both 
genes was performed. The result of the measurement demonstrated that TN-C knockdown in 
newt chondrocytes did not alter the expression levels of these molecules.  
SPARC, another prominent candidate gene, which was selected from the cDNA 
microarray, was present in several tissues in untreated newt legs including osteocytes, 
articular cartilage, blood vessels and skin. As SPARC is known to be important for the 
normal function of these tissues, in the regenerating newt knee joint already at day 20 after 
surgery treatment, this matricellular protein was localized abundantly in distinct areas in the 
skeletal muscle and periosteum. Of note, this expression was not directly related to the 
regeneration process since these tissues were not primarily damaged by the surgical 
treatment. 
Similar to the results obtained from the TN-C and SPARC experiments, several other 
matrix repair associated molecules were found to be upregulated and expressed at different 
time points during the newt knee joint regeneration process, providing interesting new 
insights into this fascinating phenomenon. However, the experiments of this doctoral thesis 
also showed the still existing limitations of an experimental approach in an organism, for 
which the technical systems still need to be fully established. 
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7 Zusammenfassung 
Läsionen des Gelenkknorpels führen zu einer irreversiblen degenerativen 
Gelenkerkrankung, einschließlich der Osteoarthritis. Die Krankheit verursacht neben 
Schmerzen einen Funktionsverlust des betroffenen Gelenks, eine schwere Behinderung 
sowie eine erhebliche Einschränkung der Lebensqualität der betroffenen Patienten. Der 
menschliche Organismus besitzt keine Möglichkeit, die Struktur und Funktion eines 
arthrotisch erkrankten Gelenkes selbst wiederherzustellen. Im Gegensatz hierzu besitzen 
verschiedene Tierarten wie z.B. der rotgetüpfelte Teichmolch (Notophthalmus viridescens 
viridescens), die Fähigkeit verletzte Organe und Gewebe z.T. vollständig zu regenerieren. 
Nach Verletzung des Gelenkknorpels durch Kollagenase-Injektion und OP sind diese Molche 
z.B. in der Lage, den Knorpel zu reparieren und die Funktionsfähigkeit des Gelenkes 
wiederherzustellen. 
Die zu Grunde liegenden Mechanismen dieses Regenerationsprozesses wurden 
primär durch einen cDNA-Microarray untersucht. Es wurden aus diesem verschiedene Gene 
in beiden OA Modellen als hochreguliert nachgewiesen und im Rahmen dieser Arbeit im 
Detail untersucht. Basierend auf diesen Ergebnissen wurden die Gene, die in der zuvor 
durchgeführten cDNA-Microarray-Untersuchung als dysreguliert nachgewiesen wurden, 
Gene aus dem gelenkaktiven Vitamin A Signalweg sowie dem angeborenen Immunsystem 
näher untersucht. Die Expression der ausgewählten Kandidatengene wurde mittels Real-
time-PCR-Analyse bestätigt und eine Deregulierung von unterschiedlichen Molekülen, 
einschließlich des secreted protein acidic and rich in cysteine (SPARC), periostin (POSTN), 
decorin (DCN), complement factor B (CFB), tenascin-C (TN-C), toll-like receptor 2 (TLR2) 
und retinoic acid receptor responder 1 (RARRES1) auf mRNA Ebene verifiziert werden.  
Die immunohistochemische Analyse zeigte, dass die Lokalisation der Expression von 
TN-C im Kniegelenkregenerationsprozess spezifisch für jedes OA-Modell zeichnete. TN-C 
war im defekten Knorpel des behandelten Kniegelenks in zwei von drei Tieren am Tag 10 
und 20 nach der OP-Behandlung nachweisbar. Im Gegensatz dazu konnte bei den 
Kollagenase- behandelten Tieren keine TN-C-Expression im defekten Knorpel nachgewiesen 
werden. Diese Ergebnisse unterstützen die Hypothese, dass unterschiedliche 
Reparaturvorgänge in Abhängigkeit von der Art der Schädigung ablaufen. Das Erscheinen 
dieses matrizellulären Proteins im defekten Knorpel der OP behandelten Tiere kann auch im 
Rahmen einer lokalen Entzündungsreaktion gesehen werden. Am Tag 20 nach der 
Behandlung war noch undifferenziertes mesenchymales Gewebe in den regenerierenden 
Molch-Kniegelenken aller untersuchten Tiere histologisch erkennbar. TN-C wurde in diesen 
noch nicht differenziertem Geweben ausgeprägt exprimiert. Diese Beobachtung deutet 
ebenfalls daraufhin, dass dieses matrizelluläre Protein wesentlich an der Kniegelenk-
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regeneration beteiligt ist. An Tag 40 nach der Behandlung konnte bei allen drei Kollagenase-
behandelten Tieren und in einem von zwei OP-Tieren eine TN-C-Expression im bis dahin 
neu gebildeten Gelenkknorpel nachgewiesen werden. Hier könnte TN-C in die Neubildung 
dieses Gewebes involviert sein. Im regenerierenden Kniegelenk eines analysierten Tieres in 
den OP behandelten Tieren war TN-C nur im neuen gebildeten Gelenkknorpel sichtbar, es 
fehlte aber im alten, defekten Gelenkknorpel. 
Um die Beteiligung von TN-C im Reparaturvorgang des Kniegelenks näher zu 
untersuchen, wurden Gene Silencing-Experimente in primären Molchchondrozyten mithilfe 
von TN-C esiRNA, die mittels Nukleofektion in die Zellen eingebracht wurde, in vitro 
durchgeführt. In zwei voneinander unabhängigen Experimenten konnte die TN-C-Expression 
hiermit bis zu 45% bzw. 71% reduziert werden. Das Migrations- und Adhäsionsverhalten der 
primären Molchchondrozyten nach TN-C Knockdown im Vergleich zu Kontrollzellen war 
hierbei nicht signifikant verändert. Um den Effekt des TN-C-Knockdowns auf andere 
deregulierte Kandidaten Gene einschließlich SPARC und DCN näher zu untersuchen, wurde 
deren Expression mittels Real-time PCR untersucht. Das Ergebnis der Messung zeigte, dass 
der TN-C-Knockdown in Molchchondrozyten die Expression dieser beiden matrizellulären 
Proteine nicht beeinflusst. 
Basierend auf dem cDNA-Microarray wurde SPARC ebenfalls als vielversprechender 
Kandidat aus den cDNA-Microarray ausgewählt. Die Expression dieses Proteins konnte in 
verschiedenen Geweben z.B. Osteozyten, Gelenkknorpel, Blutgefäßen und in der Haut in 
unbehandelten Molchbeinen nachgewiesen werden. Während der Regeneration nach OP 
Schädigung konnte dieses matrizelluläre Proteinverstärkt in verschiedenen Bereichen des 
Skelettmuskels und des Periosts ab Tag 20 nachgewiesen werden. Die SPARC-Expression 
in diesen Geweben war wahrscheinlich nicht direkt mit dem Regenerationsprozess 
verbunden, da diese Gewebe nicht direkt durch den Eingriff alteriert wurden.  
Neben den Ergebnissen für die matrizellulären Proteine TN-C- und SPARC konnte 
mehrere andere Matrixreparatur-assoziierte Moleküle zu verschiedenen Zeitpunkten 
während des Regenerationsprozess des Molch-Kniegelenks ebenfalls als hochreguliert 
nachgewiesen werden, was interessante neue Einblicke in diese faszinierende Phänomen 
der Regeneration bietet. Allerdings zeigten die Experimente in dieser Doktorarbeit auch die 
noch vorhandenen Grenzen eines experimentellen Ansatzes in einem Organismus auf, für 
den die technischen Systeme noch nicht vollständig etabliert sind. 
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9.3 List of abbreviations 
ac articular cartilage 
acr articular cartilage rest  
BME basal medium eagle 
bv blood vessel 
C coll day 10 control knee joint collagenase model day 10 
C coll day 20 control knee joint collagenase model day 20 
C coll day 40 control knee joint collagenase model day 40 
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C surgery day 10 control knee joint surgery model day 10 
C surgery day 20 control knee joint surgery model day 20 
C surgery day 40 control knee joint surgery model day 40 
calc calcified zone of articular cartilage 
CFB complement factor B 
coll collagenase 
Coll D10 collagenase model day 10 
Coll D40 collagenase model day 40 
CRYGB gamma β crystalline 
Ct cycle threshold 
da defect area  
DCN decorin 
ddH2O double-distillated H2O 
der dermis 
dsDNA double-stranded DNA 
dsRNA double-stranded RNA 
dz deep zone of articular cartilage 
end endosteum 
esiRNA endoribonuclease small interfering RNA 
fm femur 
HEPES N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid 
hr hour 
IHC immunohistochemistry 
ISH in-situ hybridization 
ITS insulin transferin selenium 
min minute 
ms muscle 
MyD88 myeloid differentiation primary response gene 88 
nac newly formed articular cartilage  
nb newly formed bone 
ns not significant 
OA osteoarthritis 
oac old articular cartilage 
ob osteoblasts 
OLFML3 olfactomedin-llike 3 
OP surgery 
OP day 20 surgery model day 20 
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OP day 40 surgery model day 40 
OP day10 surgery model day 10 
os osteocytes 
osd osteoid 
PBS phosphate buffer saline 
PCR polymerase chain reaction 
POSTN periostin 
prs periosteum 
RARRES1 retinoic acid receptor responder 1 
RAR-α retinoic acid receptor-α 
RAR-β retinoic acid receptor-β 
RAR-δ retinoic acid receptor-δ 
RETSAT retinol saturase 
RT room temperature 
RXR retinoid X receptor 
rz remodelling zone 
sb subchondral bone 
sec second 
siRNA small interference RNA 
SPARC secreted protein acidic and rich in cysteine  
ssRNA single-stranded RNA 
T col day 40 treated knee joint collagenase model day 40 
T coll day 10 treated knee joint collagenase model day 10 
T coll day 20 treated knee joint collagenase model day 20 
T surgery day 10 treated knee joint surgery model day 10 
T surgery day 20 treated knee joint surgery model day 20 
T surgery day 40 treated knee joint surgery model day 40 
tb tibia 
TLR2 toll-like receptor 2 
TLR5 toll-like receptor 5 
TMSB4 thymosin β 4 
TN-C tenascin-C 
ut undifferentiated tissue  
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9.4 Result of relative quantification of candidate genes with real-
time PCR 
 
 
Table 15: Relative quantification (Ct) of all candidate genes from cDNA microarray, innate 
immune system and vitamin A biosynthesis pathway during newt knee joint regeneration after 
collagenase- and surgically-induced OA. Artificial knee joint damage was induced in the red-
spotted newts (Notophthalmus viridescens) using collagenase and surgery treatment. 10, 40 days 
after collagenase and 10, 20, 40 days after surgery treatment, the regenerating and the control knee 
joint were isolated from each 2 pool (pool A) and 3 pool animals (pool B). After isolation of total mRNA 
from these knee joints, the cDNA was synthesized for relative quantification using real-time PCR. 
Afterwards, Ct was calculated for each candidate genes. The result of the calculation and the 
standard deviation were presented in this table. Heat-shock protein 27 (HSP-27), complement factor B 
(complement factor B), periostin (POSTN), thymosin 4 (TMSB4), decorin (DCN), tenascin-C (TN-C), 
gamma B crystalline (CRYGB), secreted protein acidic and rich in cysteine (SPARC), olfactomedin-like 
(OLFML3), retinol saturase (RETSAT), retinoid X recetor (RXR), retinoic acid receptor  (RAR-), 
retinoic acid receptor  (RAR-), retinoic acid receptor  (RAR-), myeloid differentiation primary 
response gene 88 (MyD88), toll-like receptor 2 (TLR2), toll-like receptor 5 (TLR5), and retinoic acid 
receptor responder -1 (RARRES1). 
 
 
Candida-
te genes 
Collagenase model Surgery model 
Day 10  Day 40 Day 10 Day 20 Day 40 
Pool 
A 
Pool 
B 
Pool 
A 
Pool 
B 
Pool 
A 
Pool 
B 
Pool 
A 
Pool 
B 
Pool 
A 
Pool 
B 
CFB 4.5 
±0.35 
3.2 
±0.41 
0.8 
±0.04 
4.9 
±0.20 
11.8 
±1.01 
4.5 
±0.32 
4.4 
±0.06 
23.6 
±2.94 
5.2 
±0.57 
2.7 
±0.65 
POSTN 2.8 
±0.15 
1.3 
±0.11 
1.7 
±0.09 
4.9 
±0.16 
2.3 
±0.16 
3.3 
±0.04 
3.9 
±0.26 
8.9 
±1.26 
1.3 
0.18 
1.0 
±0.02 
TMSB4 2.7 
±0.02 
1.3 
±0.21 
1.2 
±0.07 
1.3 
±0.04 
0.5 
±0.04 
0.4 
±0.04 
0.5 
±0.01 
0.4 
±0.04 
1.5 
±0.19 
0.4 
±0.02 
DCN 8.6 
±0.38 
0.4 
±0.05 
2.4 
±0.06 
1.7 
±0.15 
1.2 
±0.06 
1.8 
±0.27 
2.1 
±0.03 
1.4 
±0.06 
2.0 
±0.09 
1.0 
±0.05 
TN-C 22.4 
±0.60 
3.5 
±0.06 
3.8 
±0.13 
12.2 
±0.50 
15.6 
±0.79 
12.3 
±1.89 
10.1 
±0.26 
33.8 
±7.85 
1.1 
±0.10 
0.9 
±0.04 
CRYGB 1.5 
±0.04 
1.0 
±0.06 
1.7 
±0.12 
0.7 
±0.01 
6.7 
±1.9 
2.5 
±0.05 
1.1 
±0.02 
1.6 
±0.10 
0.9 
±0.07 
1.0 
±0.02 
SPARC 2.1 
±0.05 
1.4 
±0.13 
1.7 
±0.06 
2.6 
±0.08 
1.4 
±0.08 
2.5 
±0.09 
3.4 
±0.12 
2.4 
±0.16 
1.7 
±0.07 
1.1 
±0.03 
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Candida-
te genes 
Collagenase model Surgery model 
Day 10  Day 40 Day 10 Day 20 Day 40 
Pool 
A 
Pool 
B 
Pool 
A 
Pool 
B 
Pool 
A 
Pool 
B 
Pool 
A 
Pool 
B 
Pool 
A 
Pool 
B 
OLFML3  3.8 
±0.20 
1.7 
±0.07 
1.1 
±0.03 
4.4 
±1.00 
3.7 
±0.32 
2.2 
±0.11 
5.0 
±0.15 
4.1 
±0.06 
3.0 
±0.27 
1.0 
±0.02 
Retsat 1.8 
±0.08 
0.4 
±0.02 
1.2 
±0.03 
1.4 
±0.16 
1.4 
±0.06 
0.7 
±0.11 
1.0 
±0.07 
0.9 
±0.18 
1.8 
±0.19 
0.5 
±0.05 
RXR 4.6 
±0.37 
0.6 
±0.08 
1.1 
±0.02 
0.6 
±0.02 
1.6 
±0.12 
2.6 
±0.20 
1.2 
±0.07 
1.5 
±0.08 
1.4 
±0.10 
1.0 
±0.08 
RAR-α 2.8 
±0.21 
0.6 
±0.10 
1.1 
±0.14 
0.8 
±0.04 
1.1 
±0.16 
1.9 
±0.12 
0.8 
±0.08 
1.8 
±0.17 
1.6 
±0.14 
1.3 
±0.20 
RAR-β 0.9 
±16 
0.4 
±1.26 
1.1 
±0.21 
1.4 
±0.30 
1.0 
±0.19 
1.4 
±0.32 
0.9 
±0.24 
2.5 
±0.21 
1.2 
±0.21 
0.6 
±0.25 
RAR- 3.6 
±0.41 
0.9 
±0.11 
1.4 
±0.16 
0.8 
±0.10 
2.1 
±0.26 
2.4 
±0.35 
1.1 
±0.03 
2.1 
±0.22 
1.4 
±0.13 
1.3 
±0.09 
RARRES
1 
4.6 
±0.86 
1.7 
±0.11 
1.9 
±0.13 
1.7 
±0.19 
2.7 
±0.29 
1.0 
±0.72 
1.0 
±0.14 
3.7 
±0.27 
1.2 
±0.24 
0.6 
±0.24 
MyD88 1.6 
±0.10 
0.6 
±0.01 
1.4 
±0.12 
0.8 
±0.02 
1.8 
±0.58 
1.8 
±0.21 
1.2 
±0.11 
1.3 
±0.06 
1.1 
±0.12 
0.6 
±0.01 
TLR2 1.8 
±0.14 
2.0 
±0.16 
1.4 
±0.03 
1.9 
±0.09 
8.9 
±1.42 
6.6 
±2.76 
0.6 
±0.08 
2.1 
±0.54 
0.7 
±0.14 
0.5 
±0.09 
TLR5 1.4 
±0.42 
0.8 
±0.06 
0.3 
±0.19 
1.3 
±0.25 
8.1 
±3.99 
1.5 
±0.50 
0.3 
±0.14 
1.8 
±0.26 
0.6 
±0.07 
1.6 
±0.56 
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